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Summary 
Background: 
Childhood obesity has both long- and short-term health 
consequences and is a growing public health problem in Ireland (O’Neill et al, 
2007; Finucane et al, 2008; Riddoch et al, 1991). Medications used in the 
treatment of chronic medical conditions like epilepsy and psychiatric illness 
might be contributing to this epidemic (Ben-Menachem, 2007, Pickrell, 2013; 
Martine). Epilepsy affects about 50 million people worldwide with about 
40,000 people living with the condition in Ireland (JEC, 2011, Linehan et al, 
2010). Sodium valproate (VPA) is an effective anti-epileptic drug, but up to 
71% of the patients exposed to the drug report weight gain as an adverse 
drug reaction (Biton, 2003). The clinical and genetic risk factors associated 
with this ADR are unknown.   
Objective 
To identify clinically relevant predictors of VPA-induced weight 
change in children with epilepsy within the first year of initiation of therapy. 
Methods: 
Under a retrospective framework, we recruited and performed clinical 
phenotyping on paediatric epilepsy patients treated with VPA.  We employed 
maximum percentage weight change, and change in weight-for-age z-score 
as weight change phenotypes. We extracted DNA from these subjects and 
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carried out genotyping for 17 SNPs that had previously been robustly 
associated with changes in BMI and weight in healthy individuals. Meta-
analysis of our results was conducted using a fixed-effects model.  
Results: 
We recruited 251 children, of which 218 underwent genotyping. About 48% of 
the children experienced a gain in weight of ≥5% from that predicted by 
weight at initiation of therapy. None of the clinical factors tested significantly 
influenced weight change. Meta-analysis indicated that the genetic variants 
rs10938397, rs7498665 and rs1805081 showed nominally significant 
association with quantitative weight change due to VPA. However none 
survived correction for multiple testing.  
Conclusions: 
None of the clinical phenotypes tested in this study was associated 
with VPA-induced weight change, nor did our results support clinical 
predictors reported in previous studies. Although three of the SNPs 
associated with changes in BMI showed nominally significant association 
with weight change associated with VPA, none of them survived Bonferroni 
correction. A large multi- centre research is required to provide sufficient 
power to identify any genetic factors associated with this ADR.  
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Chapter 1: General Introduction/ Background  
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1. Introduction 
Childhood obesity is a growing and serious public health problem in 
Ireland (O'Neill et al., 2007, Finucane et al., 2008). Over the last decade the 
proportion of overweight children in Ireland has trebled (Evans et al., 2011).  
The health consequences of this increased prevalence of overweight and 
obesity cannot be overemphasised (Finucane et al., 2008, Riddoch et al., 
1991). The increased prevalence of obesity in Irish children has been 
attributed to various factors including increased consumption of energy-rich 
food and reduced physical activity (Riddoch et al., 1991, Murrin et al., 2012). 
Medications used in the treatment of such chronic childhood conditions as 
diabetes, psychiatric illness and epilepsy may also be contributing to this 
epidemic (Ben-Menachem, 2007, Pickrell et al., 2013, Martinez-Ortega et al., 
2013, Pramyothin and Khaodhiar, 2010, Overbeek et al., 2010, Maayan and 
Correll, 2011, Dori and Green, 2011, Thon et al., 1992, Davis et al., 2012). 
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1.1  What is epilepsy?  
Epilepsy is defined as a brain disorder which manifests as a tendency to 
recurrent, unprovoked seizures (Shovron, 2009). About 50 – 80 new cases of 
epilepsy are diagnosed per 100,000 people per year, while 4 – 10 per 1000 
population are living with epilepsy. The lifetime prevalence of seizures is 
about 10%. The incidence and prevalence of epilepsy are higher in the 
developing world compared to developed countries. Of the estimated 50 
million people with epilepsy worldwide, 40 million (80%) live in the developing 
world where more than 75% of people living with epilepsy do not receive 
adequate care (JEC, 2011). In the Republic of Ireland, the prevalence of 
epilepsy in people over the age of five years is 9 per 1,000 with about 40,000 
living with the condition (Linehan et al., 2010). About 1 in 200 Irish children 
are affected (EpilepsyIreland). Epilepsy is associated with health, social, 
psychological and economic problems. Epilepsy increases the standardised 
mortality rate two to three folds (Shovron, 2009). It is also associated with 
social isolation and problems in personal relationships, education, 
employment and family life (Shovron, 2009). About 1 in 10 people with 
epilepsy experience frequent seizures, occurring more than once weekly. 
Epilepsy demands intense medical resources and associated direct and 
indirect costs. In the UK for instance, the management of epilepsy takes up 
about 0.25% of the total health care costs (Shovron, 2009). Using the 
2012/2013 NHS health budget of 109 billion GBP, the cost of epilepsy 
amounts to about 270 million GBP per annum in the UK alone.(NHS, 
2013). 
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1.2.   How is epilepsy treated?  
Epileptic seizures in children and adults can be managed with anti-epileptic 
drugs (AEDs), dietary measures and/ or epilepsy surgery procedures. Most 
children diagnosed with epilepsy are subjected to a trial of one or more AEDs 
in an attempt to control seizures. Around 24 AEDs have been approved for 
use for the treatment of epilepsy in the United States (Sirven et al., 2012). 
The number of available AEDs has increased over the last few years. For 
example, from 2010 to 2012, five new AEDs have been approved for the US 
market (Sirven et al., 2012) (see Fig 1 below). This increase in the number of 
approved AEDs has been associated with slightly improved control of 
seizures for the majority of the people with epilepsy but this improvement is 
largely limited to those patients living in developed countries, with access to 
appropriate health care (Loscher et al., 2013b). Although the new generation 
AEDs are associated with less severe ADRs their use has not resulted in a 
significant reduction in the proportion of people with drug-resistant epilepsy 
(DRE) (Privitera, 2011, Mattson, 1995). Novel approaches to the treatment of 
DRE are currently being tried (Sorensen and Kokaia, 2013). Gene therapy 
using cell transplantation and viral vectors is also another promising 
approach to epilepsy treatment (Riban et al., 2009).  
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AEDs are functionally and structurally diverse (Howard et al., 2011). 
Despite the fact that AEDs have been used for many years, the relationship 
between their clinical effects of seizure control and the mode of action are 
still poorly understood (Howard et al., 2011). The principal modes of action 
include membrane stabilization through sodium channel blockage and 
reduced release of neurotransmitters and enhancement of GABA mediated 
inhibition (Howard et al., 2011). It is probably due to this wide range of action 
on different parts of the central and peripheral nervous systems that AEDs 
are used in many other neurological and psychiatric conditions including 
neuropathic pain, mania, anxiety, hiccups, hot flushes, pruritus, spasms, 
trigeminal neuralgia, migraine and restless leg syndrome.  
The design and development of AEDs is subject to the established 
phases of standard clinical trials, but preclinical AED trials are hampered by 
the limited number of relevant animal models of epilepsy. Experimental 
models such the electroshock seizure model, maximal electroshock seizure 
(MES)(Loscher et al., 2013a) test and the pentylenetrazole seizure models in 
mice and rats are only suitable for AED discovery targeted at generalized 
tonic-clonic seizures.  While amygdala kindling is used for AED development 
for partial seizures, the genetic absence epilepsy-prone rat (GAERS) model 
has been employed for genetic generalised epilepsy (Loscher et al., 2013a).  
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Figure 1. Timeline of antiepileptic drugs approval by the USA Food and Drug 
Administration in the USA and outside of the USA. +Date of approval outside 
of the USA  
(figure reproduced from (Cavalleri et al., 2011) 
 
1.2.1. Drug resistant epilepsy  
About a third of people with epilepsy do not respond well to the AEDs 
that are currently available and have what is frequently referred to as “drug 
resistant epilepsy” (or “refractory” epilepsy) (Loscher et al., 2013a, Herranz, 
2006, Arroyo et al., 2002, Kwan and Brodie, 2000). The International League 
Against Epilepsy (ILAE) recently defined this as epilepsy “….in which the 
seizures are not controlled after having correctly taken two appropriate and 
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well tolerated anti-epileptic drugs…..”(Sanchez-Alvarez et al., 2012). OR 
“The failure of adequate trials of two tolerated, appropriately chosen and 
used anti-epileptic schedules (whether as monotherapies or in combination) 
to achieve sustained seizure freedom.” (Kwan et al., 2010). Study in animal 
models of resistance indicates that compared to AED resistant animal 
models, the AED resistant animals had higher frequency of seizures prior to 
the commencement of AEDs, psychopathology, and hippocampal lesions in 
addition to the alterations in AED targets and transporters (Loscher et al., 
2013a). In patients with DRE the introduction of successive AEDs after the 
second AED yields diminishing returns in terms of additional proportion of 
patients that achieve seizure control (Kwan and Brodie, 2000) . While about 
50% of patients will be seizure free on the first AED, addition of a second 
AED will result in an additional 10 – 15% seizure freedom while the 
introduction of a third and subsequent AED will only result in additional 3 – 
5% seizure freedom (see figure 2 below).  Even in those patients with severe 
forms of epilepsy, being treated with multiple AEDs, debilitating ADRs are a 
great impediment to seizure control as it is difficult to achieve full effective 
doses, and compliance with therapy is poor as a result (Perucca and Gilliam, 
2012, Sanchez-Alvarez et al., 2012). This group of patients therefore bear 
the combined burden of uncontrollable seizures and severe ADRs resulting 
from the use of multiple AEDs (Perucca and Gilliam, 2012, Perucca and 
Meador, 2005).  
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Figure 2: Diminishing returns of seizure freedom from addition of subsequent 
AEDs 
Patients with DRE can be tried on a ketogenic diet. Epilepsy has 
been treated with fasting and other dietary measures since the year 500 BC 
(Wheless, 2008). However, the ketogenic has been in use since the 1920s 
when Wilder and Peterman, two paediatricians at the John Hopkins 
University, postulated that starvation which results in ketosis resulted in 
improved seizure control (Wheless, 2008). Its use dropped after AEDs were 
initially discovered, but there has been resurgence in its use in the last 15 – 
20 years (Rogovik and Goldman, 2010). Randomised controlled trials (RCTs) 
have demonstrated the efficacy of the ketogenic diet in the reduction of 
intractable childhood epilepsies (Neal et al., 2008, Neal et al., 2009). The 
classical ketogenic diet is a high-fat (80%), low-carbohydrate (5%) and 
normal-protein (15%) regime. Other types of ketogenic diets include the 
medium chain triglyceride (MCT) oil which is low in carbohydrate, modified 
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ketogenic (Atkins) diet and the use of foods with low glycaemic index 
(Haberlandt et al., 2013, Klepper and Leiendecker, 2013, Liu and Wang, 
2013).  The ketogenic is typically used in drug resistant childhood epilepsies, 
in children whose epilepsy syndrome is not amenable to surgery, in those 
with Dravet syndrome and myoclonic astatic epilepsy (Rogovik and Goldman, 
2010, Wang and Lin, 2013). In those with glucose transporter 1 (GLUT1) and 
pyruvate dehydrogenase deficiency treatment with ketogenic diet is life-long 
(De Giorgis and Veggiotti, 2013). Although, this diet is poorly tolerated in 
adults compared with children but it is suitable for in all ages. This diet should 
however be avoided in patients with the following metabolic and organ 
system disorders: porphyria, fatty acid oxidation defect, pyruvate carboxylase 
deficiency, kidney disease, severe malnutrition, severe gastro-oesophageal 
reflux and pancreatitis (Wang and Lin, 2013). In addition to performing 
metabolic screen prior to the initiation of therapy, patients metabolic profile 
are usually monitored at six-monthly intervals and supplementation with 
multivitamins calcium, vitamin D and trace elements might be required(Neal 
et al., 2012).  
Surgical procedures are also an option for patients with DRE. The 
most common paediatric epilepsy surgical procedures are temporal and 
frontal lobectomies, for children with cortical malformations (Jadhav and 
Cross, 2012, Harvey et al., 2008). Other procedures include 
hemispherectomies and multilobar procedures. Children who are unsuitable 
for resective surgical procedures may benefit from either a callostomy or the 
implantation of a device stimulating the vagus nerve (Jadhav and Cross, 
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2012, Harvey et al., 2008). Seizure freedom rates of up to 80% have been 
achieved in some selected cohorts of patients who had undergone 
hemispherectomies or multilobar procedures (Jadhav and Cross, 2012). In 
addition to seizure freedom, improved seizure control could be achieved in a 
variable proportion of candidates depending on the causative lesion (Engel, 
1996). A randomised controlled trial of anterior temporal lobectomy surgery 
versus medical treatment in 80 patients with temporal lobe epilepsy clearly 
demonstrated the superiority of surgical treatment over medical treatment in 
this condition at the end of the first year of follow up (58% of those that 
underwent lobectomy were seizure free compared to 8% of medically treated 
patients) (Wiebe et al., 2001).  
The success of epilepsy surgical procedures depends on three main factors: 
early referral to a specialised epilepsy surgical unit; the nature of the lesion 
and; the completeness of the resection of the seizure focus (Jadhav and 
Cross, 2012, Tonini et al., 2004).  
Other positive prognostic factors are febrile seizures, mesial temporal 
sclerosis, tumours and concordance between EEG and MRI (Tonini et al., 
2004). The negative predictors of successful epilepsy surgery include the 
presence of post-operative electroencephalographic (EEG) discharges and 
the use intracranial monitoring prior to the procedure (Tonini et al., 2004). A 
dedicated epilepsy surgery team is vital to the success of epilepsy surgery in 
suitable candidates. 
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1.2.2.  Adverse reactions associated with antiepileptic drugs 
An adverse drug reaction (ADR) is defined by the WHO as “ a 
response to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease or 
for modification of physiological function.” (WHO, 1972). ADRs have been a 
factor in epilepsy treatment since the introduction of bromide (the first AED) 
more than160 years ago. However, it is only in recent years that there have 
been efforts to define, quantify and address the importance of ADRs in 
epilepsy care (Perucca and Gilliam, 2012). 
The consequences of ADRs include early discontinuation of 
treatment in about 25% of the patients. ADRs impede the attainment of 
optimal doses and may lead to poor treatment compliance (Cavalleri et al., 
2011). ADRs are also associated with increased disability, morbidity and 
mortality. ADRs not only increase the burden on health care use but also 
increase health care costs (Perucca and Gilliam, 2012, Perucca and Meador, 
2005). In a study of 767 adult and paediatric patients with epilepsy, 
Buchanan (1992) identified 155 different ADRs (the majority being 
pharmacodynamic in nature) in 134 of the patients (Buchanan, 1992). The 
withdrawal and replacement of the offending AEDs was the most common 
management approach (Buchanan, 1992).  
The ideal AED controls seizures without any associated ADR. This 
does not seem to exist in clinical epileptology as all the AEDs in current use 
have associated ADRs (Cavalleri et al., 2011). While some of the ADRs are 
mild and could be ignored, others are severe or even life-threatening.  
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ADRs associated with AEDs can be classified according to the 
affected organ or system, severity, associated symptoms, frequency of the 
ADR or according to the pathophysiological mechanism (Perucca and 
Gilliam, 2012). Five distinct biological classes have been proposed by 
Perucca and Gilliam (2005). These are   
(i) sleep, mood and emotion, 
(ii) cognition and coordination,  
(iii) weight and iv) cepalalgia and  
(iv) tegument and mucosa.  
Other classification systems have also been used including the WHO 
classification and the classification of ADRs into CNS, Non-CNS 
manifestations and hypersensitivity (Cavalleri et al., 2011, Perucca and 
Meador, 2005, Perucca and Gilliam, 2012). Table 1 illustrates the type and 
frequency of the common CNS, non-CNS and hypersensitivity ADRs of the 
commonly prescribed AEDs. 
Many factors, including genetic variation, are thought to play an 
important role in the development of AED-induced ADRs (Holmes, 2002 , 
Cavalleri et al., 2011). The trial-and-error method of AED selection currently 
being employed by the physicians to determine the most effective AED is 
contributing to the incidence of treatment failures and AED-induced adverse 
effects (Yoshida et al., 2011). It is hoped that pharmacogenomic testing 
would reduce the incidence of these events.  
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Table 1.CNS and non-CNS side effects of common and non-CNS side 
effects of common anti-epileptic drugs 
Drug Non-CNS ADRs  CNS ADRs 
Carbamazepine Nausea, vomiting, diarrhoea, hyponatremia, rash, pruritus Drowsiness, dizziness, blurred or double 
vision, lethargy, headache 
Clobazam Increased salivation, nausea, vomiting, constipation Somnolence, aggression, irritability, ataxia, 
insomnia 
Ethosuxamide Nausea, vomiting Sleep disturbance, drowsiness, 
hyperactivity 
Ezogabine Nausea, fatigue, change in colour of urine, dysuria, 
urinary hesitancy, weight gain 
Dizziness, somnolence, confusion, vertigo, 
blurred or double vision, tremor, abnormal 
coordination, inattention, memory 
impairment  
Felbamate Nausea, vomiting, anorexia, weight loss Insomnia, dizziness, headache, ataxia 
Gabapentin Weight gain Somnolence, dizziness, ataxia 
Lacosamide Nausea, vomiting, fatigue Ataxia, dizziness, headache, diplopia 
Lamotrigine Rash, nausea, blood dyscrasias, rash Dizziness, tremor, diplopia 
Levetiracetam Infection,  Fatigue, somnolence, dizziness, agitation, 
anxiety, irritability, depression 
Oxycarbazepine Nausea, rash, hyponatraemia Sedation, headache, dizziness, vertigo, 
ataxia, diplopia 
Perampanel Weight gain, fatigue Dizziness, somnolence, irritability, gait 
disturbance, falls, aggression, mood 
alteration 
Pregabalin Weight gain, peripheral oedema, dry mouth Dizziness, somnolence, ataxia, tremor 
Primidone, 
Phenobarbitone 
Nausea, rash Alteration of sleep cycles, sedation, 
lethargy, behavioural changes, 
hyperactivity, ataxia, tolerance, 
dependence,  
Rufinamide Nausea, vomiting, fatigue Dizziness, somnolence, headache 
Tiagabine Abdominal pain Dizziness, lack of energy, somnolence, 
nausea, nervousness, tremor, difficulty 
concentrating 
Topiramate Weight loss, paraesthesia Fatigue, nervousness, difficulty 
concentrating, confusion, depression, 
anorexia, language problems, anxiety, 
mood problems, tremor 
Valproate Weight gain, nausea, vomiting, hair loss, easy bruising Tremor, dizziness 
Vigabatrin Vision loss Drowsiness, fatigue, dizziness 
Zonisamide Nausea, anorexia Somnolence, dizziness, ataxia, confusion, 
difficulty concentrating,  
Depression 
Legend 
CNS – central nervous system; ADRs – adverse drug reactions 
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1.2.2.1. Weight change is an important adverse drug reaction in 
epilepsy treatment  
There is an intricate relationship between obesity and epilepsy 
(Hamed, 2007). While some epilepsy syndromes are associated with obesity, 
some AEDs are associated with excessive weight gain predisposing the 
person so treated to obesity, while other AEDs are associated with weight 
loss (Benson et al., 2010) (see Table 2 below). Indeed, weight change is one 
of the most common ADRs associated with AED therapy (Pickrell et al., 
2013). In some people with epilepsy AED-associated weight change is a 
treatment-limiting problem in the management of their epileptic seizures 
(Ben-Menachem, 2007, Biton, 2003). While weight loss is a major issue in 
growing children and in adults and adolescents with eating disorders, the 
most concerning weight-related ADR is weight gain which has both short 
term and long term personal, social, health and psychological consequences 
(Biton, 2003). Several important AEDs are known to cause some degree of 
weight change (See Table 2 below). Sodium valproate, carbamazepine 
ezogabine, perampanel and pregabalin are associated with weight gain; 
topiramate, felbamate and zonisamide are associated with weight loss (Ben-
Menachem, 2007, Biton, 2003, Zaccara et al., 2013). Lamotrigine, phenytoin 
and oxycarbazepine are considered weight-neutral AEDs (Biton, 2003).  
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Table 2: Effects of commonly  prescribed AEDs on weight 
Weight gain AEDs Weight neutral AEDs Weight loss AEDs 
Sodium valproate Lamotrigine Felbamate 
Gabapentin Levetiracetam Topiramate 
Pregabalin Phenytoin Zonisamide 
Vigabatrin   
Carbamazepine.   
Ezogabine   
Perampanel   
   
Legend: AEDs – Anti-epileptic drugs 
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1.2.2.2 Do clinical predictors of antiepileptic drugs-associated weight 
change exist?  
Since weight-associated ADRs are associated with a high degree of 
treatment failure, and long-term morbidity, the clinical prediction of these 
ADRs would be of great value to both physicians and patients with epilepsy. 
Several clinical predictors of AED-induced weight change have been 
investigated by several authors in recent years. Although such factors as 
gender, body mass index at the initiation of therapy, neurocognitive status 
and primary generalized seizure type have been suggested from the results 
of different studies of valproate induced weight change, none of these have 
been consistently replicated (Egger and Brett, 1981a, Novak, 1999, Corman 
et al., 1997, Egger and Brett, 1981b, El-Khatib, 2007, Wirrell, 2003). 
Pregabalin induced weight gain appears to be dose related (Arroyo et al., 
2004, Stephen et al., 2011). While AED-induced weight loss also appears to 
be dose-related, in addition, baseline BMI seems to be predictive of this ADR 
in patients exposed to either topiramate or zonisamide (Ben-Menachem et 
al., 2003, Gilliam et al., 2003, Arroyo et al., 2005b, Privitera et al., 2003, 
Reife et al., 2000, Wellmer et al., 2009, Gadde et al., 2012a) (See Table 3 
below). A description of some of epidemiology and clinical predictors of 
weight change associated with a sample of commonly used AEDs will now 
follow. 
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1.2.2.2.1.  Zonisamide  
Exposure to zonisamide (ZNS) is associated with a mean weight loss 
of 3.7% of the pre-exposure weight in up to 35% of subjects so exposed 
(Wellmer et al., 2009, Gadde et al., 2012b, Guerrini et al., 2013, Kothare et 
al., 2006). This has been demonstrated in a retrospective study involving 
patients older than 17 years with epilepsy and in a randomized control trial 
involving obese adults and paediatric patients with epilepsy where ZNS was 
used for weight reduction. (Wellmer et al., 2009, Gadde et al., 2012b, 
Guerrini et al., 2013, Brodie et al., 2012, Kothare et al., 2006).The main pre-
exposure risk factor for weight loss in ZNS-treated subjects is being 
overweight pre-treatment (Wellmer et al., 2009). ZNS has been used in 
weight reduction programs in obese adults (Gadde et al., 2012b).  
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1.2.2.2.2. Topiramate  
In both randomized double blinded trials and in prospective 
observational studies, between 16% and 86% of subjects exposed to 
topiramate (TPM) for a period of 3 to 12 months experienced some weight 
loss (Gilliam et al., 2003, Arroyo et al., 2005b, Ben-Menachem et al., 2003, 
Arroyo et al., 2005a, Privitera et al., 2003, Reife et al., 2000). Weight loss on 
TPM appears to be more common in children than in adults, and occurs 
within the first 5 months of exposure to TPM (Gilliam et al., 2003, Verrotti et 
al., 2011, Ben-Menachem et al., 2003, Reife et al., 2000). TPM-induced 
weight loss may be sustained for two years after the onset of the ADR (Reiter 
et al., 2004). The degree of weight loss ranges from 3.9%  to 7.3% of the pre-
exposure weight and has been reported to correlate with dose, pre-treatment 
weight, reduced caloric intake, higher baseline BMI and duration of treatment 
(Reife et al., 2000, Sachdeo et al., 1999, Ben-Menachem et al., 2003, Verrotti 
et al., 2011).  However, TPM dose appears to be the only clinical risk factor 
that has been consistently replicated in these studies (Gilliam et al., 2003, 
Arroyo et al., 2005b, Reife et al., 2000, Alberici et al., 2009). TPM has been 
approved as anti-obesity drugs in some countries (Gadde et al., 2012b). 
 
1.2.2.2.3. Pregabalin  
Pregabalin (PGB) is associated with weight gain in about 6 – 16% of 
those exposed to the medication as has been shown in two prospective 
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observational studies, two randomized control trials and a meta-analysis of 
pooled data from 106 studies involving more than 40,000 patients (Stephen 
et al., 2011, Cabrera et al., 2012, Perez-Vicente et al., 2006, Arroyo et al., 
2004, Moon et al., 2010, Ben-Menachem et al., 2003).  Although the baseline 
BMI, PGB dose and duration of therapy have been identified as clinical 
predictors of this ADR, PGB dose and baseline BMI remain the only 
predictors that have been consistent replicated (2012, Stephen et al., 2011, 
Arroyo et al., 2004, Ben-Menachem et al., 2003). See Table 3 below. The 
enhancement of GABA transmission is the main molecular mechanism 
thought to be associated with PGB-induced weight gain (Arroyo et al., 2004). 
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Table 3: Epidemiolgical studies of the effects of anti-epileptic drugs on weight 
AED Direction 
of 
weight  
effect 
% Patients 
showing 
effect 
Study design & references Clinical predictor(s) Observed in 
adults &/or 
paediatric 
subjects? 
VPA Gain 44% Retrospective (Egger and Brett, 1981b) Female gender Paediatric 
VPA Gain 11% Prospective (Novak, 1999) Initial weight z-score  
Initial body mass index 
Paediatric 
VPA Gain 71% Retrospective (Corman et al., 1997)) No history of weight problems 
BMI at initiation of therapy 
Adults 
VPA Gain 44% Retrospective (Egger and Brett, 1981a) None tested Paediatric 
VPA Gain 27% in males 
56% in 
females 
 Prospective, observational (El-Khatib, 
2007) 
Gender (female) 51 males; 55 
females 
VPA Gain 58%  Retrospective (Wirrell, 2003) Weight at initiation 
Neurocognitive status 
Primary generalized epilepsy 
Paediatric 
PGB Gain 11% 
 
Randomised placebo-controlled trial 
(Siddall, 2006) 
None tested Adults 
PGB Gain  7%-
150mg/day 
14%-
600mg/day 
 Randomised double-blinded placebo-
controlled trial (Arroyo et al., 2004) 
 
Dose Adults 
PGB Gain 10% Prospective, observational (Stephen et al., 
2011) 
Dose Adults 
PGB Gain 21%-600mg 
BID 
15%-600mg 
TID 
 
Randomised double-blinded placebo-
controlled trial (Beydoun et al., 2005)) 
None tested Adults 
 
TPM Loss 86% at 1 
year 
Prospective observational (Ben-Menachem 
et al., 2003) 
Baseline BMI Adults 
TPM Loss 15%-200 or 
500mg/day 
Randomised double-blinded trial (Gilliam et 
al., 2003)  
Dose Both 
TPM Loss 69%-
400mg/day 
Randomised double-blinded trial (Arroyo et 
al., 2005b) 
Dose Both 
TPM Loss 12%-
200mg/day 
Randomised double-blinded trial (Privitera 
et al., 2003) 
Dose (suggestive) Adults 
TPM Loss 13%-600-
1000mg/day 
Randomised double-blinded placebo-
controlled trial (Biton et al., 1999) 
Dose (suggestive) Adults 
TPM Loss 
 
13%600-
100mg/day 
Randomised double-blinded placebo-
controlled trial (Reife et al., 2000) 
Dose Adults 
ZNS Loss 35% Retrospective (Wellmer et al., 2009) Weight pre-treatment Adults 
ZNS Loss 55%-
400mg/day 
Randomised double-blinded placebo-
controlled trial (Gadde et al., 2012b). 
 
Dose Adults 
Legend:  
AED – antiepileptic drug; ZNS – Zonisamide; TPM – Topiramate; PGB – Pregabalin; VPA – Valproic acid; gain – weight gain; loss –weight 
loss; * adapted from (Chukwu et al., 2014) 
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1.2.2.2.4. Sodium valproate  
Among the AEDs associated weight gain, valproate (VPA) appears to 
be the most problematic in terms of patient management. VPA therapy is 
associated with weight gain in up to 71% of subjects exposed to the 
medication (Biton, 2003). The weight gain usually occurs within the first 3 
months of initiation of VPA and reaches a peak at 6 months of therapy 
(Demir, 2000). With VPA treatment, about 10% of the patients experience 
weight gains ≥ 10% of the pre-exposure weight.  
Several clinical predictors of this ADR have been studied in both 
adult and paediatric populations. However there has not been any 
reproducible predictor of this ADR in either of the subject groups.   
 
1.2.2.2.4.1 Adult studies of clinical predictors of VPA-induced weight 
change 
Corman et al., (1997) in a retrospective record review and interview 
of 70 adults with epilepsy identified low or normal initial BMI and a lack of 
personal history of weight problems as the two clinical factors predictive 
of this ADR (Corman et al., 1997). However a previous retrospective study in 
63 adults with epilepsy by Dinesen et al., (1984) found no clinical predictors 
(Dinesen et al., 1984). 
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El-Khatib et al (2007) identified female gender as a clinical predictor of weight 
gain in a study of 160 adult patients with epilepsy who have been on 
valproate therapy for at least six months (El-Khatib, 2007) . This retrospective 
study was conducted in the neurology outpatient department of a university 
teaching hospital and was aimed at determining the effects of gender on the 
degree of VPA-associated weight change and carbohydrate craving among 
other things. The result indicated that women were much more likely than 
men to gain weight than men and that the magnitude of weight gain was 
significantly higher in women than in men (El-Khatib, 2007). 
  
1.2.2.2.4.2. Paediatric studies of clinical predictors of Valproate-induced 
weight change 
Several candidate clinical predictors have been identified in children. 
The initial weight z-score and the initial body mass index (BMI) were the two 
clinical predictors identified by Novak (1999) in a retrospective hospital 
outpatient-based study of 55 children with epilepsy aged 1.8 to 16.9 years 
who have been on VPA therapy for 8.6 – 33.8 months. These two 
parameters showed a positive correlation with weight gain in the subjects 
studied (Novak, 1999).  
60 
 
Normal neurocognitive status and primary generalized epilepsy 
type positively correlated with BMI difference in another retrospective study 
by Wirrell (2003) of 43 children with epilepsy aged 10 – 17 years being 
treated with VPA for at least 2 months. Although these two factors did not 
achieve statistical significance in the final analysis both approached statistical 
significance (Wirrell, 2003). 
Duration of therapy was a negative predictor of weight change in 
children with epilepsy being treated with VPA (Sharpe et al., 2009) . In this 
retrospective chart review conducted in a paediatric neurology office 
involving 94 children with epilepsy who were aged between 2 – 20 years who 
have been followed for a period of 4 – 89 months, change in BMI z-score was 
used as a measure of weight change. There was a negative correlation 
between change in the BMI z-score and duration of VPA therapy (Sharpe et 
al., 2009). 
Other studies have failed to identify clear clinical predictors for this 
ADR. For example Demir (2000) in a retrospective study that included 100 
children with epilepsy aged 15 months to 18 years on VPA dose of 30 – 50 
mg/kg/day over a period of 6 months to 5 years using weight velocity as a 
measure of weight change found that neither epilepsy syndrome nor seizure 
control were predictors of this ADR (Demir, 2000, Tanner and Whitehouse, 
1976) .  
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Pre-treatment BMI was not a significant clinical predictor of increased 
BMI in children who became obese while on treatment with VPA in a 
prospective study conducted in a paediatric department of a university 
hospital to determine the incidence and risk factors for the development of 
metabolic syndrome in VPA-treated children. One hundred and fourteen 
children with epilepsy on VPA monotherapy, mean age 10.1 (±4.7) years, 
were enrolled in the study and they were followed up for at least 24 months 
(Verrotti et al., 2010). 
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1.2.2.2.4.3. Studies involving both paediatric and adult patients 
Biton et al (2001) conducted a prospective multicentre double blind controlled 
trial to evaluate the effect of VPA and lamotrigine on body weight in 141 
patients 12 years or older who have been on either medication for less than 
90 days. The predictors of weight gain studied included drug dose, plasma 
concentration and weight at initiation of therapy.  None of these predictors 
correlated with weight change in these patients (Biton, 2001)No clinical 
predictor of weight gain was identified in a case/control study of 88 female 
adults and children (age 6 years to 20 years) with epilepsy. The study was 
conducted in a tertiary endocrine centre in order to determine the effect of 
VPA on growth and weight gain. The two patient groups studied were 45 girls 
who were already on VPA treatment and 43 who were yet to start treatment. 
There was no correlation between the duration of therapy and BMI standard 
deviation score (de Vries et al., 2007).   
In a pooled data analysis of nine open label trials comparing the 
efficacy and tolerability of the delayed and extended release VPA 
formulations in 321 adult and paediatric patients aged between 5 years and 
85 years being treated with medication for either epilepsy or psychiatric 
disorders, Smith et al (2004) observed that weight gain was significantly 
more common with the delayed release, compared to the extended release 
formulation (Smith et al., 2004).  
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No common clinical predictor has been consistently observed in adult 
and paediatric studies. However, this observation is qualified by the fact that 
it is difficult to compare across studies, due to the variety of study designs 
applied. For example, groups have used different measures of weight change 
(BMI z-score, weight velocity, BMI difference, weight for age z-score. Also 
many of these paediatric studies involved heterogeneous age groups and 
studied different clinical parameters. 
 
  
1.2.2.2.4.4 Mechanism underlying VPA-induced weight gain 
The mechanisms underlying VPA-induced weight gain are poorly 
understood.  This might be attributable to the broad spectrum nature of this 
medication which affects many biochemical pathways (Johannessen, 2000). 
While this wide range of effects may have some clinical benefit (VPA is also 
used for bipolar disorder, neuropathic pain, and migraine) it has contributed 
to the difficulty in understanding both its mechanism of action and the 
mechanism of its side effects (Johannessen, 2000).  
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An association between VPA therapy, hyperinsulinaemia/ insulin 
resistance and weight gain has been observed, although the causal 
mechanism is not well understood (Verrotti et al., 2009a, Pylvanen et al., 
2002) (see Table 4 below).  Hyperinsulinaemia is associated with 
hyperleptinaemia in children with VPA-induced weight gain (Verrotti et al., 
2009a, Pylvanen et al., 2002).   Direct stimulation of the β-cells of the 
pancreas and suppression of peripheral insulin uptake are the two main 
mechanisms VPA cause hyperinsulinism and insulin resistance (Verrotti et 
al., 2009a). VPA also interferes with hepatic insulin metabolism leading to 
hyperinsulinaemia without concomitant increase in the serum C-peptide 
levels (Pylvanen et al., 2006).  VPA also Inhibits of GLUT-1 activity in normal 
astrocytes and fibroblasts resulting in reduced glucose transport (Vorbrodt et 
al., 2005).  
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Table 4: Proposed mechanism of valproate-induced weight gain  
AED Molecular mechanism 
Sodium Valproate GABA stimulation of the hypothalamus: Increased (Demir, 
2000, Breum et al., 1992, Biton et al., 2003)) 
Sodium Valproate Hyperinsulinism and insulin resistance (Demir, 2000, 
Isojarvi et al., 1998, Verrotti, 2002, Pasquali and Casimirri, 
1993);  
Sodium Valproate Hyperleptinemia and leptin resistance (Verrotti et al., 
1999a, Verrotti, 2002, Reiterer et al., 1999, Considine, 
2005). 
Sodium Valproate Leptin, ghrelin and adiponectin (Diez and Iglesias, 2003, 
Gil-Campos, 2004, Greco, 2005) 
Sodium Valproate Increased serum level of GLP-1 (Martin et al., 2009) 
Legend: 
AED – antiepileptic drug; GABA – gamma aminobutyric acid 
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1.3. What I set out to achieve:  
This study sets out to test the hypothesis that specific ‘clinical’ factors 
and genetic variants influence the degree of VPA-induced weight change.  By 
‘clinical’ factors I refer to patient-specific factors (age, gender, weight centile 
at initiation) and treatment-specific factors (max VPA dose, serum level, 
duration of therapy) (see Experimental Chapter 1 section 2.9.3 for full 
description of the phenotypes).  
In terms of genetic variants, I have chosen to focus on a series of 17 variants 
that have previously been shown to associate robustly with BMI in a healthy 
population. As a sub-hypothesis, the study sets out to determine whether the 
effect size (in terms of weight) of these 17 variants changes, when 
considered in the context of VPA exposure (see Table 20 in the Experimental 
Chapter 2 for a full description).  
These questions were addressed by recruiting and studying 251 
paediatric patients on VPA for at least six months, for whom retrospective 
data was extracted and stored in an electronic database. A comprehensive 
set of VPA response phenotypes and clinical details were obtained from each 
participant. This resource was used to explore various ‘clinical’ factors 
influencing the VPA-induced weight gain. The first 218 children recruited into 
the study were genotyped against the top 17 SNPs associated with BMI 
changes in the general population.  
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While Experimental Chapter 1 will focus on the clinical predictors of VPA-
induced weight change, Experimental Chapter 2 will be focused on 
identifying the genetic predictors. 
It was hoped that this work might help further personalise epilepsy 
care in patients (children in particular) being treated with VPA by minimizing 
the occurrence of this ADR and maximizing the potential benefits of the 
treatment for suitable patients. In addition to this, understanding the 
molecular mechanism of VPA-induced weight gain might enhance the 
scientific understanding of the contribution of genetic factors to obesity in the 
general population.  
 
. 
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Chapter 2:  Experimental Design and Methods 
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2.0. Experimental Design and Methods 
2.1. Ethics Approval 
Ethics approval for this study was granted separately by the research 
ethics committees (REC) of the three institutions involved. Initial ethics 
approval was granted by Our Lady’s Children’s Hospital Crumlin (OLCHC) 
(REC Reference Number: SAC/114/08 and the Children’s University Hospital 
(CUH) Temple Street Ethics Committees (Ethics Protocol Number 08.014) 
(see Appendix 4). An expedited ethics approval was then granted by the 
REC of the National Children’s Hospital (NCH) Tallaght (REC Reference 
Number 2011/08/08) on the basis that the project had already being 
approved by the REC of the other two hospitals (see Appendix 4). 
 
2.2.    Funding 
Funding for this project was provided by the Children’s Medical 
Research Foundation (CMRF) through the National Children’s Research 
Centre (NCRC) located at OLCH Crumlin, Dublin 12 Ireland (NCRC, 2013, 
CMRF, 2013). The NCRC provided stipend and college fees for the principal 
researcher while the RCSI provided laboratory support through the Epilepsy 
Research Program. 
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2.3. Overall study aim: 
To identify clinically relevant predictors (environmental and/or 
genetics) of VPA induced weight change. 
  
2.4. Study design 
We recruited paediatric patients through outpatient clinics and 
paediatric wards at OLCHC, CUH and NCH. This was a retrospective, cross-
sectional study. There was however an observational, prospective element. 
 
2.5. Objectives 
We identified the following specific objectives to achieving our overall 
study goal: 
i. To identify and recruit in to the study, 250 paediatric patients with 
epilepsy who been exposed to valproate for at least six months. 
ii. To record and database high quality clinical phenotypes in these 250 
patients. 
iii. To execute genotyping of all participants against the 17 SNPs that has 
been robustly associated with changes in BMI. 
iv. Using the phenotypic and genetic resources, to analyse for 
environmental and genetic risk factors influencing valproate induced 
weight change. 
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The following sections will explain in details the rationale for the study 
objectives outlined above. 
 
2.5.1. Task 1: To identify and recruit in to the study, paediatric patients 
exposed to valproate 
Rationale:  The 250 participants we aimed to recruit seemed a 
reasonable target given the size of the patient population in the three 
institutions involved in the study. Further, this number was adequately 
powered to detect the phenotypic and genetic factors that would explain 
some of the variations in the patterns of weight change in these individuals 
(see Section 2.10 for sample size and power calculation).  
2.5.2. Task 2: To prepare high quality treatment phenotypes in 
participants 
Rationale: Collecting and storing clinical information relating to 
weight change in the study participants is a critical component of this study. 
Growth in healthy children is natural and predictable. As a result, data on the 
expected natural growth have been collected in different populations over the 
years. From these data, epidemiologists have constructed ‘growth centile 
curves’ which are routinely used by paediatric health care professionals, to 
monitor growth and development over time. These centile charts are 
regularly revised and updated to account for secular changes in growth 
patterns (Wright et al., 2013, Rao and Simmer, 2012, Grummer-Strawn et al., 
2010, Perry et al., 2009).  
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In Britain and Ireland, Hoey et al (1987) developed a standard centile 
chart based on data generated from the normal growth patterns in a cross 
sectional survey of 3,509 healthy Irish children between the ages of five  
years and nineteen years from varying geographical and socio-economic 
backgrounds. (Hoey et al., 1987). Prior to this survey study, there was no 
growth charts for Irish children beyond the newborn period (Hayes et al., 
1983). Using the cross-sectional data and information from longitudinal 
studies, a longitudinal tempo-conditional growth chart for weight and height 
was constructed for children between 2 years to 18 years old. The method 
adopted for constructing the growth chart was similar to that adopted by 
Tanner and Davis (1985) in constructing similar growth standards for North 
American children ((Tanner and Davies, 1985). The main deficiency of the 
growth standard developed by Hoey et al (1987) is the lack of growth data on 
Irish children below the age of two years (Hoey et al., 1987). Hence current 
growth standard used for Irish children below the age of two years is not 
based on locally derived data (FSAI, 2011). 
Paediatric health care providers measure and plot the weight and 
height of each child, at every clinic visit, as part of routine paediatric care. 
Deviations from the predicted growth curve might necessitate further 
evaluation and possible intervention to return the growth trajectory to the 
desired path (Panpanich and Garner, 2000).   As a result of this long-
established ‘standard care’ procedure, VPA-induced weight gain can 
theoretically be identified as a deviation over and above the child’s natural 
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growth curve. In this context, we recorded the following parameters on each 
participant: 
i. All weight and height measurements taken prior to and within the 
first twelve months after the commencement of VPA 
ii. A range of syndrome and treatment response related phenotypes  
(see Appendix 6) 
 
2.5.3.  Task 3: To execute genotyping in all participants 
Rationale: The completion of the HGP in 2003 led to great advances 
in the knowledge of human genetic variations (Sabeti et al., 2007). In 
addition, the HapMap Project catalogued this information in a manner that 
allowed the natural redundancy in the human genome to be characterized. 
The development of Genome Wide Association Studies (GWAS) has 
provided a framework for the study of the role of common genetic variations 
in obesity.  As of January 2013, over 13 GWAS studies have been published 
on weight-related phenotypes. The largest of these studies contained data on 
over 249,000 individuals, leading to the robust association of 32 loci with 
weight.  Loci including Fat mass and obesity-associated protein gene (FTO), 
Melanocortin 4 receptor gene (MC4R), and Ets Variant 5 gene (ETV5) had 
previously been identified whilst others like G protein-coupled receptor, family 
C, group 5, member B (GPRC5B), Serine/Threonine Protein Kinase 
(TNNI3K), Protein kinase D1 (PRKD1) were novel (Speliotes et al., 2010).  
However, despite the size of the study, the 32 loci identified together only 
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account for 1.45% of inter-individual variations in BMI, the largest locus-
specific effect coming from FTO (0.34%).  In all, about 52 loci for obesity 
traits have now been discovered through GWAS.   These have only modest 
effect sizes with odd ratios (per allele) of between 1.2 and 1.5 (Farooqi, 
2013).  However, the genes so far identified may provide insights into the 
biology of obesity in humans. This study sets out to test the influence of the 
top 17 SNPs robustly associated with BMI on valproate-induced weight 
change. 
  
2.5.4.  Task 4: To identify the environmental and genetic risk factors 
influencing valproate induced weight change 
Rationale: The analysis of the phenotype data collected in the 
second milestone will allow for the exploration of the ‘environmental’ factors 
influencing valproate-induced weight change. Any relevant ‘environmental’ 
factors will then be applied as co-factors in the identification of the genetic 
factors influencing this ADR. The participants will be genotyped against the 
17 top SNPs associated with BMI changes (Skol et al., 2006). Correction for 
multiple testing in the 17 top SNPs will be done using Bonferroni correction 
(Hendricks et al., 2013, Rice et al., 2008, Rao and Gu, 2001).  
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2.6.    Recruitment centres 
The participants were recruited from the three separate specialized 
paediatric epilepsy tertiary referral centres in Dublin namely Our Lady’s 
Children’s Hospital in Crumlin (OLCHC), the Children’s University Hospital 
Temple Street (CUH) and the National Children’s Hospital Tallaght (NCH). In 
these three hospitals paediatric neurologists (Drs David Webb, Anthony 
Bouldin, and Blathnaid McCoy at OLCHC; Drs Mary King and Brian Lynch at 
CUH; Dr David Webb at NCH) run once- (NCH) to twice- (OLCHC and CUH) 
weekly paediatric neurology clinics where children (from 0 to 18 years) with 
epilepsy and other neurological conditions are managed (see Appendix 5 for 
the full contact details of the collaborators). In addition, children presenting 
with acute neurological conditions including epilepsy are admitted to the 
hospitals for further management by the neurologist in conjunction with other 
paediatric specialists. Dublin and adjoining towns are the primary catchment 
areas for these hospitals, however children with difficult to treat epilepsies 
are referred from other towns and cities in Ireland. The children in this study 
were mainly Irish children of male or female gender with epilepsy who were 
between the ages of 2 years and 18 years at the time of recruitment.  
 
2.7.   Inclusion criteria 
Potential participants satisfied the following inclusion criteria:  
i. Age: between 2 and 18 years at the time of recruitment 
ii. A diagnosis of epilepsy, defined as recurrent, unprovoked seizures. 
76 
 
iii. On valproate therapy for a continuous period of at least 6 months 
at some point in their clinical history. 
iv. Have records of weight at the time of  initiation of valproate therapy 
and at least one other point within 12 months of initiation of 
valproate therapy;  
v. Must be attending any of the three paediatric hospitals in Dublin 
participating in this study, within the study period (between June 
2008 and June 2013. 
 
2.8.   Exclusion Criteria 
Those excluded include: 
i. Patients with known chromosomal abnormalities that might affect 
growth (e.g. Down’s syndrome) 
ii. Children on nasogastric (NG) or percutaneous gastro-enterostomy 
(PEG) feeds. 
2.9.   Recruitment 
 2.9.1.  Ethical considerations  
The ethical issues involved in this research project included: 
confidentiality, protection of personal clinical and genomic information, 
reduction of pain and discomfort, informed consent and truthful presentation 
of research findings. Respect, beneficence and justice which are the basic 
principles governing research in human subjects as contained in the 
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Declaration of Helsinki guided this work(Bosnjak, 2001). Confidentiality and 
anonymity were maintained by ensuring respect for the privacy of personal 
information. Both clinical and laboratory information were rendered 
anonymous by developing study codes that de-identified the individual once 
the clinical and laboratory information left the paediatric hospital. Keys to 
these codes were only known to the principal researcher and the principal 
investigator. Prior to enrolment into the study a written informed consent was 
obtained from all the participants (see Appendix 8). While parents of children 
who were younger than 16 years signed the consent form on their children’s 
behalf, those children who were older than 16 years signed the consent 
themselves but in addition required parental permission to proceed with the 
study. Informed consent was obtained by explaining the research process to 
the participants; providing them further information which was contained in 
the participants’ information leaflet (PIL) (see Appendices 7 and 8); 
answering their questions and finally by ‘negotiating permission to do’ the 
study (Blaxter et al., 1996). Although children who gave blood samples might 
have experienced some mild to moderate physical pain as a result, this was 
alleviated as much as possible by informing them prior to the procedure 
about what to expect and providing some pain relief in the form of topical 
anaesthetic cream or spray. As much as possible blood sampling was only 
undertaken if the child was getting blood tests done for some other clinical 
indications. No undue suffering was inflicted on any of the participants. Some 
humane clinical judgement was exercised by the researcher in participants’ 
selection thus seriously ill children in the intensive care unit (ICU) were not 
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approached. The findings in this study have been presented truthfully 
(Blaxter et al., 1996).  
 
2.9.2.   The recruitment process 
The study employed convenience sampling as potential participants 
were recruited from among the children who attended the neurology clinic or 
who were admitted to the paediatric ward. Since there was no sampling 
frame, no form of randomization was employed.  
In order to identify children who fulfilled the inclusion criteria, the 
principal researcher conducted a brief review of the case notes of the 
potential participants on a clinic day or on the ward. The parents of children 
meeting the study criteria were approached and informed of the study by 
either the principal researcher or any of the other members of the neurology 
team according to guidelines set out in the relevant ethics protocols (See 
Ethics approval section 2.9.1 above). The purpose and details of the study 
were explained to the parents and their children. Then the parents and 
children were provided with the participants’ information leaflet (PIL) and 
written consent statement (see Appendices 7 and 8). They were allowed time 
to study the PIL and the consent form.  Further clarifications regarding the 
study were provided by the principal researcher or the recruiting staff. 
Questions regarding the aspects of the study were treated accordingly to the 
satisfaction of the participants. If the parents and the children were satisfied 
with the provisions of the study and were freely willing to participate in the 
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study they would be invited to sign the written informed consent form. The 
recruiting staff then collected information from the child and the parents and 
from the case notes using the case report form (CRF – see Appendix 6). A 2 
ml saliva or 5 ml blood sample was collected from each participant. The 
saliva was collected using Oragene DNA collection kits [Oragene DNA OG-
500 for saliva collection; Oragene DNA OG-575 or Oracollect OCR-100 for 
buccal swab collection](DNA Genotek Inc, 2013). If the child is too young to 
spit saliva either 5ml blood sample in EDTA tube was collected or an oral 
swab  was taken [Oragene DNA OG-575 or Oracollect OCR-100 for buccal 
swab collection](DNA Genotek Inc, 2013). DNA was extracted from these 
samples and stored at the Royal College of Surgeons in Ireland (RCSI) 
Biobanking facility at the Beaumont Hospital Dublin. 
2.9.3.   Phenotype collection and storage 
  A secure Microsoft Access database was designed to store the 
participants’ phenotype information in line with the criteria set by the relevant 
ethics committees (see the Ethical consideration in Section 2.9.1 above). 
Criteria was set for each phenotype (e.g. definition of each seizure type etc. 
according the International League Against Epilepsy (ILAE) classification of 
epilepsy syndromes prior to initiation of recruitment to allow for consistent 
phenotype assignment (ILAE, 1989). By accessing traditional hard copy 
patient records and by participants’ questionnaire, the following clinical 
information was recorded for each participant: 
The following information was derived from the subjects’ medical records:  
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i. Basic information – name, date of birth, gender and contact number  
ii. Epilepsy Syndrome covering the 5 axes of classification (semiology, 
seizure types, syndrome classification, aetiology, co-morbidities)(ILAE, 
1989); 
iii. Clinical interpretation of the electroencephalogram (EEG) and 
neuroimaging data. The recording of the EEG report in the CRF 
indicated whether the EEG was supportive, unsupportive or unhelpful 
in the diagnosis of epilepsy. Neuroimaging included magnetic 
resonance imaging (MRI) or computed tomography (CT) of the brain. 
The neuroimaging details recorded in the CRF indicated whether the 
MRI was ‘non-lesional’ in which case the MRI was normal; ‘lesional’ in 
which case a well-defined abnormality involving a limited portion of the 
brain was reported ‘global’ in a case where the abnormality in the 
brain imaging was generalized. In addition, a detailed entry on the 
abnormalities in the neuroimaging and EEG was made in the free text 
sections of the CRF (see Appendix 6). 
iv. Information on valproate therapy – start date, finish date, maximum 
dose, serum levels if available (see Appendix 6). 
v. Data on polytherapy – names and doses of AEDs co-administered 
during valproate therapy; the commencement and discontinuation 
dates of the co-administered AEDs (see Appendix 6). 
vi. Data relevant to weight change – all measurements of weight and 
height and plotting these on centile charts(see Appendix 6);   
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vii. Medical history – birth history, neonatal problems (including the 
presence or absence of perinatal hypoxia and hypoxic ischaemic brain 
insult, neonatal seizures, hypoglycaemia and other perinatal 
problems), abnormalities in development, history of febrile seizures, 
head trauma or CNS infection, and other medical diagnoses.  
The following information was derived from parents’ and/or the 
children’s reports (investigator administered questionnaire, see Appendix 6): 
i. Family history of obesity – the parents and children were asked 
whether there was any family member with weight problems which 
includes overweight and/or obesity. These were dichotomous ‘yes’ or 
‘no’ options. If the child had a family history of weight problems the 
degree of relationship to the family member with this problem was 
enquired into – i.e. whether it was a first degree, second degree or 
third degree relative (see Appendix 6). 
ii. Activity level – parents were asked about the children’s activity level. 
Activity level was classified in the questionnaire into four categories: 
zero, low, normal or high. This was a subjective grading of the 
children’s perceived activity level. (See Appendix 6). 
iii. Mobility level- the child’s mobility level was graded into three 
categories which were: normal activity, impaired activity, and 
wheelchair bound. Information for completing this phenotype was 
gathered using a combination of the researcher’s observation, 
information volunteered by the parents or information gathered from 
the medical notes. (See Appendix 6). 
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iv. Special diet – parents were asked whether their children were on any 
special diet. The initial response options were dichotomous ‘yes’ or 
‘no’. Parents whose children were on special diets were asked to give 
details of the type of special diets their children were on. (See 
Appendix 6). 
 
2.9.4.   The Database 
The Microsoft Access database for holding the phenotypic 
information was designed by a statistician based at the RCSI on the 
Microsoft Access 2007 platform (see Appendix 3) (Microsoft, 2013).The 
information on the case report form (see Appendix 6) was made use of in 
designing the database. It consisted of five sections: the bio data, epilepsy 
history, VPA specific history, weight and height information and other patient 
information (see Appendix 6 and the Phenotype Collection and Storage 
Section 2.9.3 above). The text data collected were linked to database codes 
to allow for easy transformation of data and integration with data analysis 
software such as Microsoft Excel and International Business Machine (IBM) 
Statistical Package for Social Sciences (SPSS)(IBM, 2011)} (see Appendix 
2). The database was robust and secured with a password known only to the 
principal researcher and the principal investigator. The database was 
installed in a password-protected computer located within the NCRC’s facility 
at OLCHC in Dublin.  Data was entered directly from the CRF to the 
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database from Monday to Friday. Data was interrogated at monthly intervals 
to monitor data quality.  
 
2.9.5.   The growth assessment tools 
2.9.5.1.  Clinical growth standard for Irish children 
 Hoey et al., (1987) developed a standard centile chart based on data 
generated from the normal growth patterns in a cross sectional survey of 
3,509 healthy Irish children between the ages of five  years and nineteen 
years (Hoey et al., 1987). From this cross-sectional data and information 
from longitudinal studies, a longitudinal growth standard was constructed for 
children from 2 years to 18 years old. This was supplemented with similar 
data on British children between the ages of five and 19 years in developing 
the Hoey and Tanner growth chart (Hoey et al., 1987).  
 
2.9.5.2.   The WHO multi-centre growth reference for healthy breastfed 
babies. 
This multi-centre growth study was conducted between 1997 and 
2003 and involved a longitudinal follow up of 882 breastfed infants from birth 
to 24 months in six countries representing all the six regions of Africa, Middle 
East, Asia, South America and North America. The longitudinal data was 
combined with data from the cross-sectional survey of 6,669 children aged 
18 – 71 months living in ideal environmental conditions to construct the WHO 
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growth standard for children(de Onis et al., 2009, de Onis et al., 2004) . The 
aim of the project was to develop a single international reference for the 
physical growth of children (de Onis et al., 2004). The data has since been 
expanded to include children over five years old (Turck et al., 2013). This 
standard has been adopted by about 125 countries by April 2011 (de Onis et 
al., 2012). Some countries have not implemented this standard because they 
preferred local growth reference standards (de Onis et al., 2012). 
 
2.9.5.2.1.    WHO AnthroPlus for personal computers 
The WHO AnthroPlus for Personal Computers is a software for 
assessing the growth of the world's children and adolescents, designed and 
developed by  Monika Blössner and colleagues at the WHO’s Department of 
Nutrition for Health and Development, Geneva in Switzerland (WHO, 2009). 
It incorporates both the WHO Child Growth Standards for 0-5 years and the 
WHO Reference 2007 for 5-19 years and thus could be used to monitor the 
growth of children from age 0 – 19 years (Turck et al., 2013). Parameters that 
could be measured using the WHO AnthroPlus include: weight-for-age, 
height-for-age and BMI-for-age, head-circumference-for-age, arm-
circumference-for-age for children between the ages of 0 and 10 years; the 
height-for-age and BMI-for age can be determined in children older than 10 
years. The software has three modules namely: the Anthropometric 
Calculator, the Individual Assessment and the Nutritional Survey (Turck et 
al., 2013). 
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2.9.5.3.   The R code for the prediction of weight for age and weight for 
age centile 
The R code for weight centile prediction was developed by the 
collaborating statistician, Dr Gabor Borgulya. With this function it was 
possible to determine the weight for age centile (WAC) at initiation of therapy 
given the age (in years), gender and weight of the subject at initiation of 
therapy. This WAC becomes the baseline WAC and was assumed to be 
constant in children unaffected children by the VPA induced weight change. 
Using this function it was also possible to determine the expected weight at 
each visit post-initiation of VPA given the baseline WAC. Hence the degree 
of deviation of the observed weight from the expected weight could be 
calculated manually by subtracting the expected from the observed weight.  
This function was developed independently for boys and girls. The 
data used in the development of the code was derived from the original Hoey 
et al 1987 paper (See section 2.9.5.1 above) (Hoey et al., 1987). While the 
data in Hoey’s paper approximated the boys’ centile prediction, it did not 
approximate those of the girls. Various approaches were undertaken to 
smoothen the centile curve including removing or modifying some data that 
were outliers. The smooth interpolation approach of the 3rd, 10th, 25th, 50th, 
75th 90th and 97th percentiles for boys and girls, use of loess model in R 
were some of the approaches used. See Appendix 9 for a full description of 
the method employed in developing the function. 
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2.9.6.      DNA extraction from tissue samples 
The tissue samples used in this study includes whole blood in 
Ethylenediaminetetraacetic acid (EDTA) tube, saliva and oral/buccal swabs. 
The following subsections will detail the method of DNA extraction from each 
of the tissue types. 
 
2.9.6.1. DNA extraction from whole blood 
The 5ml whole blood sample collected in EDTA tube was 
immediately stored in the fridge at 4C at the Children’s Neurosciences 
Centre, Our Lady’s Children’s Hospital Crumlin. These samples were then 
transferred (in batches) for DNA extraction, to the Royal College of Surgeons 
in Ireland Bio-banking facility at Beaumont Hospital, Dublin.  
DNA was extracted from blood using either the manual or the 
automated methods with the aid of the (Qiacube) machine (Model: Qiagen; 
Serial no:10632) (QIAGEN  N.V, 2013). The Qiacube automated sample 
preparation uses spin-column kits (see Appendix 12). 
 
2.9.6.1.1  Manual DNA extraction from whole blood 
Manual DNA extraction from blood followed a two-phase protocol. 
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2.9.6.1.1.1.   Phase 1 
The 5ml whole blood sample in EDTA tube was poured into a 50ml 
universal tube. Standard Laboratory Reagent (SLR) (consisting of 10ml of 2M 
Tris(hydroxymethyl)aminomethane (TRIS) (pH 7.6), 10ml of 1M Magnesium 
chloride (MgCl2), 6.6ml M sodium chloride (NaCl) diluted to a volume of 2 
litres in distilled water) was then poured into the same tube to fill it up to 
capacity. The mixture was left to stand in ice for 15 minutes and then 
centrifuged at 4 degrees centigrade (ºC) at 3500rpm for 15 minutes. The 
supernatant was then poured away while the pellet was re-suspended in 
another 50ml SLR by vortexing. The re-suspended pellet was then 
centrifuged for 10 minutes at 3500rpm at 4 degrees centigrade. The resulting 
supernatant was again poured away leaving the white pellets. To the white 
cell pellets, 3ml of Tris-EDTA 10:1/NaCl (0.4M) was then added. This mixture 
was vortexed until aggregates disappeared. The sample which then 
contained buffy coat was separated into two aliquots labelled A and B. As a 
precaution at least one of the aliquots was stored in the freezer for future use 
(See . Appendix 10). 
 
2.9.6.1.1.2.     Phase 2 
The second phase of DNA extraction form whole blood involved the 
preparation of a Proteinase K buffer solution (1 mg/ml). This was prepared as 
follows: to a 15ml plastic tube was added 1mL of Proteinase K stock solution, 
1mL of 10% sodium dodecyl sulphate (SDS) and 1mL of 0.5M EDTA (pH 8). 
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This was then made up to 10ml with polymerase chain reaction (PCR)-grade 
water.  
Next 500 microliter (µl) of the Proteinase K buffer solution and 200 µl 
of 10% SDS were added to the white blood cell mixture in a tube. The 
mixture was then incubated in a water bath at 65°C for 10 minutes while 
being shaken. The tube was then transferred into an ice/water mix for 10 
minutes. One millilitre (1 ml) of 5 molar sodium chloride (5M NaCl) was 
added to the chilled mixture and it was then vortexed thoroughly. This was 
centrifuged at 3000 rpm for 15 minutes at 4°C. The resulting supernatant was 
then transferred to a 50 ml tube containing 5 ml of isopropanol and 
centrifuged again at 3500 rpm for 15 minutes at 4°C and the supernatant was 
discarded. 
To the pellet, 1ml of 70% ethanol was added and the mixture was 
transferred to a new DNA storage tube which was centrifuged at 10,000rpm 
for 15 minutes. The pellet was left to dry for 30 minutes when the supernatant 
had been discarded. The dried pellet was re-suspended in 1 ml (Tris and 
EDTA) TE buffer. 
2.9.6.1.1.3.    Quantifying the extracted DNA 
Nanodrop spectrophotometer (Thermo Scientific, Wilmington 
USA(Thermo Scientific, 2013) was used to quantify the concentration of DNA 
extracted. This device measures the DNA concentration in the extract by 
comparing the wavelength of ultraviolet light absorbed between 260nm and 
280nm in 1 µl of blank water sample to that of the DNA extract. 
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2.9.6.1.1.4.    Qualifying the extracted DNA 
 To determine whether the extracted DNA is free from protein 
contamination the 260/280 ratio (A260/280) was measured. High quality DNA 
has an A 260/280 ratio greater than 1.8 as this indicates low protein-
contamination. After measuring and recording the DNA concentration and 
quality, the remaining DNA solution was stored in a freezer at -20°C. 
2.9.6.1.2.  Automated DNA extraction from blood 
For the automated extraction of DNA from blood, a Qiacube 
automated sample preparation machine by Qiagen was used. This machine 
uses the buffy coat obtained from phase 1 of the manual process as input 
and extracts DNA using spin columns and reagents from the QIAamp DNA 
Blood Mini QIAcube Kit  (Model: Qiagen; Serial no:10632)  (Qiagen). The 
process is considerably more efficient in reducing hands-on work and 
processing time from whole blood to genomic DNA (See Appendices 10 & 
12).   
 
2.9.6.2.  DNA extraction from saliva 
An Oragene saliva collection kit (Oragene DNA OG-500)  (DNA 
Genotek Inc, 2013) which contains a nucleic acid stabilization buffer allowing 
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a sample to be retained for years in a stable form between collection and 
processing was used for saliva collection. With this kit sufficient quantity of 
DNA could be obtained for most DNA analysis including PCR and Sanger 
sequencing. The main disadvantage of using this kit is the risk of 
contamination of the sample with bacterial DNA from the normal oral flora 
might make the saliva samples unsuitable for GWAS and next-generation 
sequencing due to the sensitivity of the enrichment assays.  
2.9.6.2.1.  Protocol for DNA extraction from saliva 
The protocol for extracting DNA from saliva samples is as follows: 
The 2ml saliva sample collected in the Oragene collection kit is mixed 
with the nucleic acid stabilization buffer immediately after collection by 
inverting and gently shaking the collection tube for a few seconds.  
To ensure adequate DNA release from the sample and permanent 
inactivation of the nucleases, the sample was incubated at 50˚C in a water 
incubator for a minimum of 1 hour.  
The sample volume after incubation was noted before it was then 
transferred with a pipette to a 15mL centrifuge tube.  
A 1/25th volume of Oragene Purifier reagent (DNA Genotek Inc, 
2013) was then added to the tube (for example 200μl the purifier was added 
to a 5ml total sample volume). Mixing was done by vortexing the tube for a 
few seconds before it was incubated immediately on ice for 10 minutes to 
remove impurities.  
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After removal of impurities, the sample was centrifuged at a minimum 
of 2,500 g at room temperature for 10 minutes. The higher the centrifugal 
force, the less the amount of turbid material that will be carried over into 
purified DNA.  
The clear supernatant was then carefully transferred with a pipette to 
a fresh 15 mL centrifuge tube and the pellet was discarded. An equal volume 
of 95-100% ethanol at room-temperature was added and mixed by gentle 
inversion 10 times to the clear supernatant. The sample was then allowed to 
stand at room temperature for 10 minutes to allow the DNA to fully 
precipitate. The sample was then centrifuged for the second time at room 
temperature for 10 minutes at a minimum 2,500g. The supernatant was 
discarded and care was taken to avoid disturbing the DNA pellet. The DNA 
pellet was dissolved in 1 ml of 10x TE buffer (pH 8.0) for rehydration and 
transferred to a 1.5 ml micro-centrifuge tube. The rehydrated DNA was 
centrifuged at room temperature for 15 minutes at 15,000g. The supernatant 
which contained the extracted DNA was transferred to a fresh 1.5 mL micro-
centrifuge tube and labelled. See Appendix 11 for a copy of the protocol.   
A Nanodrop spectrophotometer device (Thermo Scientific, 2013) was 
employed to quantify the DNA extracted. The remaining DNA solution was 
then stored in a -20°C freezer. 
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2.9.7.      KASPTM Genotyping Chemistry by LGC Genomics 
Genotyping of the top 17 top BMI SNPs was carried out at the LGC 
Genomics (Kbio Sciences) Laboratory based at Hoddesdon in the United 
Kingdom. The genotyping assay used was the KASP which was based on 
“…competitive allele-specific scoring of single nucleotide polymorphisms 
(SNPs) and insertions and deletions (indels) at specific loci” (See Appendix 
13). Quality control of the process was carried by the company by testing the 
assays on the company’s in-house validation DNA. The company was able to 
determine when the assays were working well when there are distinct 
clusters and consistently high call rates. Automatic quality control was also 
carried out on a SNP by SNP basis by using no template controls (NTCs) on 
each plate to detect contamination. Callable genotypes are those that are > 
90%.  Chi-squared distribution based on Hardy-Weinberg equation was also 
applied to determine the quality of the genotyped SNPs (Annon., n.d).  
The KASPTM Genotyping involves 35 cycles of PCR initially which 
was then read on BMG PHERA Star plate reader. A visual inspection of the 
plates was also undertaken. The plates were then recycled at 3 cycles per 
recycle, followed by another visual inspection to ensure end point has been 
reached. Automatic genotype calling was done using the company’s in-house 
Kraken software. The data quality was checked and cross checked and any 
errors corrected before being sent to the customer (see Appendix 13). 
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2.10.     Sample Size and Power calculations  
The power of a study may be described as the ability of that study to 
give a statistically significant rejection of the null hypothesis (Evans and 
Purcell, 2012), assuming specific parameters relating to effect size. Overall 
study power depends on the study design, sample size, magnitude of the 
effect to be detected and the false positive rate of the test (Evans and 
Purcell, 2012). Power calculations should be conducted before a study is 
initiated, in order to determine the design and the sample size (in terms of 
study participants) required. Power calculations at the conclusion of negative 
study are useful to determine the detectable effect size given the actual 
sample size used in the study (Purcell et al., 2003). Power in genetic 
association studies is dependent not only on sample size but also a range of 
other parameters which includes (Purcell et al., 2003, Evans and Purcell, 
2012):  
i. the frequency of the risk genotype (i.e. how common it is in the 
population under study); 
ii. the effect size of the risk variant (i.e. the relative risk it confers);  
iii. the genetic model in question (dominant, recessive, multiplicative 
etc.);  
iv. the prevalence of the trait in the population(s) being studied.  
v. The sample size, N 
vi. The statistical significance level, α 
Since the frequency, the genetic model and effect size of the risk 
variant being looked for in our study is unknown it is difficult to accurately 
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estimate the power of this study. The power for this study was therefore 
calculated based on the discrete trait of weight gain due to VPA therapy of 
>5% of baseline weight. This level of weight gain occurs in about half of the 
patients exposed to this medication according to data from previous studies 
(Kanemura et al., 2012, Dinesen et al., 1984, Biton V, 2001, Biton V, 2003). 
Power in the study was calculated using two main approaches: one for 
calculating power and sample size in discrete trait association studies    
(Power for Genetic Association studies (PGA) and the other for calculating 
power in quantitative trait studies. (GWASPower/QT). The steps involved in 
calculating power and sample size in this study are described in the following 
sections. 
2.10.1.  GWASPower/ QT   
The GWASPower/QT is a statistical power calculator for GWAS and 
SNP studies developed by Shenghu Wang and Sheng Feng of the Dukes 
University Durham, USA (Feng et al., 2011).  The power calculator helps in 
estimating the statistical power of detecting SNP associations with  
quantitative traits in natural populations (Feng et al., 2011).It is useful in 
exploratory studies such as our study as the phenotype mean of each marker 
is unknown (Mybiosoftware, 2012). The effect size is inputted as heritability 
measures. The parameters required for calculating power using this software 
include:  
i. The heritability or the effect size of the trait (the proportion of 
the phenotypic variation in the population that could be 
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ascribed to the genetic variation). This is a compulsory 
parameter. 
ii. The sample size is a compulsory input parameter 
iii. The type one error rate is also a required parameter 
iv. The linkage disequilibrium between the SNPs and the genetic 
variant being tested is an optional input,  
v. The number of co-variates and how much of the variance is 
explained by the co-variates (LD). The covariate input is 
optional. (See Fig 4 below).  
The outputs from the GWASPower/QT calculator include a statistical power 
and a set of power curves for each of the SNPs being tested. The figure 
below illustrates the power of study at different effect sizes (Fig 5- below). 
Given the number of SNPs tested and the number of individuals being tested 
what is the power of the study to detect a certain degree of 
variance/heritability? I.e. how much of the quantifiable trait observed (VPA-
induced weight change) is due entirely to genetics as opposed to genetic 
factors? Genetic and environmental factors could have had varying degrees 
of influence on this ADR. It could have been 100% genetic and 0%. It is 
however rare to have a phenotype that is entirely genetic without any 
environmental contribution. The steps in calculating power using the 
GWASPower/QT calculator include: 
1. The GWASPower/QT software was opened 
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2. The number of individuals genotyped (214) was entered. Four 
individuals were excluded from the calculation as their sample did not 
genotype well. 
3. The total number of SNPs (17 SNPs) was entered 
4. The LD value was set at value 1(i.e. the marker correlates 100% with 
the marker. 
5. We assumed there was no covariate so a value of zero was entered. 
6. Power was then calculated at different levels of heritability (variance) 
starting from as low as 0.001(0.1%) to a high of 0.11 (11%).  
7. After entering the values the ‘RUN’ button is pressed and the output 
displayed is the power.  
Eighty percent power, which is considered adequate in GWAS/ SNP 
studies, was achieved at a heritability of about 5.8%. That is, we had 80% 
power to detect a variant explaining 5.8% or more of the trait variability. 
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Figure 3: Screen shot of the PowerGwAS/QT calculator 
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Figure 4: Power calculation using the GWASPower/QT software. The blue 
curve demonstrates the statistical power at different effect sizes (heritability) 
of the 17 SNPs genotyped for in the study. 
 
2.10.2.  Power for Genetic Association Analyses  
The Power for Genetic Association Analyses (PGA) software, - a 
graphical user interphase software developed in the Matlab platform for 
power and sample size calculation in discrete association trait studies, was 
used to determine power of each of the 17 SNPs to detect varying degrees of 
effect sizes or heritability (Menashe et al., 2008, NIH, 2013). The PGA has 
two different types of calculators: the sample size calculator and effect 
size calculator. The sample size calculator is based on having a known 
number of SNPs or sets SNPs and will calculate the number of individuals to 
test in order to detect an association. The second calculator is able to 
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calculate the lowest detectable risk with a given sample size. i.e if the 
number of individuals in the study is known but one needs to determine the 
lowest level of association that could be detected with the available sample 
size. The power of the study to detect increasing effects sizes (using Odds 
Ratios) for each SNP based on the known Minor Allele Frequencies (MAF) in 
the public databases was calculated by assuming a weight gain prevalence 
of 40% in the sample population exposed to VPA. We assumed that the 
disease model was co-dominant i.e. a single carrier could show signs of the 
disease but an individual that inherits two alleles shows stronger signs of the 
disease. The co-dominant model of inheritance carries the least of 
assumptions compared to the dominant and recessive models. A co-
dominant model with two degrees of freedom assumes that there is a 
covariate involved while a co-dominant model with one degree of freedom 
assumes that no covariate is involved. An odd ratio or effect size was 
assumed- this determines the relative risk of the individual with the disease 
allele to manifest the disease. The steps taken in calculating power for each 
of the 17 top BMI SNPs genotyped in this study are as follows: 
i. Based on previous studies it was assumed that the prevalence of 
weight gain in those exposed to VPA was 40%. 
ii. The MAF of each of the 17 SNPs the subjects were genotyped against 
was determined from the dbSNP database (NCBI, 2013). 
iii. A co-dominant model with one degree of freedom was assumed 
iv. A relative risk or odd ratio of 2 was assumed  
v. The linkage disequilibrium (LD) value was assumed to be 1 (100%) 
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vi. The alpha (p) value was set at 0.05 
vii. The control to case ratio was set at 1 (i.e. an equal number of cases 
and controls) 
viii. The maximum sample size was set at 300 
ix. The 'RUN’ button was pressed. 
x. The output for each SNP is illustrated in figure 6 below. 
The PGA 1 was used to calculate the sample size while PGA 2 was 
employed in calculating the effect size. As illustrated in figures 5, at 
80% power the study was powered to detect effect sizes as low as about 1.2 
and anything higher. As shown in figure 7, a sample size of about 100 was 
required to achieve 80% power in one of the 17 SNPs (rs10508503) with the 
lowest MAF of 0.041. For most of the other SNPs sample sizes as low as 50 
was required to achieve 80% power (see figure 6 below) 
It was decided to recruit one and a half times the required minimum 
sample size in the study to allow for children with incomplete data. The study 
therefore set out to recruit 250 children exposed to VPA.  
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Figure 5: Power of each of the 17 BMI SNPs to detect and effect at varying 
relative risks. Each curve represents one of the SNPs.   
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Figure 6: Sample size calculation for some of the 17 BMI SNPs 
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Figure 7: Sample size calculation for the rest of the 17 BMI SNPs 
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Chapter 3: Experimental chapter 1 – clinical 
predictors 
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3.0.   Experimental chapter 1 – clinical predictors 
3.1.  Introduction 
The first stage of analysis focused on identifying environmental 
factors influencing the valproate induced ADR. 
 
3.2.  Valproate  
VPA is a broad spectrum anti-epileptic medication which has been in 
use since 1973 (See Figure 2 above). Its anti-epileptic effect was discovered 
by chance in 1963 as it was being used as a solvent for khellin derivatives 
(Egger and Brett, 1981b, Meunier et al., 1963). It is a branched short chain 
(8-carbon) fatty acid consisting of 2-propylvaleric acid with the chemical 
formula C8H16O2 (Terbach and Williams, 2009, Drugbank, 2005, Egger and 
Brett, 1981a). The chemical structure of VPA is illustrated in Figure 9 below. 
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Figure 8: The chemical structure of Valproic Acid  
(taken from www.drugbank.ca (Drugbank, 2005) 
Figure 8 legend: C – carbon; H – hydrogen; O - oxygen 
 
Valproate products include valproate sodium, valproic acid, divalproex 
sodium and some other generic formulations. VPA is rapidly absorbed from 
the gastrointestinal tract. It is protein bound and displaces fatty acids from 
protein binding sites. It penetrates the blood brain barrier hence its use in 
neurological diseases. The volume of distribution is 11 L/1.73 m2 for total 
valproate and 92 L/1.73 m2 for the unbound valproate. It is completely 
metabolized by the liver and excreted in the urine mainly as a glucuronide 
conjugate (Drugbank, 2005). 
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3.2.1.   Indications for the use of sodium valproate 
VPA is approved for the treatment of tonic-clonic seizures, absence 
seizures, complex partial seizures, and seizures in subjects with Lennox-
Gestaut syndrome (Egger and Brett, 1981a, Dulac et al., 1982). Other 
indications include manic, bipolar mood disorders and for migraine headache 
prophylaxis and treatment. It is also used off label for the treatment of other 
psychiatric and non-psychiatric conditions such as outbursts of aggression in 
children with attention deficit hyperactive disorder (ADHD) and in 
schizophrenia. In combination with highly active anti-retroviral therapy 
treatment, VPA therapy results in 75% reduction in latent human 
immunodeficiency virus (HIV) infection (Lehrman et al., 2005, Drugbank, 
2005).  
 
3.2.2.   Mechanisms of action of sodium valproate  
The mechanism of VPA’s anti-epilepsy action is not fully understood 
(Rosenberg, 2007). It has multiple mechanisms of action including the 
inhibition of gamma amino butyric acid (GABA) transaminase an enzyme that 
catabolises GABA. Inhibition of GABA transaminase results in increased 
brain concentration of GABA - an inhibitory neurotransmitter (Drugbank, 
2005).  In addition to GABA inhibition, VPA inhibits voltage-gated sodium 
channels and inhibits histone deacetylase (Juengel et al., 2013, Matsushita 
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et al., 2013, Drugbank, 2005). VPA metabolites have a ketogenic diet-like 
effect which is thought to contribute to seizure control (Egger and Brett, 
1981a) 
3.2.3.  Adverse reactions associated with sodium valproate  
The common ADRs associated with this medication include 
dizziness, vomiting and abdominal discomfort, tremor and hair loss in about 5 
-10% of patients; behavioural changes such as irritability in children and 
depressed moods in adults and weight gain (up to 71%) (NYU, n'd, Biton, 
2003, Drugbank, 2005, Egger and Brett, 1981a, Caksen  et al., 2002). Other 
adverse effects associated with VPA include liver toxicity, pancreatitis, 
hyperammonemia and sedation (Egger and Brett, 1981a).  
 
3.2.3.1.  Weight gain as a sodium valproate-induced adverse drug 
reaction 
Weight gain is one of the most difficult clinical problems encountered 
with the use of this medication because it has both long- and short-term 
health consequences. In the short term weight gain is associated with non-
compliance with treatment and with discontinuation of therapy in about a third 
of the patients on this medication (Egger and Brett, 1981a). Given that some 
of these patients have gained good seizure control on VPA prior to the onset 
of this ADR and that such seizure control might not be achievable with any 
other AED, this ADR contributes to failure of medical control of epilepsy. The 
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affected patients hence are forced to live with the debilitating effect of 
uncontrolled seizures with associated increased morbidity and mortality. The 
increased weight associated with this medication might elevate the risk of  
toxicity from other drugs (especially in children where drugs are calculated in 
units per kilogram body weight) as the dose of co-administered drugs are 
adjusted upwards to account for the weight gain (Egger and Brett, 1981a). 
Other short term complications of weight gain includes psychological 
morbidities – depression, anxiety,  decreased morale and self-confidence, 
increased risk of bullying especially school-aged children (Egger and Brett, 
1981a). Overweight individuals are also at increased risk of respiratory 
morbidities such as sleep-disordered breathing and obstructive sleep apnoea 
(Newman et al., 2005) 
Long term complications of VPA-induced weight gain include 
increased risk of the metabolic syndrome characterised by abdominal 
obesity, dyslipidaemia, hypertension and glucose intolerance (Verrotti et al., 
2009c). This syndrome is associated with increased risk of cardiovascular 
disease and the development of type 2 diabetes (Verrotti et al., 2009c). 
VPA therapy is associated with weight gain in up to 71% of the 
patients exposed to the medication (Corman et al., 1997, Wirrell, 2003). 
However in most studies the incidence of weight gain is usually about 10% of 
pre-treatment weight (Biton, 2003). Most patients with this ADR experience it 
within the first 3 months and it peaks at 6 months after initiation of therapy 
(Demir, 2000). In addition, there is a wide inter-individual variation in the 
degree of weight gain on this medication. While a very small proportion of the 
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subjects lose weight on this medication probably due to the gastrointestinal 
discomfort caused by the medication, others experience weight gain of up to 
71% of their pre-exposure weight ((Egger and Brett, 1981a). Around 10% of 
patients experience severe weight gain (defined as weight gain ≥ 10% of the 
pre-exposure weight)(Corman et al., 1997). Significant weight gain (≥7%) 
occurs in even a larger proportion of these patients (Zipursky et al., 2005) .  
Previous studies in adults have reported the following two pre-
exposure risk factors associated VPA induced weight gain body mass index 
pre-treatment (Corman et al., 1997); 
i) no personal history of weight problems(Corman et al., 1997) 
and 
ii) longer duration of therapy (Verrotti et al., Mikkonen et al., 
2005a, Prabhakar et al., 2007) 
In children the following predisposing factors have been reported:  
i) potentially overweight or overweight at the time of VPA 
initiation; 
ii)  normal neurocognitive status in older  children and teens 
(Wirrell, 2003); 
iii) initial weight Z-score and initial body mass index in children 
aged 1.8 to 16.9 years (Novak, 1999); 
iv)  gender (Egger and Brett, 1981a) and; 
v) pubertal status (Mikkonen et al., 2005b). 
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It is important to note that the predictors listed above have not been 
consistently replicated across studies (Egger and Brett, 1981a, El-Khatib, 
2007, Corman et al., 1997, Wirrell, 2003) and indeed other studies have not 
reported any predictors (Dinesen et al., 1984, Pylvanen et al., 2003). As a 
result, there are no accepted clinical predictors of VPA-induced weight gain. 
There have been no randomized control trials and some of the studies were 
underpowered to detect clinically relevant predictors (Biton, 2003).  
Since this ADR is very common in both adults and children, and has 
both short and long term medical and psychosocial implications, this study 
was undertaken to determine the phenotypic and genetic factors associated 
with this ADR in children. This analysis is therefore aimed at addressing two 
basic questions:  (1) Does VPA induce a weight change in our patient 
population? (2) What clinical variables influence this weight change in our 
patient population? 
 
3.3.  Methods – Patients cohorts  
For description of patient phenotypes see General Methods Sections 
2.6 and 2.7 
 
3.4.  Methods – regression modelling 
We applied standard multi-linear regression modelling to explore the 
influence of a variety of clinical variables on weight gain due to VPA. The 
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clinical variables we tested were: the duration of VPA exposure, maximum 
dose, serum VPA levels, gender, pre-exposure weight for age centile (WAC), 
polytherapy, epilepsy syndrome, family history of weight problems, age at 
initiation of therapy, mobility status and special diet.  The main phenotypes 
we used as a measure of VPA-induced weight gain were:  
i) maximum percentage weight change and 
ii) change in weight for age z-score (WAZ) within the first 12 
months of therapy. 
 Details of the analysis of the influence of clinical factors on maximum 
percentage weight change are outlined below:  
Phenotypic analysis was conducted on the 251 patients recruited into 
the study (see General Methods Section 2.9.3). We employed two growth 
monitoring tools to determine the main clinical phenotypes (maximum 
percentage weight change and average WAZ change) (see Section 2.9.5 in 
the General Methods Chapter for a full description of the growth assessment 
tools). The WHO AnthroPlus software was employed to determine the 
change in weight for age z-score (WAZ) (average WAZ change) in children 
between two years and ten years at the time of initiation of VPA while the R-
code developed from the Hoey et al 1987 growth chart was applied to 
children ≥ 2 years at the time of initiation of VPA (Hoey et al., 1987, WHO, 
2013). 
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3.4.1.  Determining the maximum percentage weight change using the 
Hoey et al growth chart and the R code derived from the data in the 
original paper 
The basic steps in determining weight change (maximum percentage 
weight change) using the Hoey et al growth charts were (Hoey et al., 1987) 
(see Section 2.9.5 in the General Methods Chapter): 
i. The weight at initiation of VPA was determined from the clinical 
records (data stored in Microsoft Access database). 
ii. The subject’s age at initiation was calculated in years by subtracting 
the date of birth from the date of initiation. This was calculated using 
the Microsoft Excel function (=YEARFRAC).  
iii. The subject’s gender was also determined from clinical records (data 
stored in the Access database). 
iv. The weight for age centile (WAC) at initiation of therapy was 
determined by entering the gender, age and weight (in kilograms)   in 
the R-function developed from the Hoey et al data.  This WAC was 
taken as the baseline WAC.  
v. It was assumed that, during the first 12 months of VPA exposure, any 
deviation from ‘initiation’ centile was attributable to VPA.  
vi. During subsequent visits within the study period, the expected weights 
(in kilograms) were determined by first determining the child’s age at 
that visit using the Excel function – (=YEARFRAC) then entering the 
gender, the baseline WAC and the age in the R-function. The R-
function outputs the expected weight in kilograms. 
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vii. Weight deviation from the expected weight for each visit was 
calculated by subtracting the observed (measured) weight at that visit 
from the expected weight (determined using the R-function).  
viii. Percentage weight change was calculated by dividing the weight 
deviation at each visit by the expected weight at that visit and 
multiplying by 100. 
ix. The percentage weight change (percentage weight deviation) was 
calculated for each visit and recorded. The percentage weight change 
with the highest value within the first twelve months was taken as the 
maximum percentage weight change and this determines the 
phenotype for each of the subjects. 
x.  Weight deviation at the end of twelve months of therapy was obtained 
by subtracting the last recorded observed weight from the expected 
weight at the same period. Observed weight at 12 months (OW12) or 
any time close to the 12 month period minus the predicted weight at 
that time period (PW12). 
 
3.4.2.   Determining the average weight for age z-score using the World 
Health Organization Anthro Plus software 
For children between the ages of zero and ten years at the time of 
initiation of therapy, the WHO-AnthroPlus software was used  to calculate the 
change in weight for age z-score (WAZ) from the time of VPA initiation 
(WHO, 2013) (see Section 2.9.5.3 for a full description of the WHO 
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AnthroPlus weight assessment tool). The steps involved in calculating the 
average WAZ change are outlined below:  
i. The Individual Assessment module of the WHO AnthroPlus was used 
to calculate the WAZ at initiation of therapy by entering the individual’s 
gender, date of birth, date of first visit and weight at the first visit (see 
Section 2.9.5.2 in the General Methods chapter).  
ii. For each subsequent visit within the first twelve months, the measured 
weight and date of visit were entered from which the software 
calculated the WAZ. This serves as the initiation WAZ. 
iii. At subsequent visits post VPA initiation, the date of the visit, and the 
observed weight were entered for each individual. The software then 
calculates the WAZ for each of these visits. 
iv. The difference in WAZ between the initiation WAZ and WAZ at 
subsequent visits was calculated by subtracting the initiation WAZ 
from the WAZ at each visit 
v. The mean WAZ difference for each individual was calculated summing 
all the WAZ difference for all the visits after initiation and dividing this 
by the number of visits post-initiation of VPA. 
vi. This becomes the main phenotype for determining weight change for 
those children assessed using the WHO AnthroPlus software (WHO, 
2013, WHO, 2009).  
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3.4.3.   Derivation of the other clinical phenotypes  
The sources of data for the other clinical phenotypes include the 
medical notes/ CRF, calculated data and data from the investigator-
administered questionnaire (see the Phenotype Collection and Storage 
section 2.9.3 in the General Methods Chapter):  Data obtained from the 
medical notes and stored in the Access database include the following:  
i. Age at initiation of therapy derived from the subject’s date of birth and 
date of initiation of VPA  
ii. Gender (male or female) 
iii. Epilepsy syndrome – according to ILAE classification 1989 (ILAE, 
1989). The epilepsy syndrome classification was converted into a 
dichotomous data – generalised epilepsy (consisting of idiopathic 
generalised epilepsy, probable symptomatic generalised epilepsy and 
symptomatic generalised epilepsy) and focal epilepsy (consisting of 
simple focal seizures, probable symptomatic focal seizures and 
symptomatic focal seizures). Only one individual had a syndrome that 
was unclassifiable.  
Co-Administered anti-epileptic drugs (AEDs); although each individual 
AED was recorded in the CRF this was converted to dichotomous 
data: VPA monotherapy versus combination therapy. This was for 
simplicity as there too many categories of AED to make for meaningful 
analysis.  
The following data was calculated based on the information available in the 
medical notes and stored in the Access database: 
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i. Duration of follow up - this was calculated by determining the time 
interval (in years) between the initiation date and the date of last 
measured weight within the first 12 month period of initiation of VPA 
therapy. 
ii. Maximum VPA dose in milligram per kilogram body weight per day 
(mg/kg/day): The daily dose was determined by dividing the total daily 
dose of VPA (in milligrams) by the subject’s weight at each visit. The 
maximum VPA dose was assumed to be the maximum dose in 
mg/kg/day the subject was exposed to during the study period. 
iii. Average serum VPA levels in micromoles per litre, (µmol/L) was 
calculated by summing all the measured serum VPA levels done 
within the study period and dividing this by the total number of 
measurements. 
The following data was derived from the investigator-administered 
questionnaire (see Section 2.9.3 Phenotype Collection and Storage in the 
General Methods Chapter) 
i. Family history of obesity. These were dichotomous ‘yes’ or ‘no’ 
options.  
ii. Activity level – There were four categories of activity level: zero, low, 
normal or high.  
iii. Mobility level- There were three categories: normal activity, impaired 
activity, and wheelchair bound.  
iv. Special diet –. The options were dichotomous ‘yes’ or ‘no’. 
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3.4.4.   Data classification  
The data gathered were classified into quantitative (Scalar), discrete 
(Nominal) or ordered categorical (Ordinal) variables for easy analysis with the 
Statistical Package for Social Sciences (SPSS) version 20 (IBM, 2011) as 
listed below: 
i. Age at initiation (in years) (quantitative, scalar) 
ii. Gender (Dichotomous, nominal) 
iii. Centile at initiation (quantitative, scalar) 
iv. Dose – maximum dose (mg/kg/day) within 12 months (quantitative, 
scalar) 
v. Average serum VPA levels (µmol/L) (quantitative, scalar) 
vi. Duration of VPA treatment (in years) (i.e. if they have stopped 
treatment early, before 12 months) (quantitative, scalar).  
vii. Syndromic diagnosis (dichotomous, nominal) 
viii. Co-administered AEDs:  VPA only or VPA with one or  more other  
AEDs (dichotomous, nominal) 
ix. Family history of obesity (dichotomous, nominal) 
x. Mobility level  - or activity level (normal, impaired, wheelchair bound) 
(categorical, ordinal) 
xi. Diet -normal diet (yes/no) (dichotomous, nominal) 
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3.4.5.   Analyses  
The data was analysed using the SPSS statistical software version 20 
(IBM, 2011). A statistician’s advice (Dr Patrick Dicker, RCSI) was sort prior to 
the drafting of the initial analysis plan. The data was entered into the SPSS 
software and the categorical (nominal) and the ordered categorical (Ordinal) 
variables were coded to reflect the number of categories while the 
quantitative (scalar) variables were left intact. The number of categories for 
some of the categorical variables like number of AED combinations and the 
epilepsy syndrome was reduced to 2 categories to allow for easier analysis.  
The analysis was aimed at answering two basic questions:  
i. Does VPA induce a weight change in our patient population?  
ii. What clinical variables influence this weight change in our patient 
population? 
To answer the first question a one-sample T-Test was performed 
using Observed Weight at 12 months (OW12) and the Predicted Weight at 12 
months (PW12) (see–Section 3.4.1 above) . Also a one-sample t-test was 
conducted to determine whether VPA treatment induced a significant weight 
centile change at the level of the treated population as a whole within the first 
12 months of treatment? A third one-sample t-test was also conducted to 
determine whether VPA therapy induced a significant change in the WAZ 
within the study period (see the section on Determining the average weight 
for age z-score using the WHO AnthroPlus software above). 
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To address the second question (What clinical variables influence 
weight change) we applied Analysis of Covariance (ANCOVA). The following 
predictors were tested in the ANCOVA model:  
i. Age at initiation (quantitative) 
ii. Gender (discrete, nominal) 
iii. Centile at initiation (quantitative, scalar) 
iv. Dose –  maximum dose (mg/kg/day) (quantitative, scalar) 
v. Duration of VPA treatment (quantitative, scalar) 
vi. Syndromic diagnosis (2 categories, nominal)  
vii. Co-administered AEDs – VPA only or VPA + others (dichotomous, 
nominal) 
viii. Family history of obesity (dichotomous, nominal) 
ix. Mobility level - or activity level (normal, impaired, wheelchair bound) 
(categorical, ordinal) 
x. Diet  - special versus normal (dichotomous, nominal) 
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3.5.    Results 
3.5.1.    Recruitment and cohort characteristics 
We recruited two hundred and fifty one (251) individuals into the 
study. The cohort characteristics are presented in Tables 5 to 12 below. More 
than 61% of the subjects were boys. Approximately half of the children had 
generalized epilepsy while the remainder had either partial epilepsy or other 
forms of epilepsy that could not be classified (see Table 9).  About two thirds 
of the subjects were on VPA monotherapy while the rest were on a 
combination therapy (See Tables 5 and 8). Learning disability (LD) was 
present in more than half (130/100) of the children. More than a third of those 
with LD have severe LD. Mild LD was present in 44/130 (36%) while 
moderate LD was present in 32/ 130 (26%) of those with LD (see Table 5).
 Family history of weight problems (obesity or overweight) was 
reported in 78/225 (35%) of the children. About three quarters of the children 
had normal or elevated activity levels according to parental reports (see 
Table 5). VPA was initiated at a mean age of 6 (SD ± 3.98) years while the 
subjects were recruited at a mean age of 10.6 (SD ± 4.3) years. The mean 
interval between the initiation of therapy and recruitment into the study was 
3.2 (SD ± 3.6) years (see Tables 6 and 7). 
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Table 5: Descriptive characteristics of the cohort 
Characteristics Characteristics Frequency (n) Proportion (%) 
Gender    
 Male 153 61.2 
 Female 97 38.8 
VPA monotherapy    
 Yes 133 64.6 
 No 73 35.4 
Epilepsy Syndrome    
 Generalized 118 50.0 
 Focal 108 46.0 
 Other 9 4.0 
Learning Disability (LD)   
 Yes 130 56.5 
 No 100 43.5 
LD  severity    
 Mild 44 36.1 
 Moderate 32 26.2 
 Severe 46 37.7 
FH weight problems    
 Yes 78 34.7 
 No 147 65.3 
Activity Level    
 Zero 5 2.2 
 Low 47 20.5 
 Normal 139 60.7 
 High 38 16.6 
Mobility    
 Normal 195 83.3 
 Impaired 32 13.7 
 Wheelchair 7 3.0 
Special diet    
 Yes 12 5.2 
 No 219 94.8 
Legend: n – sample size; % - percentage of sample; LD – learning disability 
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Table 6: Descriptive statistics at the time of recruitment and at last follow up 
visit comparing the male with the female participants 
Characteristics  Males Females p-value (independent 
sample t-test) 
  (N =  151) (N = 96)  
Start Age (years) Mean (sd) 6.34 (4.09) 5.45 (3.77) 0.08287 
 Median (range) 5.88 (6.4) 4.73 (5.36)  
Last visit Age (years) Mean (sd) 10.91 (4.34) 10.08 (3.94) 0.12 
 Median (range) 11.73(7.15) 9.55 (6.53)  
Length of follow up at last visit 
(years) 
Mean (sd) 4.54 (3.43) 4.56 (3.12) 0.95 
 Median (range) 3.49 (4.47) 4.05 (4.08)  
Start weight for age centile Mean (sd) 0.68 (0.30) 0.57(0.34) 0.03 
 Median (range) 0.80 (0.52) 0.66 (0.64)  
WAC at end of 1 year of  therapy Mean (sd) (0.76) (0.27) 0.61(0.33) 0.0049 
 Median (range) 0.87 (0.33) 0.72(0.66)  
WAC last follow up visit Mean (sd) 0.69 (0.30) 0.62 (0.34) 0.08432 
 Median (range) 0.80 (0.42) 0.73 (0.60)  
WAC change start versus last 
follow up 
Mean (sd) 0.03 (0.29) 0.05 (0.24) 0.6614 
 Median (range) 0.001(0.226) 0.0226(0.227)  
Maximum VPA_dose_1st Year 
(mg/kg/day) 
Mea (sd) 25 (12) 27 (12) 0.2885 
 Median (range) 23 (15) 24 (16)  
Average serum VPA level 
(µmol/L) 
Mean (sd) 442 (232) 435 (183)  
     
Length of follow up first year 
(years) 
Mean(sd) 0.66 (0.23) 0.68 (0.25) 0.5238 
 Median (range) 0.72 (0.36) 0.72 (0.39)  
Legend 
 sd =standard deviation; max = maximum; VPA = valproate; WAC = weight for age centile; WAC – weight for age centile; 
VPA- valproate;  
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Table 7: Age at recruitment, VPA start age interval between VPA initiation 
and recruitment and duration of VPA therapy at the time of recruitment 
 Age at 
recruitment 
(years) 
VPA start age 
(years) 
Interval between VPA 
initiation and 
recruitment 
(years) 
Duration of VPA 
therapy at the 
time of 
recruitment 
Maximum 18.13 15.95 17.11 11.83 
Minimum 2.47 0.12 0.19 0.38 
Mean 10.62 5.96 3.22 2.80 
Median 10.90 5.23 1.64 2.16 
Standard 
deviation 
4.30 3.98 3.64 2.36 
Legend:  
              VPA = valproate 
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Table 8: Anti-epilepsy drugs taken in combination with valproate 
Anti-epileptic drug (AED) Number of subjects Percentage  
Lamotrigine 57 23 
Clobazam 28 11 
Oxycarbazine 27 11 
Carbamazepine  40 16 
Ethosuxamide 13 5 
Topiramate 14 6 
Phenytoin 5 2 
Adrenocorticotrophic 
hormone (ACTH) 
10 4 
Vigabatrin 7 3 
Zonisamide 11 4 
Acetazolamide 20 8 
Gabapentin 2 1 
Phenobarbitone 7 3 
Rufinamide 5 2 
Felbamate 2 1 
Total 248 100 
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Table 9: Epilepsy syndrome classifications according to ILAE 2004 
Epilepsy Syndrome Frequency Percen
t 
 Idiopathic generalised epilepsy 89 37.9 
Symptomatic generalised epilepsy 10 4.3 
Probable symptomatic generalised epilepsy 
syndrome 
19 8.1 
Benign focal 27 11.5 
Symptomatic focal  50 21.3 
Probable symptomatic focal 31 13.2 
Specific Syndrome 8 3.4 
Unclassifiable  1 0.4 
Legend 
ILAE – international league against epilepsy 
 
Clinically significant weight gain (maximum percent weight deviation 
>5% of expected weight) was observed in 76/157 (48%) of the subjects 
whose weights were analysed using the Hoey et al growth chart.  Forty three 
out of 157 (27%) of the subjects so analysed had severe weight  gain 
(maximum percent weight deviation ≥ 10% of expected weight) while 33/157 
(21%) of the subjects experienced moderate weight gain (maximum percent 
weight deviation between 5% and 9% of expected weight) (see Table 10 
below).  
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Table 10: Weight change categories post initiation of valproate 
Weight change category Number Percentage Range of maximum 
percent weight 
change 
 
No clinically significant weight gain (maximum 
percent weight gain < 5%) 
 
 
81 
 
52% 
 
-13% to 4% 
Moderate weight gain (maximum percentage 
weight gain 5 - 9%) 
 
33 21% 5% to 9% 
Severe weight gain (maximum percent weight 
gain > 10%) 
43 27% 10% to 66% 
Total  157 100% 
 
 
 
3.5.2.    Weight for age centile at initiation of valproate therapy  
Analysis revealed that the mean WAC at initiation of VPA therapy 
was 0.65 (See Table 12 below). Fourteen per cent (14%) of children were 
overweight. 81% were in the normal weight category while the rest were 
underweight.  
  
3.5.3.    Weight for age centile within the first 12 months of valproate 
therapy 
 Within the first twelve months of therapy, the mean WAC of the group 
had increased from 0.65 to 0.70. The median WAC also increased from 0.76 
to 0.82 (see Table 12 below). The proportion of children described as 
overweight had increased from 14% at initiation of therapy to 34% at the end 
of the first year of therapy. The proportion of the underweight had decreased 
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from 5.2% at the initiation of therapy to 2.6% at the within this period. The 
same pattern though less dramatic change was seen in the normal weight 
category. There was a slight decrease in the proportion of children in the 
normal weight category from 81% at the initiation of therapy, to 75% at the 
end of the first year of therapy See Table 11 below.  
Table 11: Comparison of the proportion of children in the different weight 
categories at initiation of VPA and at twelve months post initiation 
Period Number WAC ≤ 0.10 WAC 0.11 - 0.96 WAC ≥0.97 
Initiation (n) 155 8 125 22 
Initiation (%) 100 5.2 80.6 14.2 
End of follow up (n) 153 4 115 34 
End of follow up (%) 100 2.6 75.2 22.2 
Legend: 
              WAC – weight for age centile 
 
The mean weight for age centile (WAC) for the boys at the time of 
commencement of VPA was significantly higher than that of the girls (mean 
WAC of 0.76 (± 0.30) for the boys versus 0.57 (± 0.34) for the girls) (p = 
0.005). See Table 6 above. The mean weight deviation from expected weight 
after 12 months of therapy was 1.56 (± 3.9) kg. More than half of the patients 
gained 0.64 (range, 29.59) kg. The mean maximum percentage weight 
deviation from baseline weight was 7.3% (± 11.7 %).The median weight 
deviation was 4% with a range of 79% as illustrated in Table 12 below. 
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Table 12: Subjects characteristics pre and post initiation of VPA therapy 
 Mean (± SD) Median (± Range) 
Age at initiation of therapy 6.02 (± 3.99) 5.34 (± 16.00) 
Number of visits post-initiation of therapy 2.01 (± 1.05) 1.05 (± 12.00) 
Length of follow up within the first year 
(years) 
0.67 (± 0.24) 0.72 (± 1.00) 
Maximum VPA dose (mg/kg/day) 25.91 (± 11.71) 23.00 (± 74.00) 
Serum VPA levels (µmol/L) 439 (± 211) 435 (± 1474) 
Weight for age centile at initiation  0.65 (± 0.32) 0.76 (±1.00) 
Weight for age centile at the end of follow up 0.70 (± 0.30) 0.82 (±1.00) 
Weight deviation from expected weight at 
the end of follow up (kg) 
1.56 (± 3.00) 0.64 (± 29.59) 
Maximum percentage weight change from 
expected weight (%) 
7.27(± 11.70) 4.00 (± 79.00) 
Legend: 
          VPA – sodium valproate; SD – standard deviation; kg – kilograms; % - percent 
 
3.5.4.   Weight for age z-score  
Subjects younger than 10 years old with weight data had their mean 
weight for age z-score (WAZ) determined using the WHO AnthroPlus 
software (see General Methods Chapter, section 2.9.5.2). The software is not 
able to determine WAZ for children older than 10 years because weight is not 
a good measure of growth in those groups of children. There was an overlap 
in the number of subjects analysed with both the Hoey and WHO WAZ 
methods for children between the ages of two years and ten years (see Fig 
10). All patients  between the ages of 2 and 18 years were analysed using 
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the Hoey chart while all patients between the ages of zero and 10 years 
inclusive were analysed using the WHO WAZ methods. The mean WAZ 
change for children between the ages of 0 and 10 years (n= 145) was 0.2172 
(SD: 0.70347). (See figure 11 below). 
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Figure 9: Overlap of the WHO weight for age z-score and Hoey weight for 
age centile determination 
Figure 9 legend: WHO – World Health Organisation; yrs – years;  
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Figure 10: Boxplot of mean weight for age z-score change in boys and girls 
after 12 months of VPA therapy 
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3.5.5.   Valproate dose and serum levels 
The mean maximum valproate dose was 26 mg/kg/day. About half of 
the subjects were on a maximum dose of 23 mg/kg/day (see Table 12). While 
the mean maximum doses were slightly higher in girls than boys (27 
mg/kg/day versus 25 mg/kg/day), the difference was not significant (p= 0.29) 
(see Table 6). The average serum VPA level was 439µmol/L. There was no 
significant difference between the boys and the girls in the average serum 
VPA levels within the treatment period. While the average serum level was 
slightly higher in boys than in girls (442 µmol/L in the boys compared with 
435 µmol/L in the girls), this difference did not reach statistical significance as 
illustrated in Tables 6 above. 
 
3.5.6.   Other antiepileptic drugs 
The AEDs commonly combined with VPA include lamotrigine in 
about 23% of those on combination therapy, carbamazepine (16%), 
clobazam (11%) and oxycarbacine (11%). Other AEDs commonly combined 
with VPA include topiramate (6%), zonisamide (4%), adrenocorticotropic 
hormone (ACTH) (4%), phenytoin (2%) and vigabatrin (2%), (See Table 8 
above).  
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3.5.7.    Length of follow up 
Although the target period of follow up was 12 months, follow up 
visits occurred at variable time-points during the first year of VPA treatment 
depending on the severity of the illness, the source of referral and the 
physicians’ practice style. While majority of the patients had complete 12 
months follow up data others had less than that. The mean length of follow 
up was 8 months or 0.67 (± 0.24) years. The mean number of visits post-
initiation of VPA therapy was 2 visits. Half of the children had only visited 
once see Table 12 above. Some of the children were not followed up at any 
of the three tertiary hospitals within the first year of therapy. The follow up 
data for this group of children was obtained from the district hospitals where 
they were referred from (if applicable) otherwise their data was excluded from 
the final analysis.   
3.5.8.   Co-morbidities 
The following co-morbidities were commonly reported in consented 
subjects – autistic spectrum disorder, attention deficit hyperactivity disorder 
(ADHD), behavioural difficulties, and developmental co-ordination disorders. 
Others include: cerebral palsy, hydrocephalus and asthma.  
 
3.5.9.    Seizure aetiology 
Although majority of the epilepsies were idiopathic in nature there 
were a number of symptomatic epilepsies and some were probably 
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symptomatic epilepsies in this group. Common aetiologies for the 
symptomatic seizures were: tuberose sclerosis, hypoxic ischaemic 
encephalopathy, viral encephalitis and bacterial meningitis, cortical dysplasia, 
dysplastic neuro-endothelial tumours (DNET) and Moya-Moya disease.  
 
3.5.10.    Epilepsy syndrome types 
Epilepsy syndrome was classified according to the ILAE 1989 
classification(ILAE, 1989) . Epilepsy syndrome could be determined in 235/ 
251 (94%) of participants. About a third of the subjects had idiopathic 
generalized epilepsy (IGE). The second most common epilepsy classification 
in the subjects was symptomatic focal seizures reported in about one fifth of 
the patients. See Table 9 for a breakdown of syndromic classifications in the 
study cohort. 
 
3.5.11.    Weight change beyond the first year of therapy 
At the last follow up visit there was no significant difference in the 
mean WAC between the sexes – 0.69 (± 0.30) for the boys versus 0.62 (± 
0.34) for the girls (p = 0.08). There was also no significant difference 
between the boys and the girls in the mean WAC change at the last follow up 
visit – 0.03 (± 0.29) for the boys versus 0.05 (± 0.24) for the girls (p = 0.66). 
See Table 6 above. 
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3.6.    Inferential Statistics 
 
3.6.1.    Does sodium valproate treatment induce a significant weight 
change at the level of the treated population as a whole within the first 
12 months of treatment? 
 
 To address this question we conducted a 1-sample T-Test using 
Observed Weight at 12 months (OW12) and the Predicted Weight at 12 
months (PW12) (see Section 3.4.1 for description of the phenotype).  There 
was a significant deviation from the expected weight at the end of the first 
year of therapy in this population (p < 0.001).The result of this test is as 
illustrated in Table 13. 
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Table 13: One-Sample Test Maximum Percent Weight Change, maximum 
weight difference, mean change in weight for age z-score and weight 
deviation at 12  months (oW12_eW12): Test Value = 0 
 
t-statistics df Sig. 
(2-
tailed) 
Mean 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
Lowe
r 
Upper 
Maximum Percent Weight 
Change 
7.785 156 0.000 7.271 5.43 9.12 
Maximum Weight 
Difference  
7.283 156 0.000 2.21554 1.614
6 
2.8165 
Mean WAZ change 3.717 144 0.000 0.21717 0.101
7 
0.3326 
Weight deviation at 12 
months of therapy 
(oW12_eW12) 
4.875 148 0.000 1.55812 0.926
5 
2.1897 
Legend: 
df – degrees of freedom; sig – significance; WAZ – weight for age z-score; oW12 – observed weight at 
end of twelve months of follow up; eW12 – expected weight at the end of twelve months of follow up 
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3.6.2.    Does sodium valproate treatment induce a significant weight 
centile change at the level of the treated population as a whole within 
the first 12 months of treatment? 
 
To address this question we conducted a paired sample t-Test using 
Weight centile initiation (WC0) and weight centile at 12 months (WC12) for 
each child (See section 3.4.1for description of the phenotype). We observed 
a significant difference in the paired t-scores of the WAC between the start 
WAC and the WAC at the end of the first 12 months of therapy (See Tables 
14 and 15).  
Table 14: Paired Samples Statistics: paired sample t-test weight for age 
centile at initiation compared with weight for age centile at the end of the first 
12 months of VPA therapy 
   Paired  Differences t-
statistics 
Df Sig (2-
tailed) 
 Mean Std 
Dev. 
Std. 
error 
mean 
95% C.I of the 
difference 
   
    Upper Lower    
C0 – 
C12 
-0.54 0.178 0.014 0.084 0.025 -3.685 43 0.000 
Legend 
C0 = weight for age centile at initiation of therapy; C12 = weight for age centile at the 
end of 12 months of therapy; df – degrees of freedom; std – standard; C.I – 
confidence interval 
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Table 15: Paired Samples Statistics: paired sample t-test weight for age 
centile at initiation compared with weight for age centile at the end of the first 
12 months of VPA therapy 
 Mean n Std. 
deviation 
Std. error 
mean 
WAC at initiation 0.634477 144 0.3147738 0.0262312 
WAC at the end of first 12 
months 
0.689191 144 0.3038613 0.0253218 
Legend 
WAC = weight for age centile; n – sample size; std – standard 
 
 
3.6.3.    Is sodium valproate therapy associated with a significant 
maximum percentage weight change in this population?  
To address this question we conducted a one-sample t-test comparing the 
maximum weight change at time zero with the maximal percentage weight 
change at the end of 12 months of VPA therapy. The result indicates that 
there was a significant maximum percentage weight change (p < 0.001) as 
shown in Table 13. 
 
3.6.4.    Clinical predictors of sodium valproate-induced weight gain. 
This analysis focused on the clinical predictors of:  
i) the maximum percentage weight change (during 12 months) 
and  
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ii) the weight centile change/ weight deviation at 12 months of 
therapy.  
Analysis of Covariance (ANCOVA) was applied using the 
‘clinical’/phenotypic factors outlined in the clinical phenotype description 
section above (Section 3.4.1)  In the ANCOVA model the phenotypic factors 
were tested together and each phenotypic factor was also tested individually. 
The results are illustrated in Table 17. The reason for adopting both 
approaches in the ANCOVA is to increase the number of subjects fitting the 
model. Due to the proportion of subjects with missing data testing the whole 
cohort together in an ANCOVA will result in only a few of the subjects fitting 
the model. However, when each clinical profile was tested individually 
against the maximum percentage weight change, maximum number of 
subjects fitted into the model. Analysis of co-variates: maximum percent 
weight change.  
This was tested against the following phenotypic factors: age at 
initiation, length of therapy, epilepsy syndrome, presence or absence of 
learning difficulty, maximum valproate dose, anti-epileptic combination, family 
history of obesity, family history of epilepsy, activity level, mobility status, 
special diet, initiation centile and gender. The fixed factor was gender and the 
number of subjects that fitted the model was 86 consisting of 53 males and 
33 females. The combined model does not have any significant influence on 
the maximum percentage weight change. As shown in table 16 below even 
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when the influence of other phenotypic factors was removed from each other 
none of them achieved statistical significance. 
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Table 16: Results of ANCOVA testing each of the clinical factors together 
against maximum percentage weight change 
Source Type III Sum of 
Squares 
df Mean 
Square 
F-test p-value Significance 
Corrected Model 1331.126a 12 110.927 0.701 0.745 Not 
significant 
Intercept 153.394 1 153.394 0.969 0.328 Not 
significant 
Age at initiation 445.270 1 445.270 2.813 0.098 Not 
significant 
Length of exposure 0.919 1 0.919 0.006 0.939 Not 
significant 
Epilepsy syndrome 62.964 1 62.964 0.398 0.530 Not 
significant 
Learning difficulty 243.079 1 243.079 1.536 0.219 Not 
significant 
Maximum Dose 3.147 1 3.147 0.020 0.888 Not 
significant 
Monotherapy versus polytherapy  24.611 1 24.611 0.155 0.695 Not 
significant 
Obesity FH 0.131 1 0.131 0.001 0.977 Not 
significant 
Activity level 248.119 1 248.119 1.568 0.215 Not 
significant 
Mobility 4.473 1 4.473 0.028 0.867 Not 
significant 
Special Diet 200.605 1 200.605 1.267 0.264 Not 
significant 
Initiation WAC 181.259 1 181.259 0.145 0.288 Not 
significant 
Sex 0.405 1 0.405 0.003 0.960 Not 
significant 
Error 11237.879 71 158.280    
Total 15760.995 84     
Corrected Total 12569.006 83     
Legend: a. R Squared = .106 (Adjusted R Squared = -.045); df – degrees of freedom; F - ; FH – family history; WAC – 
weight for age centile;  
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3.6.4.1.    Testing individual phenotypic factors independently 
ANCOVA was run on individual phenotypic variables to determine 
their individual influence on the maximum percentage weight change. The 
result of this analysis indicates that none of the phenotypic variables 
significantly influenced the maximum percentage weight change. The results 
of these analyses are outlined in the Table 17 below.  
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Table 17: Results of ANCOVA testing each of the clinical factors individually 
against maximum percentage weight change 
Dependent variable Independent 
variable tested 
Number of 
subjects  
r
2
 Adjusted r
2
 p-value  Significance 
Maximum percentage weight 
change 
Maximum dose 128 0.009 -0.007 0.392 Not significant 
Maximum percentage weight 
change 
Number of visits 148  0.004 -0.010 0.519 Not significant 
Maximum percentage weight 
change 
Start age  148 0.009 -0.004 0.504 Not significant 
Maximum percentage weight 
change 
Length of 
exposure 
154  <0.001 -0.013 0.971 Not significant 
Maximum percentage weight 
change 
Epilepsy 
syndrome 
148 0.001 -0.013 0.676 Not significant 
Maximum percentage weight 
change 
Gender 156 <0.001 -0.006 0.950 Not significant 
Maximum percentage weight 
change 
Age at initiation 157 0.009 0.003 0.234 Not significant 
Maximum percentage weight 
change 
Length of 
exposure 
155 <0.001 -0.006 0.879 Not significant 
Maximum percentage weight 
change 
Learning difficulty 144 0.008 0.001 0.295 Not significant 
Maximum percentage weight 
change 
Average serum 
VPA levels 
53 0.015 -0.004 0.384 Not significant 
Maximum percentage weight 
change 
AEDs 
(monotherapy 
versus 
polytherapy 
131 0.001 -0.007 0.706 Not significant 
Maximum percentage weight 
change 
Mobility 147 0.001 -0.006 0.727 Not significant 
Maximum percentage weight 
change 
Special diet 145 0.003 -0.004 0.533 Not significant 
Maximum percentage weight 
change 
WAC at initiation 141 0.021 0.014 0.083 Not significant 
Maximum percentage weight 
change 
Family history of 
obesity (degree) 
48 0.002 -0.020 0.761 Not significant 
Legend: 
r
2 
 - co-efficient of multiple correlation; VPA – sodium valproate; AEDs – antiepileptic drugs; WAC – weight for age centile;  
 
3.6.4.2.    Deviation from the expected weight at the end of the first 12 
months of sodium valproate therapy 
Analysis of co-variates was conducted using the weight deviation 
from the expected weight at the end of twelve months of VPA therapy 
(oW12_eW12) as dependent variable and the following phenotypic factors as 
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independent variables: sex, number of visits, length of exposure to VPA, 
epilepsy syndrome, maximum VPA dose, learning difficulty, family history of 
epilepsy, family history of obesity, activity level, mobility and special diet. The 
number of subjects tested was 83.The age at initiation variable was not 
tested in this model as it is known that age highly correlates with weight in 
children therefore the degree of weight deviation from the expected weight at 
the twelve months of therapy would be highly correlated with the children’s 
age at that point.  
The result of this analysis indicates that none of the phenotypic 
factors significantly influenced the weight deviation. This is displayed in Table 
18 below. 
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Table 18: Analysis of covariates with the dependent variable as oW12_eW12 
with all the clinical phenotypes except age at initiation as co-variates, (N = 
83) 
Source Type III 
Sum of 
Squares 
df Mean 
Square 
F-
test 
p-
value  
Significance 
Corrected Model 194.361
a
 13 14.951 0.824 0.633 N.S 
Intercept 148.757 1 148.757 8.203 0.006 N.S 
Maximum VPA dose 16.703 1 16.703 0.921 0.341 N.S 
Sex 20.019  1 20.019 1.104 0.297 N.S 
Number  of Visits 4.467 1 4.467 0.246 0.621 N.S 
Length of exposure  1.523 1 1.523 0.084 0.773 N.S 
Epilepsy syndrome 19.557 1 19.557 1.078 0.303 N.S 
Learning difficulty 7.713 1 7.713 0.425 0.516 N.S 
Family history of epilepsy 1.350 1 1.350 0.074 0.786 N.S 
AED other 3.388 1 3.388 0.187 0.667 N.S 
Family history of obesity 36.924 1 36.924 2.036 0.158 N.S 
Activity level 1.014 1 1.014 0.056 0.814 N.S 
Mobility 54.613 1 54.613 3.012 0.087 N.S 
Special diet 57.157 1 57.157 3.152 0.080 N.S 
Weight for age centile at 
initiation 
23.855 1 23.855 1.315 0.255 N.S 
Error 1251.288 69 18.135    
Total 1563.423 83     
Corrected Total 1445.648 82     
Legend:  a. R Squared = .134 (Adjusted R Squared = -.029); df – degrees of freedom; VPA 
– sodium valproate; AED – antiepileptic drug; N.S – not significant 
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3.7.    Mean weight for age z-score change  
The last set of regression analysis focused on the mean weight for 
age z-score as the dependent variable and the phenotypic factors tested in 
the preceding sections as independent variables. The effects of these factors 
on the mean WAZ change were tested by including all the factors into the 
model. The results of the analysis are shown in Tables 19 below.  
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Table 19: Analysis of covariates with the dependent variable mean WAZ change and the clinical phenotypes as independent variables (n= 29) 
Source Type III Sum 
of Squares 
df Mean Square F-test p-value Significance 
Corrected Model 6.728a 15 0 .449 0.479 0.913 Not  significant 
Intercept 0.758 1 0.758 0.809 0.385 Not  significant 
Sex 1.279 1 1.279 1.365 0.264 Not  significant 
Number of Visits 0.202 1 0.202 0.215 0.650 Not  significant 
Start Age 0.636 1 0.636 0.679 0.425 Not  significant 
Length of exposure  1.487 1 1.487 1.587 0.230 Not  significant 
Epilepsy syndrome 0.987 1 0.987 1.053 0.323 Not  significant 
Learning difficulty  2.174 1 2.174 2.320 0.152 Not  significant 
Family History of epilepsy 0.637 1 0.637 0.680 0.425 Not  significant 
Average VPA  level 1.184 1 1.184 1.264 0.281 Not  significant 
Maximum dose 0.105 1 0.105 0.112 0.743 Not  significant 
AED other 1.435 1 1.435 1.532 0.238 Not  significant 
Family history of obesity  0.278 1 0.278 0.297 0.595 Not  significant 
Activity Level 2.610 1 2.610 2.786 0.119 Not  significant 
Mobility 1.122 1 1.122 1.197 0.294 Not  significant 
Special diet 1.179 1 1.179 1.258 0.282 Not  significant 
Centile at initiation 0.212 1 0.212 0.226 0.642 Not  significant 
Error 12.181 13 0.937 
   
Total 21.033 29 
    
Corrected Total 18.908 28 
    
Legend  a. R Squared = .356 (Adjusted R Squared = -.387); df – degrees of freedom; VPA – sodium valproate; AED – antiepileptic drugs;  
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3.8.     Conclusions  
To the best of our knowledge, this study, investigating the predictors 
of valproate-induced weight gain in the paediatric population, considers the 
largest number of subjects studied to date. In this group of children, VPA 
therapy was associated with a significant weight gain within the first year of 
therapy. Clinically significant weight gain of ≥ 5% of expected weight based 
on pre-treatment WAC was observed in 48% of the subjects. Severe weight 
gain (≥ 10% of expected weight) was observed in 27% of the subjects.  The 
proportion of overweight children increased from a baseline of 14.2% to 
22.2% at the end of first year of VPA therapy. The mean maximum 
percentage weight change within the first year of therapy was 7.3% (± 12%). 
The mean weight for age centile change was 0.04 (±0.50), while the mean 
weight deviation from the expected weight at the end of the first year of 
therapy was 1.56 kg (± 3.90 kg). The mean change in weight for age z-score 
(WAZ) was 0.22 (± 0.70).  This weight gain was however not sustained on 
long term averaging four and a half years.  
The following ‘clinical’ factors tested were not significantly associated 
with the weight gain: sex, number of visits, length of exposure to VPA, 
epilepsy syndrome, maximum VPA dose, learning difficulty, family history of 
epilepsy, family history of obesity, activity level, mobility and special diet.  
Although some studies have reported that treatment with VPA in 
children was not associated with a significant weight change the 
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overwhelming evidence supports the contrary (Bosnak et al., 2003, Caksen  
et al., 2002). Bosnak et al studied 56 patients aged 6 months  to 12 years 
who were followed for  6 – 40 months (median 15.6 months) and the result 
indicated no change in mean BMI z-score (Bosnak et al., 2003, Caksen  et 
al., 2002). Casken et al also demonstrated that there was no weight gain in 
prepubertal children on VPA compared to controls (Caksen  et al., 2002).  
Biton et al, in a randomized double blind trial, compared patients older than 
12 years with partial or generalized seizures on valproate with those on 
lamotrigine. Those on VPA had a mean increase in BMI of 2.26 ± 1.59 kg/m2 
over 32 weeks compared to a BMI increase in BMI of 0.19 ±2.26 kg/m2 for 
those on lamotrigine over the same time period (Biton, 2001). The weight 
gain associated with VPA therapy occurred within the first ten weeks of 
therapy (Biton, 2001).VPA therapy is associated with  acute weight increase 
in the first few months of initiation of therapy which stabilizes with continued 
long term treatment (Sharpe et al., 2009).  
However Mikkonen et al (2005) noted that  some of the children who 
became while on treatment with this medication during the pubertal period 
remained persistently overweight if epilepsy and treatment with this 
medication was continued into adulthood (Mikkonen et al., 2005a). 
Prabhakar et al in a prospective study in adult women treated with VPA 
followed up for two years, also noted a persistent increase in the body weight 
and BMI (Prabhakar et al., 2007). The findings in our study do not support 
the findings in previous studies regarding the persistence of the weight gain 
after a mean follow up of four and half years.  
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Regarding the clinical predictors of VPA induced weight gain 
although clinical predictors have been studied there has not been any 
reproducible predictor of this ADR.  Corman et al., (1997) in a retrospective 
record review and interview of 70 adults with epilepsy who have been on 
VPA for a median duration 27 months (range, 3 – 189 months) using weight 
change > 5% baseline weight as a marker of weight gain investigated the 
role of the following clinical factors in VPA-induced weight gain: gender, age, 
BMI, dose, personal of family history of obesity and monotherapy versus 
polytherapy. The result of the study indicated that low or normal initial BMI 
and lack of personal history of weight problems as the two clinical factors 
predictive of this ADR (Corman et al., 1997). However a previous 
retrospective study in 63 adults with epilepsy by Dinesen et al., (1984) found 
no significant clinical predictors, having examined age, sex, pre-treatment 
overweight status, duration of treatment, dosage and serum levels of 
valproate (Dinesen et al., 1984). 
Several such studies searching for the clinical predictors of VPA-
induced weight change have been conducted in children. Novak (1999) in a 
retrospective hospital outpatient-based study of 55 children with epilepsy 
aged 1.8 to 16.9 years who have been on VPA therapy for 8.6 – 33.8 months 
assessed the following clinical predictors:  BMI, weight z-score, gender, age 
at initiation, monotherapy at start of treatment, duration of follow up, mental 
retardation, seizure type (generalized versus partial), aetiology (idiopathic or 
cryptogenic versus remote symptomatic) and dose. Children who were fed by 
nasogastric tube, those on appetite stimulants (ketogenic diet, oral 
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contraceptive pills (OCP), corticosteroids) and those with chronic systemic 
diseases (hepatic, renal failure, IBD, malignant brain tumour, etc.) were 
excluded. The initial weight z-score and the initial BMI were the two 
clinical predictors reported as significantly associated with weight change in 
that study. 
Wirrell 2003 conducted another retrospective study in 43 children 
aged 10 – 17 years (mean age 13 (SD 2) years) 77% of whom were on VPA 
monotherapy  at maintenance dose of 18 (SD; 9, range  - 4- 40) mg/kg/day. 
These children were followed up for at least two months. The mean duration 
of therapy was 17 months (SD 15; range 2 – 54). Those who were followed 
up for less than two months, or who were on medications that affected weight 
or who were fed through the nasogastric tube were excluded from the study. 
The influence of the following clinical factors on weight change was studied: 
BMI at initiation, BMI category at follow up, BMI difference, age gender, 
maximum dose, average maintenance dose, average serum level, seizure 
type, neurocognitive status, duration of treatment, monotherapy versus 
polytherapy, current VPA usage (discontinued versus continued) and seizure 
control on VPA. The result of this study indicated that none of the factors 
tested significantly influenced the BMI difference but two factors: normal 
neurocognitive status (p=0.06) and primary generalized epilepsy type 
(p=0.07) approached statistical significance(Wirrell, 2003). 
Sharpe et al. (2009) reported  that the duration of therapy was a 
negative predictor of weight change in children with epilepsy being treated 
with VPA (Sharpe et al., 2009). In that study a retrospective chart review was 
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conducted in a paediatric neurology office involving 94 children with epilepsy 
who were aged between 2 – 20 years on a mean VPA dose of 18.3 
mg/kg/day (median 16.1; Range 5 – 39 mg/kg/day) who have been followed 
for a period of 4 – 89 months (mean 30 months median 26 months). Change 
in BMI z-score was used as a measure of weight change. The clinical 
predictors studied included: age at initiation, average valproate dose, 
average valproate level, duration of treatment, formulation (regular versus 
sprinkle or extended release), gender, concurrent medication, seizure control 
and ethnicity. There was a negative correlation between change in the BMI z-
score and duration of therapy(Sharpe et al., 2009). This finding is not 
surprising given that VPA causes an acute weight gain which tends to trend 
back to normal with continued treatment. In our study although significant 
weight gain was seen within the first twelve months this was not the case on 
long term follow up. In our study children followed up for a mean period of 4 
years had no significant change in the weight for age centile.  
However other studies could not determine any predictors of this 
weight change. Demir (2000) in a retrospective study that included 100 
children with epilepsy aged 15 months to 18 years on VPA dose of 30 – 50 
mg/kg/day over a period of 6 months to 5 years using weight velocity as a 
measure of weight change found that neither the epilepsy syndrome nor the 
seizure control category was a predictor of this ADR(Demir, 2000, Tanner 
and Whitehouse, 1976). In our study epilepsy syndrome was assessed there 
was no correlation between the epilepsy syndrome and the weight change 
phenotypes used in our study. Although collected information on seizure 
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control in our cohort we could not analyse the data due to the level of missing 
data.  
  
Some of the main drawbacks of all VPA-weight change studies to 
date include the retrospective nature of the studies and the use of different 
weight change phenotypes which are not very reliable due to the nature of 
children’s growth. Weight for age z-score for example is not a good measure 
of adiposity as it fails to distinguish shorter fatter children from taller children 
who are well proportioned (Novak, 1999). BMI has its own drawback as well. 
Normal BMIs vary across a wide spectrum of patients’ characteristics such 
as race, gender and pubertal status (Novak, 1999, Daniels et al., 1997).  One 
of the other main drawbacks of using weight change or BMI as measure of 
VPA-induced weight change is the wide within-child variability in these 
measures over a long period of time (Sharpe et al., 2009, Cole et al., 2005, 
Mei et al., 2004). These shifts in growth centiles are more common in 
children younger than six months old but occur less frequently in those older 
than 60 months (Mei et al., 2004). 
The findings in our study are in line with that of previous studies in 
children and adults many of which have not been able to reliably identify any 
strong clinical predictors of this ADR. Although some studies have identified 
candidate clinical predictors these have not been reliably replicated in follow 
on studies (Sharpe et al., 2009, Wirrell, 2003, Demir, 2000).  
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Since we have not been able to determine any clinical predictor of 
this ADR in our study we might assume that this ADR is idiopathic or 
idiosyncratic. This might point to some genetic contribution to this ADR. The 
next experimental chapter will therefore explore the genetic contribution to 
this ADR. 
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Chapter 4: Experimental Chapter 2 - 
Genotyping of subjects against the top 19 
single nucleotide polymorphisms associated 
with changes in body mass index 
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4.0.   Experimental Chapter 2 - Genotyping of subjects against the top 
19 single nucleotide polymorphisms associated with changes in body 
mass index 
4.1.    Introduction 
In Experimental Chapter 1 of this work VPA therapy was shown to be 
associated with significant weight gain in our paediatric cohort. A weight 
deviation of 5% or more of the expected weight was observed in 48% of the 
children treated with this medication. However, our analysis did not identify 
any significant clinical predictors of this weight gain. Further, we were unable 
to replicate the clinical predictors proposed in previous studies (in both adult 
and paediatric populations) to influence this ADR. Given the lack of robust 
clinical predictors, our findings and the wider literature would suggest this 
ADR is idiosyncratic and may thus have underlying genetic factors. We 
therefore set out to characterise genetic factors associated with VPA-induced 
weight change.  
Obesity, defined as body mass index (BMI) greater than 30 kg/m2, 
has a strong genetic component. Heritability studies have shown that genetic 
variation accounts for between 40-70% of the trait variance in obesity (Maes 
et al., 1997, Atwood et al., 2002)   
Prior to the completion of the Human Genome Project, our 
understanding of the genetics of obesity came from i) mutations in genes 
causing monogenic obesity syndromes in humans and ii) animal studies 
((Hofker & Wijmenga, 2009). Genes identified through these efforts such as 
transmembrane protein 18 (TMEM18), FTO, MC4R, Glucosamine-6-
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phosphate deaminase 2 (GNPDA2), Brain-derived neurotrophic factor 
(BDNF), Neuronal growth regulator 1 (NEGR1), SH2B adaptor protein 1 
(SH2B1), ETV5,  Mitochondrial carrier 2 (MTCH2),  Potassium channel 
tetramerization domain containing 15 gene (KCTD15), dnaJ homolog 
subfamily C member 27 (RBJ), GPRC5B are thought to influence the 
hypothalamic energy regulatory centre (Willer et al., 2009, Speliotes et al., 
2010, Loos et al., 2008, Andreasen et al., 2009, Meyre et al., 2009, den 
Hoed et al., 2013)(Scuteri et al., 2007, Lindgren et al., 2009).  
However with the completion of the Human Genome Project there 
has been an explosion of large population-based GWAS studies focusing on 
the phenotype of obesity (Willer et al., 2009, Speliotes et al., 2010, Loos et 
al., 2008, Andreasen et al., 2009, Meyre et al., 2009, den Hoed et al., 
2013)(Scuteri et al., 2007, Lindgren et al., 2009).(Speliotes et al., 2010, 
Thomsen et al., 2012) (den Hoed et al., 2013, Willer et al., 2009, Garver et 
al., 2013, Czerwensky et al., 2013). However only about 2 – 4% of the 
variation in weight observed in a population can be accounted for by the 
SNPs identified through these large GWAS studies.  
Extreme obesity might be due to highly penetrant, rare alleles that 
might be difficult to identify through genome wide association (GWA) studies 
in the general population; as these studies focus on common variation. 
Exome or genome sequencing will be required to characterise rare variation 
in the context of obesity phenotypes. 
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Variations across the gene encoding the fat mass and obesity-
associated protein (FTO) were the first to be associated with predisposition 
to obesity in a GWA study for type 2 diabetes (Hofker and Wijmenga, 2009, 
Speliotes et al., 2010). Further studies reported the association of 
melanocortin 4 receptor (MC4R) and PCSK1 with syndromic obesity in 
humans and animals (Benzinou, 2008). Since FTO, MC4R and proprotein 
convertase subtilisin/ kexin type 1 (PCSK1), other obesity and obesity-related 
loci have been identified through GWAS including the transmembrane 
protein (TMEM18), glucosamine-6-phosphate deaminase 2 (GNPDA2), brain 
derived natriuretic factor (BDNF), neuronal growth regulator 1 (NEGR1), scr 
homology 2 containing putative adaptor protein 1 (SH2B1) and others 
(Frayling et al., 2007).  
While the initial BMI GWA studies involved large numbers of 
individuals (25,000 and 32,000) from the general population, the next 
reported study focused on 1,380 Europeans with extreme obesity. In addition 
to discovering additional loci, the studies validated two of the three loci 
(MC4R and FTO) previously associated with changes in BMI (Hofker & 
Wijmenga, 2009; Meyre et al, 2009; Thorleifsson, 2009; Willer et al 2009). 
The largest of the BMI studies involved about 250,000 individuals and 
revealed 18 new BMI associated loci (Speliotes, 2009) (See Table 20 for a 
list of some of the BMI loci). Most of these studies have employed meta-
analysis of studies from the Caucasian population in order to improve the 
power to detect further novel loci (Speliotes et al., 2010, Magi and Morris, 
2010, Willer et al., 2009) 
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 In all, about 52 loci for obesity traits have now been discovered 
through GWAS.   These have only modest effect sizes with odd ratios (per 
allele) of between 1.2 and 1.5 (Speliotes et al., 2010, Farooqi, 2013, Maes et 
al., 2011). Individuals that inherit higher number of these risk alleles are more 
likely to experience increased BMI compared to the individuals with arraying 
lower numbers of the risk alleles (Speliotes, 2010).  
 Among all the BMI loci that have been reported so far, the FTO SNPs 
account for the greatest proportion of the variance in BMI (about 0.34%) 
(Speliotes, 2010). MC4R is another common obesity locus associated with 
modest effects on BMI (Willer, 2009). For a given minor allele frequency 
(MAF) the effect sizes of the more recently discovered loci are smaller than 
the ones discovered in earlier studies (Speliotes, 2010).  
 The directional effect of the majority of these alleles seem be similar in 
both adults and children (Speliotes, 2010, Meyre, 2009). In addition, the 
alleles associated with increased BMI were closely associated with increased 
body weight and increased body fat percentage (Speliotes, 2010).  
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Table 20: Loci associated with variations in BMI 
SNP Gene Per allele change in 
BMI (beta) 
Experimental 
variance (%) 
References 
R1421085 FTO 0.39 NA Hofker & Wijmenger, 2009 
Rs155902 FTO 0.33 0.34 Willer et al, 2009; Speliotes et al, 2010 
Rs17782313 MC4R 0.20 0.10 Willer et al, 2009 
Rs571312 MC4R 0.23 0.10 Hofker & Wijmenger, 2009; Speliotes et al, 
2010 
Rs1805081 NPC1 -0.087 NA Hofker & Wijmenger, 2009 
Rs1424233 MAF 0.091 NA Hofker & Wijmenger, 2009 
Rs10508503 PTER 0.144 NA Hofker & Wijmenger, 2009 
Rs4712662 PRL 0.031 NA Hofker & Wijmenger, 2009 
Rs10938397 GNPDA2 0.19 0.13 Speliotes et al, 2010; Willer et al, 2009 
Rs10767664 BDNF 0.19 0.07 Speliotes et al, 2010; Willer et al, 2009 
Rs2515762 NEGR1 0.13 0.04 Speliotes et al, 2010; Willer et al, 2009 
Rs9816226 ETV5 0.15 0.03 Speliotes et al, 2010; Willer et al, 2009 
Rs3817334 MTCH2 0.06 0.01 Speliotes et al, 2010 
Rs29941 KCTD15 0.06 0.00 Speliotes et al, 2010 
Rs713586 RBJ 0.14 0.06 Speliotes et al, 2010 
Rs12444979 GPRC5B 0.17 0.03 Speliotes et al, 2010 
Rs2287019 QPCTL 0.15 0.04 Speliotes et al, 2010 
Rs1514175 TNNI3K 0.07 0.02 Speliotes et al, 2010 
Rs13107326 SLC39A8 0.19 0.03 Speliotes et al, 2010 
Rs2112347 FLJ35779 0.10 0.02 Speliotes et al, 2010 
Rs2241423 MAP2K5 0.13 0.03 Speliotes et al, 2010 
Rs7359397 SH2B1 0.15 0.05 Speliotes et al, 2010, Willer et al, 2009 
Rs281575 NEGR1 0.10 0.03 Willer et al, 2009 
Legend: 
 M4CR –melanocortin-4 receptor;  FTO -Fat mass and obesity  ; MAF - V-maf musculoaponeurotic fibrosarcoma oncogene homolog 
; PTER -  Phosphotriesterase-Related Protein; PRL - ;  prolactin BDNF - Brain-Derived Neurotrophic Factor ; SH2B1 - Src homology 
2 B adapter protein 1 ; TMEM18 - Transmembrane protein 18  ; MTCH2 - Mitochondrial Carrier 2 ; GNPDA2 -  glucosamine-6-
phosphate deaminase 2; NEGR1- neuronal growth regulator 1 ; KCTD15 -  potassium channel tetramerization domain containing 15; 
RBJ - dnaJ homolog subfamily C member 27; ETV5 -  ets variant 5; KCTD15  - encoding potassium channel tetramerisation domain 
containing 15;  GPRC5B - G protein-coupled receptor, family C, group 5; QPCTL - glutaminyl-peptide cyclotransferase-like; 
TNN13K; SLC39A8 - solute carrier family 39 (zinc transporter), member 8; TNNI3K- fucose-1-phosphate guanylyltransferase and 
TNNI3 interacting kinase; member 8; FLJ35779 - encoding POC5 centriolar protein homolog; MAP2K5 - mitogen-activated protein 
kinase 5; SH2B1 - SH2B- adaptor protein 1; NPC1 – Niemann-Pick disease type C1; PETR - 
 
Although genetic susceptibility to VPA-induced weight gain has been 
proposed and demonstrated in twin studies, no specific gene or SNP has 
been implicated (Maes et al., 1997, Verrotti et al., 1999b). In this chapter, we 
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test the hypothesis that valproate induced weight gain correlates with genetic 
variations that have been shown, in GWA studies, to influence BMI.  
           
4.2.   Methods 
4.2.1.    Weight change phenotype  
The primary phenotype used was the maximum percentage weight change 
from expected weight within the first twelve months of VPA therapy (see 
section 3.4.1 for the description of phenotype calculation). The second 
phenotype used was the average change in the weight for age z-score 
(WAZ).  We planned to include any clinical factor shown to be significantly 
correlated with the weight ADR (see Experimental Chapter 1 above) as a co-
factor in the analysis but since the results from the clinical predictor analysis 
indicated that none of the clinical factors influenced weight gain due to VPA, 
no co-factor was incorporated in the genetic analysis  
 
4.2.2.    Cohort  
For a full description of the cohort of subjects in the study see Sections 2.6 
and 2,7 in the General Methods Chapter above. 
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4.2.3.    Selection of variants for genotyping  
We selected 17 obesity variants (SNPs) for this study. The SNPs were 
selected based on the following criteria:  
1. The SNPs must have been replicated and validated in previous 
studies; 
2. The SNPs must have been robustly associated with changes in BMI. 
These SNPs were sourced from published GWA studies (Klein et al., 2005, 
Willer et al., 2009, Speliotes et al., 2010, Loos et al., 2008, Andreasen et al., 
2009, Meyre et al., 2009, den Hoed et al., 2013, Scuteri et al., 2007).   These 
SNPs have been replicated and validated in several studies and have thus 
been shown to robustly associate with obesity (Lindgren et al., 2009, 
Speliotes et al., 2010, Thomsen et al., 2012, den Hoed et al., 2013, Willer et 
al., 2009, Garver et al., 2013). The selected variants are listed in Table 21 
below. 
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Table 21: Top 17 SNPs associated with BMI variations in the general population 
CHR SNP CHR position Gene “weight 
gain” allele 
Effect size  
(BETA) 
Reported by 
18 rs17782313 
(C/T) 
0 57851097 MC4R C 1.22 (Czerwensky et al., 
2013, Cauchi et al., 
2009) 
18 rs17700633 
(A/G) 
0 57929432  A 0.21   (Meyre et al., 2009) 
16 rs9939609 
(A/T)  
0 53820527 FTO A 0.33 (Loos et al., 2008) 
20 rs6020846 
(A/G) 
0 36405667 CTNNBL1 G 0.83 (Willer et al., 2009) 
20 rs6013029 
(G/T) 
0 36399580 CTNNBL1 T  (Andreasen et al., 2009) 
16 rs1424233 
(A/G) 
0 79682751 MAF A  1.39 (Andreasen et al., 2009) 
18 rs1805081 
(A/G) 
0 21140432 NPC1 A 0.75  (Meyre et al., 2009) 
10 rs10508503 
(C/T) 
0 16299951 PTER C 0.64 (Meyre et al., 2009, 
Garver et al., 2013) 
6 rs4712652  0 22078615 PRL G  (Cotsapas et al., 2009, 
den Hoed et al., 2013) 
16 rs7498665 
(A/G) 
0 28883241 BDNF and 
SH2B1 
G 0.15 (Cotsapas et al., 2009, 
Robiou-du-Pont et al., 
2013) 
2 rs6548238 
(C/T) 
0 634905 TMEM18 C 0.26 (Willer et al., 2009, 
Thomsen et al., 2012) 
11 rs10838738 
(G/A) 
0 47663049 MTCH2 G 0.07 (Willer et al., 2009) 
4 rs10938397 
(G/A)  
0 45182527 GNPDA2 G 0.18 (Willer et al., 2009) 
16 rs1421085  0 53800954 FTO T -0.155  (Speliotes et al., 2010, 
Lindgren et al., 2009) 
1 rs2815752 
(A/G) 
0 72812440 NEGR1 A 0.13 (Scuteri et al., 2007) 
16 rs9930506 
(A/G) 
0 53830465 FTO G -0.118 (Speliotes et al., 2010) 
19 rs11084753 
(G/A)  
0 34322137 KCTD15 G 0.07 (Scuteri et al., 2007) 
Legend: 
  M4CR –melanocortin-4 receptor;  FTO -Fat mass and obesity  ; MAF - V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog; PTER -  Phosphotriesterase-Related Protein; PRL - ;  prolactin BDNF - Brain-Derived Neurotrophic Factor ; SH2B1 - Src 
homology 2 B adapter protein 1 ; TMEM18 - Transmembrane protein 18  ; MTCH2 - Mitochondrial Carrier 2 ; GNPDA2 -  
glucosamine-6-phosphate deaminase 2; NEGR1- neuronal growth regulator 1 ; KCTD15 -  potassium channel tetramerization 
domain containing 15;  CTNNBL1 – catenin, beta like 1;  A – adenine; G- guanine; T – thymine; C - cytosine 
Effect size –the degree of relation between each SNP and BMI 
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4.2.4.    Genotyping 
Genotyping of the 17 SNPs was carried out at LGC Genomics using the 
KASP Genotyping Chemistry method (See the KASPTM Genotyping 
Chemistry by LGC Genomics section 2.9.7 in the General Methods Chapter).  
 
4.2.5.    Genetic analysis  
The analysis was in two parts. The first part involved linear regression 
(genotype against the quantitative trait of weight change phenotype) in two 
subsets of the overall cohort (see section 1.17).   
Sub-cohort 1) 123 individuals with the following phenotyping: maximum 
percentage weight change.  
Sub-cohort 2: 73 individuals using the WAZ change in the first year of 
treatment. There was no overlap in patients between the two cohorts. A fixed 
effect meta-analysis of the summary statistics resulting from these two sets 
of linear regression was conducted using the Metal Meta statistical package 
(Studies) and a total of 196 subjects were included in the meta-analysis.  
The second part of the analysis was a case-control association of the 
discrete trait of ADR-associated weight gain in sub-cohort 1 patients only. 
The sub-cohort 1 subjects (whose weight change was analyzed using the 
Hoey et al growth chart) were divided into three main categories according to 
their maximum percentage weight change: i) ‘controls’, ii) ‘cases’ and iii) 
‘others’ – i.e. those in between the cases and controls. Controls were 
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considered as those patients whose maximum percentage weight change 
was less than 5% of the expected weight. Cases were considered as those 
patients with maximum percentage weight change equal or greater than 10% 
of the expected weight. Those in the ‘others’ group (i.e. with maximum weight 
change greater than 5% and less than 10%) were not considered in the 
case-control analysis. Case-control analysis was conducted using the 
Fisher’s exact test.  
The analysis was conducted using PuTTy-link (PLINK) software (Purcell et 
al, 2007) a bespoke analysis platform. The steps undertaken in conducting 
the genetic analysis were as follows: 
1. PED and MAP files were generated using the genotyping data. The 
genotype data was then cleaned up by using the PLINK command tool 
that includes only the SNPs with more than 90% genotype assay 
success rate. SNPs with more than 10% missing values (failure rates) 
were removed. Hence the analysis was carried out with a new PED 
and MAP files containing the ‘cleaned’ data. 
2. Individuals with incomplete phenotyping (e.g. without complete weight 
data) were also excluded. 
3. The statistical methods employed for the analysis of the association of 
the quantitative traits of maximum percentage weight gain and 
average WAZ change using the PLINK software include using the 
quantitative trait association test module. This tests for association of 
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quantitative traits with the SNP data using either the asymptotic or 
empirical significance values (Willer et al., 2009) . 
 
4.2.6.     Meta-analysis 
Meta-analysis between the maximum percentage weight change and 
average WAZ change phenotypes was conducted using the METAL software 
package (Purcell et al., 2003). METAL is used in meta-analysis of GWA 
studies by combining either the p-values or the test statistics across the 
studies. The results outputs are presented in text files (Speliotes et al., 
2010). The input file requires the following information: the effect allele, the 
non-effect allele, the marker SNP, the effect (beta value), the p-value and the 
weight or sample size (Speliotes et al., 2010). 
When carrying out the meta-analysis we ensured there was no overlap in 
subjects tested across the two phenotypes. The analysis option used was 
default mode –SCHEME SAMPLESIZE  command  which combines the p-
values and the direction of effect from all the studies taking into account the 
sample sizes of those studies being analyzed (Abecasis et al., 2011).  This 
analysis scheme applies the fixed effect meta-analysis model which assumes 
that one true effect size underlies all the studies in the analysis and that all 
the differences in the observed effects are due to sampling error (Borenstein 
et al., 2009; Abecasis et al, 2011).  
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4.2.7.     Correction for multiple testing  
As the subjects were genotyped for 17 SNPs, any p values generated from 
significance testing were corrected for the number of independent tests 
conducted using the Bonferroni method. The p-value derived from each test 
were therefore be multiplied by the number of tests (n = 17) to get the 
true/corrected p-value.   
 
4.3.    Results  
Table 21 above outlines the 17 BMI-associated SNPs that were genotyped in 
our subjects. It indicates the chromosome number, the position on that 
chromosome, gene location and reference. The results of our genotyping 
indicated that none of the SNPs violated Hardy-Weinberg equilibrium after 
correcting for multiple testing.  
Table 22 below outlines the result of the linear regression of the quantitative 
maximum percentage weight change phenotype against each of the 17 
SNPs. This analysis was conducted in ‘sub-cohort 1’ (n=123), on which the 
maximum percentage weight change phenotype was available. rs10938397 
showed a significant association with maximum percentage weight change 
(p-value =  0.03, uncorrected). While the ‘A’ allele of rs10938397 was 
associated with weight loss, the ‘G’ allele was associated with weight gain 
(see figure 11 below).  Rs1805081 SNP was borderline significant (p-value = 
0.058, uncorrected). The ‘C’ allele of the rs1805081 SNP was associated 
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with weight gain while the ‘T’ allele was associated with weight loss as shown 
in figure 12 below. 
 
 
Figure 11: Bar chart showing the average maximum percentage weight gain 
for the different genotype of rs10938397 for individuals in sub-cohort 1 
(weight change data derived from the Hoey  et. al growth chart)  
Figure 11 legend:  AA – adenine/adenine; GA – guanine/adenine; GG – 
guanine/guanine; p – level of significance 
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Figure 12: Bar chart showing the average maximum percentage weight gain 
for the different genotype of rs1805081 for individuals in sub-cohort 1 (weight 
change data derived from the Hoey et. al growth chart)  
Fig 12 legend:  CC –cytosine/cytosine; CT – cytosine/thymine; TT – 
thymine/thymine 
p = significance level 
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Table 22: Association   between maximum weight change on Hoey centile 
and the 17 top BMI SNPs showing the number of non-missing values, the 
beta standard error R2, T and p-value of the association 
CHR SNP A1 A2 BP NMISS BETA SE R2 T P 
1 rs2815752 T C 72812440 23 .257 1.724 0.000184 1491 0.8817 
2 rs6548238 C T 634905 21 -0.3559 2.003 0.000265 .1777 0.8593 
4 rs10938397 A G 45182527 123 3.529 1.635 0.0371 .159 0.03282* 
6 rs4712652 A G 22078615 121 1.476 1.636 0.006794 .9022 0.3688 
10 rs10508503 C T 16299951 122 1.055 3.115 0.000955 .3386 0.7355 
11 rs10838738 A G 47663049 123 -0.322 1.681 0.000303 0.1916 0.8484 
16 rs7498665 A G 28883241 123 1.511 1.543 0.007863 .9792 0.3294 
16 rs1421085 T C 53800954 120 1.632 1.531 0.009535 .066 0.2887 
16 rs9939609 A T 53820527 123 1.416 1.476 0.00755 .9595 0.3392 
16 rs9930506 A G 53830465 120 0.9769 1.505 0.00356 .6493 0.5174 
16 rs1424233 A G 79682751 123 1.443 1.46 0.008013 .9886 0.3248 
18 rs1805081 T C 21140432 122 3.025 1.578 0.02969 .916 0.05771* 
18 rs17782313 T C 57851097 123 -0.5084 1.912 0.000584 0.2659 0.7908 
18 rs17700633 G A 57929432 122 -0.5882 1.484 0.001308 0.3964 0.6925 
19 rs11084753 G A 34322137 123 1.489 1.745 0.005978 .853 0.3953 
20 rs6013029 G T 36399580 121 6.488 4.111 0.0205 .578 0.1172 
20 rs6020846 A G 36405667 123 5.125 3.347 0.019 .531 0.1284 
Legend: CHR – Chromosome number; SNP – SNP identifier; BP – the physical position of SNP (base pairs)  NMISS – number of non-missing 
values; BETA = regression coefficient; SE = standard error r2 –regression r-squared ;  p – statistical significance. T –Wald test (based on t-
distribution; A1 – test allele; A2 – major allele; A – adenine; G- guanine; T – thymine; C - cytosine 
 
 
Table 23 below outlines the results of the quantitative trait analysis using the 
WAZ as a dependent variable. This analysis was conducted on subcohort 2 
(n=73 individuals), for whom the weight for age Z-score phenotype was 
available. Five SNPs achieved statistical significance (uncorrected); 
rs1805081 (p = 0.03), rs7498665 (p=0.03), rs17782313 (p = 0.03), 
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rs6020846 (p=0.01) and rs10508503 (p = 0.03). (See figures 13 – 17 below). 
The only SNP that showed some association across both 
phenotypes/cohorts was rs1805081. However none of the association 
statistics achieved the Bonferroni corrected threshold of 0.002 (0.05/17). See 
Tables 24 below. 
 
 
 
Figure 13: Bar chart showing the average change in weight-for-age z-score 
for the different genotypes of rs10508503 for individuals in sub-cohort 2 
(weight change data derived from the WHO growth chart). 
Figure 13 legend: CC – cytosine/cytosine; TC – thymine/cytosine; p – level of 
significance 
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Figure 14: Bar chart showing the average change in weight-for-age z-score 
for the different genotypes of rs7498665 for individuals in sub-cohort 2 
(weight change data derived from the WHO growth chart). 
Figure 14 legend: AA – adenine/adenine; GA – guanine/adenine; GG – 
guanine/guanine; p – level of significance 
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Figure 15: Bar chart showing the average change in weight-for-age z-score 
for the different genotypes of rs6020846 for individuals in sub-cohort 2 
(weight change data derived from the WHO growth chart). 
Figure 11 legend: AA – adenine/adenine; GA – guanine/adenine; p – level of 
significance 
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Figure 16: Bar chart showing the average weight-for-age z-score for the 
different genotypes of rs17782313 for individuals in sub-cohort 2 (weight 
change data derived from the WHO growth chart). 
Figure 16 legend: CC – cytosine/cytosine; TC – thymine/cytosine; TT – 
thymine/thymine; p – level of significance 
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Figure 17: Bar chart showing the average weight-for-age z-score for the 
different genotype of rs1805081 for individuals in sub-cohort 2 (weight 
change data derived from the WHO growth chart). 
Figure 16 legend: CC – cytosine/cytosine; CT – cytosine/thymine;   
 TT – thymine/thymine; p – level of significance 
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Table 23: Linear association between weight for age Z-score change on the 
WHO weight for age centile chart and the 17 top BMI SNPs in children 
exposed to VPA for <1 year 
CHR SNP BP A1  A2 NMISS BETA STAT P BONF 
1 rs2815752 72812440 C T 73 9.725 1.084 0.2818 1 
2 rs6548238 634905 T C 73 5.811 0.499 0.6193 1 
4 rs10938397 45182527 G A 73 11.97 1.427 0.1579 1 
6 rs4712652 22078615 G A 73 4.823 0.6465 0.52 1 
10 rs10508503 16299951 T C 73 -32.24 -2.197 0.03128* 0.5318 
11 rs10838738 47663049 G A 73 -5.008 -0.5372 0.5928 1 
16 rs7498665 28883241 G A 71 18.11 2.217 0.02995* 0.5091 
16 rs1421085 53800954 C T 73 3.608 0.4359 0.6642 1 
16 rs9939609 53820527 A T 73 5.353 0.6375 0.5258 1 
16 rs9930506 53830465 G A 72 6.859 0.8441 0.4015 1 
16 rs1424233 79682751 G A 73 -0.7363 -0.08517 0.9324 1 
18 rs1805081 21140432 C T 70 17.43 2.27 0.02637* 0.4482 
18 rs17782313 57851097 C T 72 20.7 2.182 0.03249* 0.5524 
18 rs17700633 57929432 A G 72 -5.018 -0.5127 0.6098 1 
19 rs11084753 34322137 A G 72 -2.329 -0.2633 0.7931 1 
20 rs6013029 36399580 T G 72 -40.8 -1.82 0.07297 1 
20 rs6020846 36405667 G A 73 -47.64 -2.524 0.01384* 0.2353 
 Legend: 
CHR – Chromosome code ; SNP name; BP – the physical position of SNP (base pairs)  A1 – minor allele; NMISS 
– number of non-missing values; BETA=  beta coefficient, STAT = p – statistical significance. Beta  -  regression 
coefficient; BONF – Bonferroni corrected p value; STAT –coefficient t-statistics; A – adenine; G- guanine; T – 
thymine; C - cytosine 
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Fixed effects meta-analysis of the unadjusted results of the two sets of 
quantitative analysis showed that three of the 17 SNPs were significantly 
associated with quantitative weight centile change rs10938397 (p = 0.01; 
direction of effect = ++),  rs7498665 (p =  0.04; direction of effect = ++ ) and 
rs1805081 (p = 0.004; direction of effect = ++). See Table 24 below. Note 
that a positive z-score in Table 24 indicates that the major allele A2 is the 
weight gain allele while negative z-score in the same table indicates that A1 
is the weight gain allele. 
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Table 24: Meta-analysis of the results of the genetic analysis of the two 
weight change phenotypes – maximum percentage weight change and 
change in weight-for-age z-score 
SNP A1 (our 
result) 
A2 (our 
study) 
A1 
(original 
papers) 
Weight Z-score P-value Direction 
rs9930506 A G G 192 1.026 0.3051 ++ 
rs9939609 A T A 196 1.144 0.2525 -- 
rs17782313 T C C 195 1.089 0.2763 +- 
rs10938397 A G G 196 2.553 0.01069 ++* 
rs7498665 A G G 194 2.09 0.03663 ++* 
rs17700633 A G A 194 0.625 0.5323 ++ 
rs6548238 T C C 194 -0.165 0.8691 -+ 
rs1421085 T C T 193 1.104 0.2698 ++ 
rs1805081 T C A 192 2.854 0.004321 ++** 
rs4712652 A G G 194 1.104 0.2694 ++ 
rs2815752 T C A 196 0.775 0.4385 ++ 
rs10838738 A G G 196 -0.478 0.6328 -- 
rs6020846 A G G 196 -0.298 0.7659 -+ 
rs10508503 T C C 195 1.05 0.2935 +- 
rs11084753 A G G 195 -0.516 0.606 +- 
rs6013029 T C T 193 -0.145 0.8845 +- 
rs1424233 A G A 196 0.728 0.4665 -+ 
 Legend 
A1 – minor allele (test allele);  Direction of effect: ++ = both allele 1and allele 2 in a positive direction; +- = allele 
1 in positive direction, allele 2 in negative direction; -+ = allele 1 negative, allele 2 positive; ++  = both allele in 
positive direction; -- = both allele in negative direction.  A2 (our study) – other major allele; A – adenine; G- 
guanine; T – thymine; C - cytosine 
 
 
rs10938397: The ‘G’ allele of rs10938397 was associated with weight gain in 
the original discovery paper (Abecasis et al., 2011). 
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. It was reported in that original publication to explain 0.18% of trait variance.  
In our meta-analysis of the two phenotypes, rs10938397 explains 3.7% of 
trait variance.  The direction of effect in the original was the same as in our 
study, with the “G” allele as the weight gain allele. See Table 25 and figure 
18 below. 
 
 
Figure 18: Bar chart showing the maximum percentage weight change for the 
different genotypes of rs10938397 (weight change data derived from the 
Hoey et. al growth chart) 
Figure 18 legend:   AA – adenine/adenine; GA – guanine/adenine; 
 GG – guanine/guanine; p – level of significance 
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rs1805081:  The “T” allele of rs1805081 was associated with weight gain in 
the original discovery paper (Speliotes et al., 2010). The direction of effect 
was appears to be the opposite in our study, with the ‘C’ allele being 
associated with weight gain and the variant explaining 3% of trait variance 
here., See Table 25 & figure 19 
 
 
Figure 19: Bar chart showing the maximum percentage weight change for the 
different genotypes of the SNP rs18505081 (weight change data derived 
from the Hoey et. al., growth chart) 
Figure 19 legend: CC – cytosine/cytosine; CT – cytosine/thymine;  
TT – thymine/thymine; p – level of significance 
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Rs7498665. The ‘G’ allele of this variant was associated with weight gain in 
the original discovery paper (Meyre et al., 2009).  In our analysis the ‘G’ 
allele was also associated with weight gain, and explained 0.7% of trait 
variants. The direction of effect was therefore the same as that of the original 
publication. See Table 25 and figure 20 below. 
 
Figure 20: Bar chart showing the maximum percentage weight change for the 
different genotypes of rs7498665 for individuals in subcohort 1 (weight 
change data derived from the Hoey et. al growth chart) 
Figure 20 legend: AA – adenine/adenine; GA – guanine/adenine;  
GG – guanine/guanine; p – level of significance 
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rs1421085: The result of the discrete weight change analysis indicates that 
only one SNP, rs1421085 (p = 0.04; odds ratio= 1.9), was statistically 
significantly associated with weight change. However Bonferroni correction 
for multiple testing indicates that none of the SNPs was significantly 
associated with discrete weight change (see Tables 26 & 27 and figure 21 
below). 
 
Figure 21: Bar chart showing the maximum percentage weight change for the 
different genotypes of the SNP rs1421085 for individuals in subcohort 1 
(weight change data derived from the Hoey et. al., growth chart) 
Figure 21 legend: CC – cytosine/cytosine; TC – thymine/cytosine;  
TT – thymine/thymine; p – level of significance 
 
 
184 
 
 
Table 25: Comparison of the risk allele, effect size and direction of effect 
between the Speliotes (2010) study by Speliotes et al. and our study 
CHR SNP Allele 
associated 
with 
weight(origi
nal paper) 
Allele 
associated 
with weight 
(Our study) 
r
2
 (our study) r
2
 (Speloites 
2010 
study(Willer et 
al., 2009)) 
P (Our study) 
1 rs2815752 A T 0.000184 0.04 0.4385 
2 rs6548238 C T 0.000265 NA 0.8691 
4 rs10938397 G G 0.0371 0.08 0.01069 
6 rs4712652 G A 0.006794 NA 0.2694 
10 rs10508503 C T 0.000955 NA 0.2935 
11 rs10838738 G A 0.000303 NA 0.6328 
16 rs7498665 G G 0.007863 NA 0.03663 
16 rs1421085 T T 0.009535 NA 0.2698 
16 rs9939609 A A 0.00755 NA 0.2525 
16 rs9930506 A A 0.00356 NA 0.3051 
16 rs1424233 A A 0.008013 NA 0.4665 
18 rs1805081 A C 0.02969 NA 0.004321 
18 rs17782313 C T 0.000584 NA 0.2763 
18 rs17700633 A A 0.001308 NA 0.5323 
19 rs11084753 G A 0.005978 NA 0.606 
20 rs6013029 T T 0.0205 NA 0.8845 
20 rs6020846 G A 0.019 NA 0.7649 
Legend 
CHR -  chromosome code; SNP – single nucleotide polymorphism identifier; r2 – regression r-squared  or the 
fraction of variance explained  by the model; p – statistical significance 
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Table 26: Discrete factor analysis for maximum weight change (maximum 
weight change ≤ 5% versus maximum weight ≥ 10%) 
CHR SNP BP A1 F_A F_U A2 P OR 
1 rs2815752 72812440 C 0.4028 0.3433 T 0.4485 1.29 
2 rs6548238 634905 T 0.1714 0.2045 C 0.7084 0.8046 
4 rs10938397 45182527 G 0.4722 0.3433 A 0.07437 1.712 
6 rs4712652 22078615 G 0.5 0.4091 A 0.2357 1.444 
10 rs10508503 16299951 T 0.05556 0.06061 C 1 0.9118 
11 rs10838738 47663049 G 0.3611 0.3433 A 0.8784 1.081 
16 rs7498665 28883241 G 0.4444 0.3358 A 0.1335 1.582 
16 rs1421085 53800954 C 0.4265 0.2803 T 0.04063** 1.909** 
16 rs9939609 53820527 A 0.4444 0.306 T 0.06633 1.815 
16 rs9930506 53830465 G 0.4444 0.3125 A 0.06739 1.76 
16 rs1424233 79682751 G 0.5 0.4627 A 0.6617 1.161 
18 rs1805081 21140432 C 0.3889 0.3561 T 0.6515 1.151 
18 rs17782313 57851097 C 0.2639 0.2687 T 1 0.9759 
18 rs17700633 57929432 A 0.3429 0.3582 G 0.8781 0.9348 
19 rs11084753 34322137 A 0.3333 0.3284 G 1 1.023 
20 rs6013029 36399580 T 0.06944 0.02273 G 0.1335 3.209 
20 rs6020846 36405667 G 0.09722 0.03731 A 0.1162 2.778 
Legend 
CHR – Chromosome code ; SNP name; BP – the physical position of SNP (base pairs);  A1 – minor allele (test 
allele); A2- major allele;  p – statistical significance; OR – odds ratio; SE – standard error; F_A – Case allele 
frequency; F_U - control allele frequency; 
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Table 27: Discrete factor analysis for maximum weight change (maximum 
weight change ≤ 5% versus maximum weight ≥ 10%) with correction for 
multiple testing 
CHR SNP UNADJ GC BONF HOLM SIDAK_S
S 
SIDAK_S
D 
FDR_B
H 
FDR_B
Y 
16 rs1421085 0.04063 0.3066 0.5689 0.5689 0.4405 0.4405 0.2603 0.8464 
16 rs9939609 0.06633 0.3592 0.9287 0.8623 0.6175 0.5903 0.2603 0.8464 
16 rs9930506 0.06739 0.361 0.9435 0.8623 0.6235 0.5903 0.2603 0.8464 
4 rs1093839
7 
0.07437 0.3729 1 0.8623 0.6611 0.5903 0.2603 0.8464 
20 rs6020846 0.1162 0.4328 1 1 0.8226 0.7093 0.267 0.8683 
20 rs6013029 0.1335 0.4537 1 1 0.8654 0.7245 0.267 0.8683 
16 rs7498665 0.1335 0.4537 1 1 0.8655 0.7245 0.267 0.8683 
6 rs4712652 0.2357 0.5537 1 1 0.9768 0.8477 0.4125 1 
1 rs2815752 0.4485 0.7051 1 1 0.9998 0.9719 0.6977 1 
18 rs1805081 0.6515 0.8216 1 1 1 0.9949 0.8264 1 
16 rs1424233 0.6617 0.827 1 1 1 0.9949 0.8264 1 
2 rs6548238 0.7084 0.8518 1 1 1 0.9949 0.8264 1 
18 rs1770063
3 
0.8781 0.939 1 1 1 0.9949 0.8784 1 
11 rs1083873
8 
0.8784 0.9391 1 1 1 0.9949 0.8784 1 
Legend 
CHR – Chromosome code ; SNP name; BP – the physical position of SNP (base pairs);  UNADJ  - Unadjusted p-
value ; GC - Genomic-control corrected p-values;  BONF - Bonferroni single-step adjusted p-values ; HOLM - Holm 
(1979) step-down adjusted p-values ; SIDAK_SS - Sidak single-step adjusted p-values ; SIDAK _SD - Sidak single-
step adjusted p-values; FDR_BH - Benjamini & Hochberg (1995) step-up FDR control; FDR_BY - Benjamini & 
Yekutieli (2001) step-up FDR control 
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4.4.       Discussion 
 In summary, in the unadjusted linear regression analysis of the 
quantitative traits the following SNPs achieved nominally significant 
relationship with maximum percentage weight change and weight for age z-
score: rs10938397 (GNPDA2;p = 0.03), rs1805081 (NPC1; p = 0.03), 
rs7498665 (BDNF and SH2B1; p=0.03),  rs6020846 (CTNNBL1; p=0.01) and 
rs10508503 (PTER; p =0.03). A meta-analysis of the two studies indicates 
that the following SNPs were nominally associated with weight change; 
rs10938397 (GNPDA2) rs7498665 (BDNF and SH2B1) and 1805081 
(NPC1).  However, none of these nominally associated SNPs survived 
Bonferroni correction for multiple testing. It should be noted that Bonferroni 
correction in this context is highly conservative as there were clear a-priori 
evidence motivating these tests. 
Compared with the original studies, while some SNPs (rs10938397 and 
rs7498665)  that were significantly associated with quantitative weight gain in 
the general population exert the same directional effect in those affected by 
the VPA-induced weight change, other SNPs (rs1805081) associated with 
weight change in the general population have opposite direction of effect in 
those affected by the VPA-induced weight change. In addition it seems that 
VPA therapy is associated with markedly increased effect size of some SNPs 
(rs7498665 and 1805081) on weight change (See Tables 21 and 22 above). 
Discrete test analysis however indicates that only one SNP (rs1421085 near 
the FTO gene) was significantly associated with discrete weight change in 
children exposed to VPA therapy. This might be due to the more study power 
188 
 
with the quantitative measure of weight change compared with the discrete 
weight change analysis.  
These results provide some support to the views that some genetic variants 
associate i) with changes in BMI in the general population are also ii) with 
VPA-induced weight change and with the degree of weight change 
associated with exposure to this medication. It appears that individuals who 
inherit these variants have increased risks of experiencing some weight 
change when exposed to this medication. The direction of weight/ BMI effect 
exerted by the exposure of these individuals to VPA seems to be the same 
as in the general population implying that exposure to VPA enhances the 
BMI change effects of those SNPs. However in one of the three SNPs that 
had nominally significant effect on VPA-induced weight change in the meta-
analysis result, the direction of weight change in those affected by VPA-
induced weight change was in the opposite direction to that of the general 
population. This indicates that the weight change effect of the SNP can vary 
between the general population and those affected by this ADR. 
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5.0.   Discussion 
  This study sought to determine the clinical factors influencing 
valproate induced weight gain in 250 children with epilepsy who have been 
exposed to VPA for at least six months. It also sought to test the impact of 
BMI-influencing genetic variations on VPA-induced weight change. While 
none of the clinical factors tested in our study significantly influenced VPA-
induced weight change, it appears that a number of the BMI-influencing 
genetic variations do influence this ADR. 
Regarding the genotyping results, the unadjusted linear regression 
analysis of the quantitative traits (maximum percentage weight change and 
change in WAZ) indicates that six of the seventeen SNPs achieved 
statistically significant relationship and these are rs10938397 (p = 0.03), 
rs1805081 (p = 0.03), rs7498665 (p=0.03), rs17782313 (p = 0.03), 
rs6020846 (p=0.01) and rs10508503 (p =0.03). Meta-analysis of the results 
of independent analysis of WAZ change and the maximum percentage 
weight change studies indicates that only three of the six SNPs that were 
significantly associated with quantitative weight change achieved statistical 
significance and these SNPs are: rs10938397, rs7498665 and 1805081.  
None of these three signals survived Bonferroni correction for multiple 
testing, although this correction is very stringent, given that we have clear a-
priori motivation for each test. In the discrete weight change analysis 
however only one SNP (rs1421085: FTO) was significantly associated with 
weight change. Like the other SNPs in the quantitative weight change 
category, this SNP did not survive Bonferroni correction. Interestingly this 
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SNP was not among the six SNPs associated with quantitative weight 
change. Going by the genotyping result the second hypothesis that genetic 
factors are associated VPA-induced weight change could be accepted as 
there is a ‘suggestive’ evidence for this from the results of the genotyping 
analysis but further testing in a larger cohort of patients exposed to this 
medication is required in order to confirm or refute this finding. There is 
definitely more ‘suggestive’ evidence of ‘genetic’ predictors of this ADR in this 
study than there is evidence for ‘clinical’ predictors.  
Previous studies of clinical predictors of VPA-induced weight change 
in studies involving only children have reported that the following factors as 
possible positive clinical predictors of the ADR: the initial weight z-score, 
initial BMI, normal neuro-cognitive status and primary generalized epilepsy 
type (Novak, 2009; Wirrell, 2003). Duration of therapy was the only negative 
clinical predictor of this ADR that has been identified (Sharpe et al., 2009). In 
studies involving both adult and paediatric populations, subjects on delayed 
release formulations were significantly more likely to gain weight than those 
on extended release formulations. Although we did not test for all the clinical 
factors that have been explored in previous studies, our study failed to 
identify any of the previously identified clinical factors in children such as 
initial weight for age z-score, neurocognitive status or epilepsy type. We 
could not test for the influence of BMI on VPA-induced weight change in our 
study due to incomplete height data.  We also utilized a different weight 
change phenotype (weight for age centile, WAC) than the ones applied in 
previous studies and we did not investigate the influence of the VPA 
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formulation on weight gain. Although our study focused on the weight change 
within the first year of VPA exposure, the subjects had varying durations of 
exposure to the medication within the first year of therapy. The duration of 
exposure within the first had no significant effect on the degree weight 
change. Beyond the first year of therapy, we observed that the weight-for-age 
centiles (WAC) of the subjects affected by this ADR returned to their pre-
exposure status. It should also be noted that several other similar studies in 
paediatric cohorts have not identified clinical predictors of this ADR (Demir, 
2000; Verrotti et al., 2010; Biton, 2001; de Vries et al 2007).  
Similar to our effort, most of the previous paediatric studies 
investigating these clinical predictors have been retrospective in nature 
(Novak, 1999; Wirrell, 2003; Sharpe et al., 2009; Demir, 2000). However, 
there has been one prospective open trial in children treated with VPA and 
one prospective multi-centre double blind controlled trial to evaluate the 
effect of VPA and LTG on body weight in children over 12 years old (Biton, 
2001; Verrotti et al, 2010).  
The sample sizes in the previous studies that involved only children 
had been between 43 and 114 participants (Novak, 1999; Wirrell, 2003, 
Sharpe et al., 2009; Demir, 2000; Verrotti et al., 2010). To our knowledge our 
study has the largest sample of children investigated to date for the clinical 
predictors of VPA-induced weight gain. In this context our findings could be 
considered as more robust compared to other studies that had smaller 
sample sizes.  
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Since we could not replicate some of the clinical predictors in 
previous studies that involved smaller sample sizes we could assume that 
this ADR is idiopathic, motivating genetic investigation. Indeed other 
published studies have also failed to replicate any the previously reported 
clinical factors. Adult studies seem to have shown similar results indicating 
that there might be no identifiable clinical predictors of this ADR. However, it 
should also be noted that the failure to identify the clinical predictors of this 
ADR might be due to the fact that our study (along with previous efforts) was 
underpowered to detect such predictors. This might indicate a need to 
conduct a large multi-centre study with sufficient statistical power to detect 
the clinical predictors of this ADR.   
With the exception of twin studies that have demonstrated the genetic nature 
of VPA-induced weight change (Verrotti et al., 1999b, Klein et al., 2005), to 
the best of our knowledge, our work represents the first effort to decipher the 
genetics of this ADR. In this study we tested the hypothesis that individuals 
carrying any of a set of 17 variants previously associated with BMI were more 
likely to be affected by this ADR than those who do not carry these variants. 
In other words, the presence of any of these variants might enhance the 
development of the ADR or protect the individuals so affected from 
developing the ADR. We observed borderline association of some SNPs with 
VPA-induced weight change all of which had similar directions of effects with 
studies in the general population indicating that in the presence of any of 
these SNPs the VPA-induced weight change might be enhanced. However 
since this VPA-induced weight change occurs over time in children who are 
194 
 
continuously growing, it might be difficult to determine at what point in the 
development this change occurs. The main scientific question to address, in 
a case-control study involving children of the same age who are not on the 
medication, is at what point this change in susceptibility to this ADR occurs. 
In the short term the findings in our study need to be replicated in other 
studies. 
 
 
5.1.    Strengths of the study 
It is the first pharmacogenetic study of VPA-induced weight 
change: The main strength of the study lies in the fact that it is the first study 
looking at the pharmacogenetic risk factors associated with VPA-induced 
weight change in both children. Weight change associated with VPA is a 
challenging clinical problem in management of epilepsy in both adult and 
children. Studying the pharmacogenomic risk factors associated with this 
ADR would enhance the management of people with epilepsy who are being 
treated with this medication.  
It is the largest study of VPA-induced weight change in 
paediatrics to date. This study represents the highest number of children 
ever recruited into a VPA-induced weight change study to date. In this 
context it is the best-powered study for clinical predictors of this ADR to date.  
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It focused on well-motivated genetic variants: By focusing on 
SNPs that had previously been robustly associated with BMI, we enhanced 
the yield of the genotyping result without increasing the cost. This targeted 
approach ensured that only the important high yield SNPs, previously 
associated with changes in weight were genotyped. The cost of conducting 
GWAs on the whole cohort would have exceeded the budget allocated to this 
project. However, we have put in place a resource and infrastructure for 
future GWAS or next-generation sequencing studies.  
 
5.2.    Limitations of the study 
Despite the strengths of this study, there were several limitations that 
warrant discussion. 
 The retrospective nature of the study, Missing data is an inherent 
problem with retrospective studies. Some of the subjects had only one weight 
measurement after commencing VPA. In some that had more than one 
weight measurement those measurements were taken at different 
institutions. This applied in particular to those children who were referred 
from peripheral hospitals. VPA treatments were sometimes initiated at the 
referring institution. Sometimes the weight measurements at commencement 
and/or the drug dosages were not recorded in the referral letters. As no two 
weighing scales have the same precision of measurements variations in 
precision could affect the accuracy of determining the VPA effect on the 
subjects’ weight. Another issue that affected data quality was dependence on 
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paper records, some of which were missing. The recording of clinical 
phenotypes also varied among physicians. More than twenty physicians were 
involved in recording of the phenotypes assembled here. Since there was no 
standard method in place for entering these records each physician involved 
recorded the phenotypes according to his/her own training and experience 
levels. Added to this is the fact that these records span over a decade. Since 
medical knowledge has evolved over this period, there might have been 
some differences in the categorisation of the clinical phenotypes for example 
the International League Against Epilepsy (ILAE) epilepsy syndrome 
classification has changed since the commencement of recording on these 
children. 
The exact date the subject commenced the medication could not 
always be definitively ascertained for subjects whose treatments were 
initiated on outpatient basis. Date of issuance of prescription was assumed 
as commencement date. There might be a discrepancy between the two 
dates as some subjects might delay the initiation of the therapy by a couple 
of days. The record used was however the most reliable record available to 
the researcher as the pharmacy dispensary record is not routinely available 
to clinicians in this country.  
Despite these limitations, we made the best use of resources 
available. Where possible we contacted the hospitals where the VPA was 
commenced to gather information on the drug dosages, weight and height 
information at the commencement of therapy and subsequent weight 
measurements at follow up visits. 
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Our small sample was limited. Larger sample sizes provide more 
power to detect true effects. Recruitment was limited by the amount of time 
available to the researcher to complete the research project (determined by 
funding), and the logistics associated with the organisation of clinic days in 
the institutions involved. The researcher had only two years for the 
recruitment of subjects, sample collection and processing, data collection and 
analysis and submission of reports. This time frame was inadequate to recruit 
a larger number of subjects, or to record additional interactions for subjects 
already recruited (as the subjects attended the neurology clinics 
approximately once every six months). Indeed, despite these limitations we 
actually recruited more participants than we had initially targeted. 
The study sites location in tertiary institutions. Given that 
recruitment was based in tertiary institutions, the children recruited often 
had additional medical conditions (beyond their epilepsy) that could impact 
on weight. This introduces additional confounders to the influence of VPA on 
weight in these subjects. Ideally the study should be conducted in a district 
general hospital, restricting recruitment children with epilepsy only. However 
such an approach would have taken a longer time to complete as it would 
have been difficult to recruit the required number of subjects in any single 
district general hospital within the short time frame. The alternative approach 
would have been to recruit across many district general hospitals at the same 
time but the logistics of doing this with only one researcher involved would 
have been extremely challenging. 
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The convenience sampling method and the inclusion of children 
taking combination therapy: The adoption of the convenience sampling 
method might have resulted in subjects attending clinics or wards for 
treatment being more likely to be recruited than those who, for whatever 
reason, did not present for treatment. Although the profile of those not turning 
up to the clinic was not determined, it will be difficult to determine how 
different this group of patients were from the subjects recruited to the study. 
Ideally a random sampling method with a sampling frame should have been 
used in order to represent the subset of children that presented to the clinics 
or wards for treatment. However, limited time and resources were available. 
We also did include children on combination AED therapy some of which 
might influence weight change in either direction. AEDs that induce weight 
gain might have enhanced the weight gain-inducing ADR of VPA while the 
opposite effect might have applied to the combination therapy that included 
AEDs associated with weight loss. Ideally subjects on VPA monotherapy 
should have been studied. Our study findings did not support the assumption 
that combination therapy has any significant effect on the VPA-induced 
weight change although we did not analyse the AEDs according to their 
effects on weight.  
The non-availability of a uniform weight centile tool: Neither of 
two growth centile tools available for this study (the Clinical Growth 
Standards for Irish Children and the WHO Multi-Centre Growth Reference for 
Healthy Breastfed Babies see Section 2.9.5 in the General Methods Chapter) 
covered the age spectrum of subjects recruited into the study. This was 
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mainly due to the data quality in our study. Of the two growth assessment 
tools used in the study, the weight for age centile (WAC) developed by Hoey 
et al (1987) covered the age spectrum better than the WHO Anthro tool. This 
explained the adoption of the maximum percentage weight change derived 
from the use of the clinical Growth Standards for Irish Children as the main 
weight change phenotype for this study. However, the Hoey tool has some 
short comings one of which is that it did not have data on the WAC for 
children less than two years old at the commencement of VPA. The other 
disadvantage of this tool is that because it is an old tool developed to assess 
the growth of normal Irish children in the late 1980’s and early 1990’s, the 
growth trend depicted by the tool does not reflect the current secular trend in 
the growth of Irish children. The WHO AnthroPlus tool is more reflective of 
the current growth trends – but at a global level, not specific to Ireland. 
Another problem with the WHO AnthroPlus is that it requires height data in 
order to determine BMI or BMI z-scores. However height data was often not 
available in clinical notes, especially for children over 10 years of age. Up to 
the age of ten years weight measurement alone was sufficient to monitor 
growth trends using the tool but beyond this age BMI centile or BMI z-score 
is more reliable as the WHO Anthro does not have any weight centile or 
weight z-score data beyond ten years of age. It would have been ideal to 
adopt the BMI approach for all ages if the height information was available in 
most of the patients. Since this was not the case, it was decided to adopt the 
Hoey et al centile chart as the main weight change measurement tool since it 
covered most of the subjects. The WHO AnthroPlus tool was used as a 
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validation tool and also to cover those subjects aged less than two years at 
the time of VPA commencement. A meta-analysis of the genotyping result 
from both approaches was carried out to strengthen the result of the test. 
Several observers measured the weights using different weight measuring 
tools: Since this study was multi-centre, the weight measuring was done by 
several individuals involved in the care of the subjects recruited in the study. 
There was not standard weighing equipment or protocol for measurement of 
weight. Inter- and intra-observer error might have occurred during these 
measurements. These might have contributed to the wrong assignment of 
weight phenotypes. This problem is magnified by the fact that some children 
weigh so little that any little discrepancy in the weight due to differences in 
the weight measuring tool or observer techniques could affect the weight 
phenotype category. It was difficult to eliminate this problem in our study as 
in most cases these individuals were recruited years after they had been 
commenced on the medication. 
The lack of adequate control samples and the use of non-
standardized tools to assess level of physical activity: We did not include 
any age matched controls who were not taking the medication in our study. It 
would have been ideal to include controls that have been matched with our 
cohort for age, gender, epilepsy syndrome and socio-economic status.  
Non-exclusion of children with co-morbid conditions: In this study we 
included children with other co-morbid conditions that might have some 
impact on weight gain. These might have some confounding effects on the 
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weight gain associated with VPA therapy. Besides some of these children 
were on other medications other than AEDs that could have some impacts on 
their weights. Ideally these children should have been excluded from 
analysis. 
Children on ketogenic diet or other diets that could affect weight were 
not excluded: Ketogenic and other ‘special’ diets have some impacts on 
weight gain in children.  For example, children on high calorie diets for failing 
to thrive might experience more rapid weight gain than children with the 
same condition on normal diet. The effect of concomitant administration of 
high calorie diet and VPA on VPA-induced weight gain has not been studied. 
However, the number of children in this study on ketogenic or ‘special’ diets 
was very small. 
The adoption of maximum percentage weight change as the main 
weight change phenotype: We applied the maximum percentage weight 
change over the first year of study as the weight change phenotype. This 
might not be the best approach as the maximum weight change might not 
have represented the individual weight change phenotype accurately. Some 
of those changes might have been due to measurement errors or might have 
been related to differences in the observers or in the weighing scales. 
However this phenotype was chosen to capture many of the individuals who 
would experience a weight change within the first few weeks of initiation of 
VPA therapy whose weight revert to normal before the end of the first year. 
An average deviation from the expected weight over the study period would 
have been ideal.  
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Other issues related to phenotype collection: A question that was 
not well structured was that related to activity level. Activity level was 
classified in the questionnaire into four categories: ‘zero’, ‘low’, ‘normal’ or 
‘high’. This was a subjective grading of the children’s perceived activity level. 
Several validated and more objective questionnaires are available for the 
evaluation of the level of physical activity in children (Speliotes et al., 2010, 
Welk et al., 2000) 
A similar issue was noted with the question on mobility level. The 
response options to this question (mobility) were: ‘normal activity’, ‘impaired 
activity’, and ‘wheelchair bound’. Although the researcher gathered the 
information for completing this question using a combination of the 
researcher’s observation, information volunteered by the parents and/or 
information gathered from the medical notes, it would have been better to 
have an objective way of assessing mobility level. 
 
The question on special diet was vague. The parents were asked 
whether their children were on any special diet. The initial response options 
were dichotomous ‘yes’ or ‘no’. Parents whose children were on special diets 
were asked to give details of the type of special diets their children were on. 
Given that there are a number of special diets children with chronic 
conditions such as epilepsy could be on, this question was not particularly 
informative.  
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5.3.    Suggestions to improve further studies 
If budget was unlimited, an ideal study design would be a multi-
centre prospective study. The study would include children from the ages of 2 
years to 16 years on VPA monotherapy. These children should not have any 
co-morbid medical condition that would impact on weight gain. The study 
participants should ideally have their weights and heights measured on the 
day they the VPA was initiated using a uniform measuring scale that is 
regularly calibrated. Ideally the VPA would be initiated in the institution under 
direct observation by the medical personnel involved in the study. The 
definition of the clinical seizure phenotype would follow a standard protocol 
agreed among the physicians prior to the commencement of the study. 
Electronic medical record of all the participants would be kept to avoid the 
problem encountered in this study where some paper records were missing. 
This database would be backed up regularly in a secure cloud storage 
system subject to approval by the various ethics committees involved in the 
study. The sample size should ideally be very large and the study location 
should ideally be in a secondary care facility. A random sampling method 
should be employed using a sampling frame which consists of the list of all 
the children within this age group on VPA monotherapy for epileptic fits.  
The weight change phenotype would ideally be change in BMI z-
score over the study period using the most recent growth monitoring tool in 
children. The children would be followed up two monthly for 12 months after 
the initiation of therapy and weight, height, VPA dose and serum VPA levels 
would be measured at these time points. A method of checking compliance 
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with therapy would also be devised and applied. This might involve not only 
enquiring from the children and their carers but also taking some random 
serum VPA levels.  
A well-designed questionnaire using standardized tools would be 
used in assessing such measures as activity level, mobility, and diet. 
Regarding the genotyping, all subjects recruited to the study would 
ideally have GWA scans run. Epigenetic studies such as studying the 
patterns of DNA methylation and histone modifications might also yield some 
useful information regarding this ADR.  
The resources involved in funding this type of study will be enormous 
given the issues involved and the measures to be taken to ensure high 
quality phenotyping and genotyping. Conducting such a study in this era 
when VPA is off-patent would nearly be impracticable as it would be difficult 
to raise the requisite funds for such a study.  
Given the resources available to us in this study, the approach we 
have taken should therefore be considered in context. It was a pragmatic 
approach.  
 
5.4.    Looking forward 
It is hoped that in the future clinically relevant pharmacogenomic 
factors associated with this ADR would have been uncovered. This would 
personalize the care of people with epilepsy treated with VPA as prediction of 
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this ADR will be easier than what obtains at the moment. As the price of 
sequencing continually becomes cheaper it is hoped that solution to this this 
problem will be affordable to all the patients being commenced on this AED 
in the future. 
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7.0.    Appendix 
7.1.    Appendix 1: DNA collection form 
Blood/Saliva Banking – Collection Details 
Related Document 
LP-HIS-BProcess: Collection, Processing and Storage of Blood for Banking 
Specimen Identification: 
 
Blood         Saliva              Collection site/ Hospital: 
 
Patient Name: 
 
Date of birth:                                      Patient Number:    
 
Study: 
Name of the study:         Study Code:                                    
Sample Collection: 
 
Date:    Time:  
 
Number of tubes:  
 
Tube No. Tube type Volume (ml) 
A   
B   
C   
D   
 
Time and date in CRC fridge:                                               Collected By: 
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Bio-banking technician contacted (date/time): 
(email: sdonatello@rcsi.ie; Tel office: 809-3714) 
 
Lab use only 
 
         Saliva sample processed at 50C on the ……………… for 
……………hour. 
 
Sample processed by technician (data/time): 
 
Patient Internal Code: 
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7.2.    Appendix 2: Database codes 
 
T CodeValues 
CodeValueId CodeType CodeValueDescription DisplayOrder 
1 1 Male 1 
2 1 Female 2 
1 2 OLH 1 
2 2 TSH 2 
3 2 NCH 3 
3 3 GTCS 1 
4 3 Tonic 2 
5 3 Clonic 3 
6 3 Absences 4 
7 3 Drop Attacks 5 
8 3 Myoclonic 6 
9 3 Simple Partial 7 
10 3 Complex Partial 8 
11 3 Atypical absences 9 
12 3 Secondary generalised 10 
13 3 Spasms 11 
1 4 Idiopathic Generalised syndrome 1 
2 4 Symptomatic GS 2 
3 4 Probably symptomatic GS 3 
4 4 Benign focal 4 
5 4 Symptomatic focal 5 
6 4 Probably symptomatic focal 6 
7 4 Specific syndrome 7 
8 4 Unclassifiable 8 
9 4 Dual epilepsy 9 
1 5 Yes 1 
2 5 No 2 
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T CodeValues 
CodeValueId CodeType CodeValueDescription DisplayOrder 
3 5 Unknown 3 
1 6 Yes 1 
2 6 No 2 
1 7 1
st
 1 
2 7 2
nd
 2 
3 7 3
rd
 3 
4 7 Other 4 
1 8 Mild 1 
2 8 Moderate 2 
3 8 Severe 3 
1 9 Supportive 1 
2 9 Unsupportive 2 
3 9 Unhelpful 3 
1 10 Lesional 1 
2 10 Nonlesional 2 
3 10 Global 3 
1 11 Seizure Free 1 
2 11 Simple Partial Seizures Only 2 
3 11 1-3 Seizures per day (+/- auras) 3 
4 11 4 or more seizure days per year 4 
5 11 Parital Responder 5 
6 11 Possible Surgery/Candidates 6 
1 12 ACTH 1 
2 12 AZM 2 
3 12 CBZ 3 
4 12 CLB 4 
5 12 CZP 5 
6 12 DZP 6 
7 12 ETS 7 
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T CodeValues 
CodeValueId CodeType CodeValueDescription DisplayOrder 
8 12 FBM 8 
9 12 GBP 9 
11 12 LTG 11 
12 12 NZP 12 
13 12 OXC 13 
14 12 PB 14 
15 12 PHT 15 
16 12 PRM 16 
17 12 RNM 17 
18 12 TGB 18 
19 12 TPM 19 
20 12 VGB 20 
21 12 ZNS 21 
22 12 OTHER 22 
10 12 LEV 10 
1 14 <3
rd
 1 
2 14 3
rd
 2 
3 14 3-10
th
 3 
4 14 10
th
 4 
5 14 10-25
th
 5 
6 14 25
th
 6 
7 14 25th-50
th
 7 
8 14 50
th
 8 
9 14 50th-75
th
 9 
10 14 75
th
 10 
11 14 75th-90
th
 11 
12 14 90
th
 12 
13 14 90-97
th
 13 
14 14 97
th
 14 
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T CodeValues 
CodeValueId CodeType CodeValueDescription DisplayOrder 
15 14 >97
th
 15 
1 15 1st Degree 1 
2 15 2nd Degree 2 
3 15 Other 3 
1 16 Zero 1 
2 16 Low 2 
3 16 Normal 3 
4 16 High 4 
1 17 Normal 1 
2 17 Impaired 2 
3 17 wheel chair bound 3 
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7.3.     Appendix 3: Screenshots of the Access database 
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7.4.      Appendix 4:  Ethics Approval Letters 
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7.5.     Appendix 5: Names and addresses of collaborators                                                  
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 Director of Epilepsy services 
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3. Prof David B. Goldstein PhD 
 Duke Institute for Genome Sciences and policy 
 Centre for Population Genomics and Pharmacogenetics 
 Duke University 
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 Email: d.goldstein@duke.edu 
 
4. David Webb MD FRCPI FRCPCH 
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 Our Lady’s Children’s Hospital 
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 Email: david.webb@olhsc.ie 
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5. Dr Anthony Bouldin  
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 Temple Street, Dublin 1 
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 Crumlin, Dublin 12. 
 Email: blathnaid.mccoy@olchc.ie 
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7.6.    Appendix 6: Case Report Form  
Database to include all of the information from the patient 
I. Demographics: 
1. Identity: name 
2. Identity MRN 
a. Variable 
3. DOB 
4. Sex  (Male/Female) 
a. discrete 
5. Hospital (OLH/ TSH/NCH) 
a. Discrete 
6. Contact number 
a. Variable/number 
II. Epilepsy History: 
1. Semiology  
a. free text box 
2. Seizure types  
a. One or a combination of (drop down menu with new row for 
additional?):  
i. GTCS  
ii. Tonic  
iii. Clonic  
iv. Absences  
v. Drop attacks  
vi. Myoclonic  
vii. Simple partial  
viii. Complex partial  
ix. Atypical absences  
x. Secondary generalised 
xi. Spasms 
 
3. Syndrome classification  
a. Discrete 
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i. Idiopathic Generalised syndrome/ 
ii. symptomatic GS 
iii. probably symptomatic GS/ 
iv. benign focal/ 
v. symptomatic focal 
vi. probably symptomatic focal 
vii. Specific syndrome 
viii. Unclassifiable 
ix. Dual epilepsy 
 
Free text box at bottom (i.e. if you think either 7, 8 or 9 above you will fill in 
free text)  
4. Aetiology  
a. free text box 
5. Co-morbidities 
a. free text box 
6. Family history of epilepsy  
a. Discrete (yes/no) 
b. Degree (discrete – option of 1st, 2nd, 3rd, other) 
7. Learning disability  
a. Discrete(yes/no)   
b. Severity: (option of Mild, Moderate or Severe) 
8. EEG  
a. Discrete – option of  
i. Supportive 
ii. Unsupportive 
iii. Unhelpful 
Add free text box 
 
9. Neuroimaging  
a. Discrete -  option of 
i. Lesional 
ii. Non-lesional 
iii. Global 
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Add free text box 
 
10. Current (at time of data collection) seizure frequency 
a. Seizure free 
b. Simple partial seizures only 
c. 1-3 seizures days per year (+/- auras) 
d. 4 or more sz days/year 
e. Partial responder 
f. Possible/surgery candidates 
11. Early risks: 
          HI 
          CNS Infection 
          Birth problems 
12. Siblings 
     Boys (no) 
     Girls (no) 
13. Febrile seizures 
     Patient (Y / N) 
     Family (Y / N) 
III. VPA specific variables: 
1. Start date 
2. Maximum dose tolerated (mg/kg) 
a. Variable/number 
3. Maintenance dose in (mg/ kg) 
a. Variable/number 
 
4. Termination date (‘blank’ = ongoing. If that calculator box is easy i.e. 
calculate numbers of months exposed to drugs.. but don’t worry if 
messy) 
a. Variable/figure 
5. Other AEDs co-administered. (one or a combination of..  a drop down 
is fine even if it looks messy.. extra column for each additional drug? 
i.e. patient can be exposed to several) 
a. ACTH 
b. AZM 
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c. CBZ 
d. CLB 
e. CZP 
f. DZP 
g. ETS 
h. FBM 
i. GBP 
j. LEV 
k. LTG 
l. NZP 
m. OXC 
n. PB 
o. PHT 
p. PRM 
q. RNM 
r. TGB 
s. TPM 
t. VGB 
u. ZNS 
v. Other 
with free text box 
6. VPA blood levels:  
a. free text box 
7. Seizure control on VPA:  
a. Seizure free 
b. Simple partial seizures only 
c. 1-3 seizures days per year (+/- auras) 
d. 4 or more sz days/year 
e. Partial response 
f. Possible/surgery candidates 
g. Unsure 
 
IV. Weight related data: 
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This is the type of ‘table’ we’re looking to populate. I.e. patient starts drug 
on visit 0, we record date, weight, height etc. On visit 2 we do same and 
on so… 
 
Parameter Visit 0 
(start) 
Visit 1 Visit 2  Visit 3 Visit 4 
Date      
Weight (kg)      
Height (cm)      
Weight 
centile 
     
Height 
centile 
     
 
We somehow need to design ‘form’ questions that will populate this table. 
We thought something along lines of below but feel free to adjust as you 
see fit. 
1. Date of visit 
2. Weight at visit (kg) 
a. Figure 
 
3. Weight centile at visit (discrete, one of..) 
a. <3rd 
b. 3rd 
c. 3-10th 
d. 10th 
e. 10-25th 
f. 25th 
g. 25th-50th 
h. 50th 
i. 50th-75th 
j. 75th 
k. 75th-90th 
l. 90th 
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m. 90-97th 
n. 97th 
o. >97th  
 
4. Height at visit (centimetres) 
 
5. Height centile at visit (discrete, one of..) 
a. <3rd 
b. 3rd 
c. 3-10th 
d. 10th 
e. 10-25th 
f. 25th 
g. 25th-50th 
h. 50th 
i. 50th-75th 
j. 75th 
k. 75th-90th 
l. 90th 
m. 90-97th 
n. 97th 
o. >97th  
 
V. Patient related variables 
1. Family history of weight problems/obesity  
a. Discrete (yes or no)  
b. Degree of relation 
i. 1st degree 
ii. 2nd degree 
iii. other 
c. AND FREE TEXT BOX 
 
2. Activity level (discrete, one of:) 
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a. Zero 
b. Low 
c. Normal 
d. High 
 
3. mobility (discrete, one of:) 
a. normal 
b. impaired 
c. wheel chair bound 
4. special diets:  
a. discrete - yes or no  
(+ free text box) 
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7.7.    Appendix 7:  Participant’s Information Leaflet  
 
 INFORMATION LEAFLET 
 
INFORMATION FOR PATIENTS/PARENTS/GUARDIANS REGARDING THE STUDY  
1. Study Title 
A genetic exploration of weight gain associated with valproate therapy.  
2. What is the purpose of the study? 
Epilepsy affects about 30,000 people in Ireland. The treatment of epilepsy is mainly 
by anti-epileptic medications (AEDs). Side effects to AEDs are commonplace. 
Weight change is an adverse effect of several important AEDs. It can be a 
treatment-limiting problem in the management of patients with epilepsy. The most 
common AEDs associated with weight gain are sodium valproate (Epilim) and 
vigabatrin (sabril), and with weight loss are topiramate (topamax) and zonisamide 
(zonegran).  
Why these side effects are seen in only some people are not known. It is likely that 
there may be some genetic or “in-built” factors have a role to play.  
To identify these “in-built” factors, we are carrying out a genetic study on patients 
with epilepsy who are on or who have been on valproate (Epilim) therapy for at least 
6 months. To do so, it is necessary to collect a blood sample from as many patients 
as possible. This information will improve our understanding on why some patients 
develop this problem of weight gain and may have also some implication for the 
broader understanding of obesity in general population. 
 
3. Why have I been chosen? 
You/your child have been chosen because you have been on Epilim therapy for at 
least 6 months. Your record of previous medications and responses to various 
medications along with the weight measurements are available in this hospital. This 
should provide information about your type of epilepsy and the way you respond to 
medications. We are trying to study at least 300-400 patients 
 
4. Who is organizing the study? 
               This is an investigator- initiated study. 
Principal Investigator: Dr David Webb Consultant Paediatric Neurologist, Crumlin  
Other Investigators:   Dr Blathnaid McCoy Consultant Paediatric Neurologist, 
Crumlin  
                                    Dr Norman Delanty Consultant Neurologist, Beaumont 
Dr Mary King Consultant Paediatric Neurologist, Temple 
Street 
 Dr Bryan Lynch Consultant Paediatric Neurologist, Temple 
Street 
Dr Tony Bouldin, Consultant Paediatric Neurologist, Temple 
Street, Dublin 1  
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Dr Gianpiero Cavalleri Research lecturer in Epilepsy 
Genetics, and  Pharmacogenetics, RCSI, Dublin 2 
Prof David Goldstein, Institute of Genome Sciences and 
Policy, Duke University, North Carolina, USA 
Dr Joseph Chukwu, Clinical Research Fellow, National 
Children’s Research Centre Crumlin 
The Research fellow is funded by the National Children’s Research Centre Crumlin and the 
Irish Epilepsy Association- “Brainwave” 
Duration of the study: approximately 2 years              
5. What will happen to me if I take part? 
If you/your child agree to participate, you/your child will have to meet with the 
researcher once off for this study. This can be arranged to coincide with a clinic visit 
and you don’t have to come specifically for this. The researcher will take a detailed 
history from you/ your child and also go through the records and collect all the 
information and store it in a safe place. A blood or spit sample will be collected from 
you/your child. The blood sample will be collected by a needle prick. This may cause 
a bit of bruising and discomfort but it will pass without side effects. This blood or spit 
sample will be analyzed and will be looked at in the light of all the information we 
have gathered from you and your child’s records. 
 
6.          Are there any disadvantages in taking part in this study? 
There are no disadvantages in taking part in this study. Your care with your doctor 
will proceed in the same way as before. 
 
7.         What are the possible risks of taking part? 
The only risk involved is physical distress that you/your child may have from blood 
sampling. There may be a small bruise and you may be uncomfortable for a little 
after. We will try to avoid these complications as much as possible. 
 
8.        What are the possible benefits of taking part? 
You may not receive any direct benefit from taking part in the study.  However, 
information obtained during the course of the study may help us to understand better 
your condition or illness. The information we get from this study may help us to treat 
future patients with epilepsy better by predicting the side effect in advance and take 
measures to counteract that.  
 
9.           Is my doctor being paid for including me in the study? 
              No. 
 
10.        Confidentiality – who will know I am taking part in the study? 
All information, which is collected about you during the course of the research, will 
be kept strictly confidential.  Any information about you, which leaves the hospital, 
will contain no information as to your identity so that you cannot be recognised from 
it. 
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11.       GP Notification 
Your GP will not normally be informed that you are taking part in this study as it does 
not alter your/your child’s management plans 
 
12.         Hospital Ethics Committee Approval 
Our Lady’s Hospital for children, Crumlin has approved the study. Ethics Committee 
Mater Misericordiae Hospital has also approved the study and we will be recruiting 
children from Temple Street hospital. 
 
13.        What will happen to the results of the study? 
Normally the results of the research will not be made known to you or your child. But 
if you would like to know the progress you can contact your research doctor or your 
specialist doctor. 
 
14.         Voluntary participation 
It is up to you/your child to decide whether to take part or not.  If you decide to take 
part you will be given an information leaflet and consent form. Even if you decide to 
take part, you/your child are free to withdraw at any time and without giving a 
reason.  This will not affect the standard of care you will receive.  Your doctor will not 
be upset if you decide not to take part. 
 
If you need any further information please contact one of the following doctors: 
 
Dr Bryan Lynch : 01-8094200 
Dr Mary King:    01-809 4232? 
Dr Tony Bouldin 01…. 
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7.8    Appendix 8: Consent Form 
(Form to be on headed paper) 
 
CONSENT FORM 
 
 
 
 
 
 
 
 
 
1. I confirm that I have read and understand the information leaflet dated 15/07/11 
version 2 for the above study and received an explanation of the nature, purpose, 
duration, and foreseeable effects and risks of the study and what my/my child’s 
involvement will be. 
 
2. I have had time to consider whether to take part in this study.  My questions have 
been answered satisfactorily and I have received a copy of the Patient Information 
Leaflet. 
 
3. I understand that my/my child’s participation is voluntary and that I am/we are free to 
withdraw at any time without my/my child’s medical care or legal rights being 
affected. 
 
 
4. I am willing to allow access to my/my child’s medical records by representatives of 
the sponsor, Ethics Committee or local or foreign regulatory authorities but 
understand that strict confidentiality will be maintained.  The purpose of this is to 
check that the study is being carried out correctly. 
 
5. I agree to allow my child to take part in the above study. 
 
6. I understand that my name will not be used in any report that comes from the blood 
samples. In turn, I understand that I cannot restrict the use of the information that 
comes from studying the blood samples. I accept that the information may be given 
to medical regulatory authorities in Europe or elsewhere.  I am aware that the study 
resource will be owned and used by both academic and commercial researchers.  
These include, but are not limited to, the Royal College of Surgeons in Ireland. 
 
Reference Number:    
 
Title of Study: Genetics of weight gain with 
valproate therapy  
 
Research Participant’s Name: 
 
Name of Doctor and Telephone Number: 
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7. I have been made aware of my rights concerning the collection, processing and use 
of the data for this procedure.  I agree to the collection, processing and use of 
personal data as described in this document. 
 
8. I would consent for my data (both clinical and DNA) to be used for further studies.   
               Tick:  Yes/ No 
 
 
________________________________  ________________
 __________________ 
Name of Research Participant/Parent/Guardian Date   Signature 
(in block letters) 
 
 
________________________________  ________________
 __________________ 
Name of Person taking consent   Date   Signature 
(if different from doctor/researcher) 
 
 
________________________________  ________________
 __________________ 
Doctor/Researcher    Date   Signature 
 
1 copy for research participant, 1 copy for researcher, 1 copy to be inserted into the hospital 
notes 
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7.9.  Appendix 9: R-Function for growth percentiles 
 
DEVELOPING CHILD GROWTH WEIGHT PERCENTILE FUNCTIONS  
- 
MATURE DRAFT  
DR GÁBOR BORGULYA  
Contents  
1. The objective of this project  
2. Data sources  
3. Modelling cross sectional percentiles vs. individual growth curves  
4. The parametric approach  
4.1. Results for boys  
4.2. Attempt for girls  
5. The smooth interpolation approach  
5.1. Smooth interpolation for the 50th percentile of boys  
5.2. Weight-centile interpolation of 15-year-old boys  
5.3. Smooth interpolation of all the 7 percentile curves of boys  
5.4. Weight(age, centile) function  
5.5. Centile(age, weight) function  
5.6. Application to the data of girls  
5.7. Increase the span parameter for boys  
6. Results  
6.1. The results as figures  
6.2. How to use the developed interpolation functions?  
7. Summary  
8. Further possibilities  
References  
1 
1 
2 
2 
2 
3 
3 
3 
4 
6 
7 
8 
8 
9 
10  
10  
10  
11  
11  
11  
1. The objective of this project  
The aim of this project was to develop an approximate function that take the age, sex and  
weight of children as inputs and output their weight percentile as output in the weight distribution  
of children of the same sex and age; and the inverse function that outputs weight. Ideally the  
function would have been fitted on data of Irish children born in the 1990ies to match the  
population of the study where the function is planned to be applied.  
2. Data sources  
In the current study less perfect data were Saud Alhusaini provided me[1] with the paper  
Standards from birth to maturity for height, weight, height velocity, and weight velocity: British  
Date: 15/JUN/2012.  
1 
Appendix 9: R-Function for growth percentile 
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2 DR GÁBOR BORGULYA  
children, 1965. I. J. M. Tanner, R. H. Whitehouse and M. Takaishi Arch Dis Child 1966 41:  
454-471 doi: 10.1136/adc.41.219.454 to use as a possible data source. We found less old data  
for a more distant population, the USA. Saud recognised a paper referencing the above as a  
better data source candidate Hoey HM, Tanner JM, Cox LA (1987). Clinical growth standards  
for Irish children. Acta Paedicatr Scan Suppl (338): 1-31. Gábor found this article as a paper  
print in the SGUL library, then the paper was scanned at RSCI (1987_Hoey.pdf).  
3. Modelling cross sectional percentiles vs. individual growth curves  
An alternative approach to the original question would have been modelling individual growth  
curves rather than percentiles of the population, but the paper gave only limited information on  
this. A curve of the typical individual in shown on page 467 of the Tanner et al. paper. The  
population distribution can be viewed as the superposition of a large number of individual growth  
curves, this explains the widening of the distribution during adolescence: although children  
approximately follow percentile curves as they develop the age at the onset of the intensive  
growth associated with puberty is also variable.  
4. The parametric approach  
4.1. Results for boys. The first approach to fit the required function was completed on the  
14/May/2010[2] and the following R code was developed:  
## Weight and w e i g h t c e n t i l e p r e d i c t i o n f o r boys  
 3.401687 e +01 , m2=1.714676 e  
    03 , h i=  
4 . 3 8 2 7 0    01 , l a  
 08 , l k = 3 . 4 3 0 9 0 4 e +00 , s h i f t = 1 . 0 0 6 1 5 8 e +00 , a2 = 4 . 5 6 0 4 8 6 e +02 , b10  
= 2 . 4 1 6 2 5 7 e + 0 3 , me15 = 1 . 5 5 7 6 9 6 e + 0 1 , s d 2 = 1 . 3 0 1 4 2 1 e + 0 0 , c 6 2 = 1 . 1 8 3 0 2 7 e + 0 4 , r a = 1 , r k  
=1) {  
w = p n o r m ( a g e , me15 , s d 2 )  
   age + b10 ) + w c62  
lambda = m0 + m1 age + m2 age ^ 2 + m3 age ^ 3  
  l a m b d a + c  
     ( 1 / ( 1 + Mod(  
complex ( r e a l=age    ( ( age >= pa   
  1 )  
   lambda + 1 ) ^ (1 /  
 s h i f t )  
} 
 w)  
c e n t i l e = f u n c t i o n ( age , w e i g h t ) u n i r o o t ( f , c ( 0 . 0 0 0 1 , 0 . 9 9 9 9 ) , a=age , w=w e i g h t )  
$root  
## Example u s a g e :  
#1. On which p e r c e n t i l e i s t h e boy who i s 12 y e a r s o l d and 40 kg o f w e i g h t ? (68%)  
c e n t i l e (12 , 40)  
#2. What i s h i s e x p e c t e d w e i g h t one y e a r l a t e r ? ( 4 4 . 5 kg )  
weight (12+1 , . 6 8 )  
#o r more p r e c i s e l y ,  
weight (12+1 , c e n t i l e ( 1 2 , 40) )  
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The above R function corresponds to the Table 9 of the Hoey paper. It approximates the  
percentiles of boys - the percentiles of the girls are different and imprecisely approximated by  
this function.  
4.2. Attempt for girls. Unfortunately fitting the same formula for girls was unsuccessful: while  
for boys the result was a strictly monotone function, the best fit after optimisation for girls  
was non-monotone. As non-monotony could have lead to unexpected contradictions during the  
applications of the function this result was discarded.  
While it may have been possible to modify the function used in this parametric approach to  
give an acceptable fit a new approach was used where notable non-monotony can not occur.  
5. The smooth interpolation approach  
5.1. Smooth interpolation for the 50th percentile of boys. Each percentile curve is inter-  
polated using a smooth function. Here I describe the details of this function using the example  
of the 50th percentile of boys.  
5.1.1. Error in the source data. The table 9 of the Hoey paper contains the following data:  
age  2.0  2.5  3.0  3.5  4.0  4.5  5.0  5.5  6.0  
pc50 1 2 . 7 1 3 . 5 1 4 . 6 1 5 . 3 1 6 . 4 1 6 . 3 1 8 . 3 1 9 . 3 2 0 . 3  
^^^^  
6.5  
21.3  
7.0  
22.4  
...  
...  
The weight of 16.3 kg at the age of 4.5 is an outlier, it breaks the monotonously increasing  
series corresponding to growth of the boys, it must be error. The diferences between consecutive  
weights suggest that the true weight should be around 17.4. So in the following calculations I  
assume that the digit 7 was mistyped and I use 17.3 instead:  
age  2.0  2.5  3.0  3.5  4.0  4.5  5.0  5.5  6.0  
pc50 1 2 . 7 1 3 . 5 1 4 . 6 1 5 . 3 1 6 . 4 1 7 . 3 1 8 . 3 1 9 . 3 2 0 . 3  
^^^^  
6.5  
21.3  
7.0  
22.4  
...  
...  
5.1.2. Fitting the interpolation curve. In the smooth regression approach the published percentile  
curve was approximated with local polynomial regression fitting[4] using the loess[3] function of  
R[5]. This ensures that the approximating curve precisely goes through each given age-weight  
coordinate pair.  
boy_centile50_model = l o e s s ( pc50 ~ age , data=boy_pc50 , c o n t r o l=l o e s s . c o n t r o l (  
s u r f a c e = " i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y _ p c 5 0 ) )  
The fitted model can be used to construct a function that predicts the 50th percentile weight  
corresponding to any age (also ages between the tabulated ones). The 50th percentile weights of  
boys are shown in figure 1 on page 4, black circles correspont to the Hoey data, the green curve  
corresponds to the interpolation curve.  
A parameter of the loess model is the span - the higher the value the smoother the curve  
is, at the cost of not exactly going through each point. Various settings are plotted in figure 2  
on page 5; span = 5/nrow corresponds to the smoothest curve (brown) that still crosses each  
point.1  
1This was later changed to 7, see section 5.7 on page 9.  
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Figure 1. 50th percentile weights of boys and loess interpolation curve  
5.2. Weight-centile interpolation of 15-year-old boys. Each weight corresponding to a  
given percentile (at a given age) is interpolated using the 7 weights corresponding to the 7  
percentiles tabulated by Hoey et al (3rd, 10th, 25th, 50th, 75th, 90th and 97th). To get a good  
approximation of the weight at any percentile a second smooth function is fitted on these 7  
weight values. Here, however, we have to use an other kind of function, one that ensures that  
the fitted weight-centile curve (for the given age) has the appropriate quantiles at each of the 7  
values. This property was achieved using multiple normal distributions fit on quantiles. A normal  
distribution is usually parametrised using its mean and variance, i.e. two parameters. Thus two  
points of a probability density curve identify a normal distribution. For a given percentile the  
closet lower and closest higher percentile are used (e.g. the weight corresponding to the 31th  
percentile is interpolated from a Gaussian distribution for on the weights of the 25th and 50th  
percentiles). For very low or very high percentiles outside the tabulated range the two lowest  
(3rd and 10th) or two highest percentiles (90th and 97th) are used, respectively.  
boy_15y_weights = c ( 3 8 . 0 ,  
z = c ( .03 ,  
42.0 , 47.2 , 53.3 , 58.9 , 65.1 , 72.2)  
.10 ,  .25 ,  .50 ,  .75 ,  .90 ,  .97)  
boy_15y = f u n c t i o n ( c t ) {  
i f ( c t == 0 ) r e t u r n ( 0 )  
i f ( c t == 1 ) r e t u r n ( I n f )  
HighIndex = which . max( c ( z , 1 ) >= c t )  
if  ( HighIndex == 1 ) { HighIndex = 2 } e l s e { i f  
=7  } 
 1  
( HighIndex == 8 )  HighIndex  
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Figure 2. Various span settings in the loess interpolation  
L o w C e n t i l e = z [ LowIndex ]  ; LowWeight = b o y _ 1 5 y _ w e i g h t s [ L o w I n d e x ]  
H i g h C e n t i l e = z [ HighIndex ]  ; HighWeight = boy_15y_weights [ H i g h I n d e x ]  
x = c ( L o w C e n t i l e , H i g h C e n t i l e ) ; y = c ( LowWeight , H i g h W e i g h t )  
approx_mean = b o y _ 1 5 y _ w e i g h t s [ 4 ]  # median  
approx_sd    pc25  
f 1 = f u n c t i o n ( par ) {  
fitted_mean = par [ 1 ]  
fitted_sd  = par [ 2 ]  
y h a t = q n o r m ( x , mean = f i t t e d _ m e a n , s d = f i t t e d _ s d )  
 y h a t ) ^  2 )  
} 
par = c ( f it t e d _ m ea n=approx_mean , f i t t e d _ s d=approx_sd )  
o = optim ( par , f 1 , method = "BFGS" )  
par = o$par  
fitted_mean = par [ 1 ]  
fitted_sd  = par [ 2 ]  
q n o r m ( c t , mean = f i t t e d _ m e a n , s d = f i t t e d _ s d )  
} 
As it can be seen in figure 3 on page 6 this method has achieved both first order smoothness  
of the interpolating curve and it matches the tabulated weight-percentile coordinate pairs. The  
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Figure 3. Density curve and quantile curve of the weight of 15-year-old boys  
fitted on the 7 tabulated data points  
curve is not smooth, however, in the second order, which is unnatural. Better second order  
smoothness could be achieved using transformation of the weight values, but in practice this  
would mean negligible gain of accuracy.  
5.3. Smooth interpolation of all the 7 percentile curves of boys. Exactly the same  
method was used as above:  
boy_centile03_model = l o e s s ( pc03 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 0 3 = f u n c t i o n ( age ) p r e d i c t ( boy_centile03_model , data . frame ( age=age ) )  
boy_centile10_model = l o e s s ( pc10 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 1 0 = f u n c t i o n ( age ) p r e d i c t ( boy_centile10_model , data . frame ( age=age ) )  
boy_centile25_model = l o e s s ( pc25 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 2 5 = f u n c t i o n ( age ) p r e d i c t ( boy_centile25_model , data . frame ( age=age ) )  
boy_centile50_model = l o e s s ( pc50 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 5 0 = f u n c t i o n ( age ) p r e d i c t ( boy_centile50_model , data . frame ( age=age ) )  
boy_centile75_model = l o e s s ( pc75 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 7 5 = f u n c t i o n ( age ) p r e d i c t ( boy_centile75_model , data . frame ( age=age ) )  
boy_centile90_model = l o e s s ( pc90 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 9 0 = f u n c t i o n ( age ) p r e d i c t ( boy_centile90_model , data . frame ( age=age ) )  
boy_centile97_model = l o e s s ( pc97 ~ age , data=boy7 , c o n t r o l=l o e s s . c o n t r o l ( s u r f a c e  
" i n t e r p o l a t e " ) , s p a n =5/ n r o w ( b o y 7 ) )  
b o y _ c e n t i l e 9 7 = f u n c t i o n ( age ) p r e d i c t ( boy_centile97_model , data . frame ( age=age ) )  
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5.3.1. Error in the source data. Plotting the data revealed another error in the Hoey table:  
weight 15 kg at the age of 4.5 years, 25th percentile must be error, I substituted it with 16, that  
is realistic.  
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q q 
q 
q 
q q 
q 
q 
q 
q 
q q 
q 
q q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
5 10  
age  
15  
Figure 4. Weight percentile curves of 15-year-old boys: circles, raw data; lines,  
local polynomial regression fitting curves  
5.3.2. Results. The results can be seen in figure 4 on page 7.  
The original series of points look somewhat irregular as some points, this is maybe due to  
sampling error in the Hoey paper.  
5.4. Weight(age, centile) function. To get the weight(age, centile) function we first need to  
interpolate the 7 centiles for the given age using the boy_centileXX functions, then interpo-  
late between the centile, combining the above tablulated age with any percentile and tabulated  
percentile with any age approaches. Let's thus modify the boy_15y_weights function:  
boy_weight_functions = c ( boy_centile03 ,  
boy_centile10 ,  
boy_centile25 ,  
boy_centile50 ,  
boy_centile75 ,  
boy_centile90 ,  
boy_centile97 )  
...  
boy_weight = f u n c t i o n ( age , c t ) {  
boy_weights = s a p p l y ( boy_weight_functions , f u n c t i o n ( x ) x ( age ) )  
...  
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LowCentile  
HighCentile  
...  
approx_mean  
approx_sd  
= z [ LowIndex ]  
= z [ HighIndex ]  
; LowWeight = b o y _ w e i g h t s [ L o w I n d e x ]  
; HighWeight = boy_weights [ H i g h I n d e x ]  
= boy_weights [ 4 ]  # median  
  pc25  
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Figure 5. Fitted weight percentile curves (5th, 15th, 25th, . . . , 95th) and the  
original data points  
The result can be seen in figure 5 on page 8  
5.5. Centile(age, weight) function. The centile(age, weight) function is the inverse function  
of the weight(age, centile) function. While an analytic solution could be developped let's use a  
numerical inverse as that is easier and quicker to program and its main limitation the slower  
execution does not make a diference in the planned application of the function.  
 w e i g h t )  
b o y _ c e n t i l e = f u n c t i o n ( age , w e i g h t ) u n i r o o t ( b o y _ c e n t i l e 0 , c ( 0 . 0 0 0 1 , 0 . 9 9 9 9 ) ,  
age=age , w e i g h t=w e i g h t ) $ r o o t  
These results could be best visualized with a color coded or topographic chart. As this is not  
important for the understanding of the method I have not prepared this graph.  
5.6. Application to the data of girls. There were no methodical changes when the data of  
girls was modelled.  
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5.6.1. Steps.  
(1)  
(2)  
(3)  
(4)  
Data entry: typing in the Hoey paper table 10 data  
Fitting the 7 local polynomials  
Combining the 7 curves with interpolations between them  
Coding the inverse function.  
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Figure 6. The original fitted weight percentile curves (1st, 3th; 5th, 15th, 25th,  
. . . , 95th; 97th, 99th) and the original data points of girls  
5.6.2. Testing. The original results can be seen in figure 6 on page 9.  
The weight 24.8 kg (at 8.5 years, 50th percentile) is obviously error as is is less than the 24.7  
half a year earlier and girls do not shrink. As I could not explain the ourlier with mistyping I  
omitted this original data point.  
After these 3 errors identified in the Hoey tables I convinced myself that the tabulated data  
were inaccurate. Hence I gave up the condition that the fitted percentile curves should go though  
each data point, and favouring smoother curves (less declines in growth velocities) I increased  
the smoothing factor to span = 7/nrow.  
5.7. Increase the span parameter for boys. To keep the methodology uniform across the  
analysis I introduced the span = 7/nrow increase in smoothing into the modelling of the weights  
of boys as well.  
7
0
  
6
0
  
5
0
  
w
e
ig
h
t 
 
4
0
  
3
0
  
2
0
  
1
0
  
285 
 
10  DR GÁBOR BORGULYA  
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q q 
q 
q 
q q 
q 
q 
q 
q 
q q 
q 
q q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
q 
5 10  
age  
15  
Figure 7. Fitted weight percentile curves (1st, 3th; 5th, 15th, 25th, . . . , 95th;  
97th, 99th) and the original data points of boys  
6. Results  
6.1. The results as figures. The results for boys in figure 7 on page 10, the results for girls  
can be seen in figure 8 on page 11.  
6.2. How to use the developed interpolation functions?  
(1) Open and run the "20120702182159GM child weight percentiles.R" program in R.  
(2) Follow the example below:  
> boy_weight ( 1 1 , . 6 0 )  
[ 1 ] 34.45404  
> boy_centile (11 , 34.45)  
[ 1 ] 0.5997207  
> girl_weight (11 , .60)  
[ 1 ] 34.52648  
> g i r l _ c e n t i l e (11 , 34.5)  
[ 1 ] 0.59811  
Here we calculated the weight of 11 year-old 60th percenitle boys, then the percentile  
of 11 year-old boys with the weight of 34.45. The second part did similar calculations  
for girls.  
(3) These 4 functions can be built into analyses in R or other applications.  
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Figure 8. Fitted weight percentile curves (1st, 3th; 5th, 15th, 25th, . . . , 95th;  
97th, 99th) and the original data points of girls  
7. Summary  
During the analysis of the Hoey data some errors were identified and substituted with similar,  
but realistic values assuming mistyping (see sections 5.1.1 (page 3) and 5.3.1 (page 6)). As no  
substitution was straightforward one data point was omitted, see section 5.6.2 (page 9).  
Due to the errors in the published data smoothing was also introduced.  
The parametric approach yielded a compact black box solution for boys, but it failed for girls.  
A more complex double smoothed interpolation approach was successful for both boys and girls,  
also giving full methodical transparency.  
The result is an embeddable R module providing 4 functions for the user:  
(1) boy_weight(age/year, centile  weight/kg for boys  
(2) boy_centile(age/year, weight/kg  centile for boys  
(3) girl_weight(age/year, centile  weight/kg for girls  
(4) boy_centile(age/year, weight/kg  centile for girls  
8. Further possibilities  
References  
[1] Saud Alhusaini. "Growth Curve Paper" E-mail to Gábor Borgulya. 2010-02-24 23:42:23.  
[2] Gábor Borgulya. "Re: Growth Curve Paper" E-mail to Saud Alhusaini. 2010-05-14 21:33:07.  
[3] B. D. Ripley, based on the cloess package of Cleveland, Grosse and Shyu (currently available as dloess at  
http://www.netlib.org/a: the R implementation is based on an 1998 version)  
7
0
  
6
0
  
5
0
  
w
e
ig
h
t 
 
4
0
  
3
0
  
2
0
  
1
0
  
  
 
12  DR GÁBOR BORGULYA  
[4] W. S. Cleveland, E. Grosse and W. M. Shyu (1992) Local regression models. Chapter 8 of Statistical Models  
in S eds J.M. Chambers and T.J. Hastie, Wadsworth & Brooks/Cole  
[5] R Development Core Team (2012). R: A language and environment for statistical computing. R Foundation  
for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/  
E-mail address: gabor@borgulya.hu  
 288 
 
 
7.10. Appendix 10: Protocol for Isolation of White Blood Cells 
ISOLATION OF WHITE BLOOD CELLS 
 
1. Label 50 mL tubes with the study progressive number and patient 
initials. 
2. Pour the blood into the 50ml tube and rinse the blood tube with SLR, 
previously autoclaved. 
3. Fill the tube to 50 mL point with SLR. 
4. Leave tubes fully covered on ice for 15 minutes. 
5. Centrifuge at 3500 rpm for 15 minute at 4 degrees (no brake). 
6. Carefully pour off the supernatant into a urine bottle containing some 
powder Virkon. 
7. Resuspend the pellet in 10 mL SLR. 
8. Vortex until pellet is fully resuspended. 
9. Fill the tubes with SLR to 50 mL. 
10. Centrifuge for 10 min at 3500 rpm at 4 degrees C (no brake). 
11. Carefully pour off supernatant in a urine bottle with Virkon (leave the 
last mL). 
12. You are left with white blood cell pellet. You can proceed to DNA 
extraction step or stored it at -20 degrees C. 
 
 
SLR BUFFER RECIPE (FOR LYSIS OF RED BLOOD CELLS) 
 
2M Tris HCl, pH 7.6 (10mM) 10 ml 
2M MgCl2 (5mM)  5 ml 
5M NaCl (10mM)  4 ml 
Make up to 2L with de-ionised water. Autoclave for 15 minutes at 121C. 
Store at RT. 
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7.11. Appendix 11: Protocol for extraction of DNA from saliva samples 
DNA EXTRACTION FROM SALIVA SAMPLES 
 
SAFETY PROCEDURES 
Labcoat and nitrile gloves must be worn at all times, since sample may be 
contaminated with infectious agents. 
Used labware may contain hazardous infectious agents from the purification 
process. The waste has to be collected and disposed in hazardous bags in 
the yellow bins. 
 
DNA EXTRACTION 
Notes: 
 Once collected, Oragene saliva samples are stable at room 
temperature for years without processing. 
 DNA solvent used: TE buffer (10mM Tris-HCl, 1 mM EDTA, pH 8.0). 
 
1. Mix the Oragene/saliva sample in the Oragene vial by inversion and 
gentle shaking for a few seconds. 
2. Incubate the sample at 50°C in an air incubator for at least 3 hours 
(the sample may be incubated also overnight if more convenient). 
3. Transfer the content of the entire sample to a 15mL centrifuge tube. 
Note the volume of the sample. 
4. Add 1/25th volume Oragen Purifier (e.g. 160µl for 4mL of sample) to 
each tube and mix vortexing for a few seconds. 
5. Incubate on ice for 10 minutes. 
6. Centrifuge at room temperature for 10 minutes at as high speed as is 
practical. Minimum 2500xg 
7. Carefully transfer the majority of the clear supernatant with a pipette to 
a fresh 15 mL centrifuge tube. Discard the pellet. 
8. Add an equal volume of RT 95-100% ethanol to the clear supernatant. 
Mix gently by inversion 10 times. 
9. Allow the sample to stand at RT for 10 minutes to allow the DNA to 
fully precipitate. 
10. Centrifuge at RT for 10 minutes at as high speed as is practical. 
Minimum 2500xg. 
11. Carefully remove the supernatant with a glass or plastic pipette and 
discard it. Take care to avoid disturbing the DNA pellet. 
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12. Dissolve the DNA pellet in 1 ml of DNA solvent and transfer to a 1.5 ml 
microcentrifuge tube. 
13. Ensure complete rehydratation of the DNA prior to any subsequent 
step. To improve rehydratation may use: 
a. Vigorous pipetting and vortexing 
b. Incubation at 50°C for 1 hour with occasional vortexing  
c. Incubation at RT for 1 or 2 days (suggested) 
14. Centrifuge the rehydrated DNA at room temperature for 15 minutes at 
15000xg (13000rpm). 
15. Transfer supernatant to a fresh 1.5 ml microcentrifuge tube without 
disrupting the pellet. 
 
 
 
Quantification of DNA by Absorbance  
 
Dilute the DNA 1:10 in TE buffer. Use TE as blank. 
OD 260 should be between 0.1 and 1.5 and OD260/280 should be higher 
than 1.6.  
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7.12. Appendix 12: Protocol for Using the Qiacube DNA isolation 
machine 
SOPs FOR USING QIACUBE 
 
Equipment name: Qiacube 
Make/model  Qiagen 
Serial no:   10632 
 
 
SAFETY PROCEDURES USING QIACUBE 
 Sample used with this instrument may contain infectious agents. 
Labcoat, safety glasses and nitrile gloves must be worn at all times 
when using Qiacube.  
 All users have to be suitably trained before using QIACUBE. 
 Used labware may contain hazardous chemicals or infectious 
agents from the purification process. These wastes have to be 
collected and disposed in hazardous bags in the yellow bins. 
 Always have the front door closed when the machine is operating. 
 
WHAT TO DO BEFORE USE 
Sample preparation 
 Read the handbook supplied with the Qiagen kit and the relevant 
protocol sheet available at www.qiagen.com/MyQIAcube (protocol 
sheet for DNA QIAamp mini blood extraction is provided here). 
 Make sure all samples and all discarded material have been 
removed from previous runs and surfaces have been cleaned 
before starting a new run. 
 Use the rotor adaptor rack when placing the collection tube and the 
spin column in the rotor adaptor in the position suggested by the 
relevant protocol sheet. 
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Figure 1 
 
 Place the sample to be processed in the specific tubes: conical 
tubes with screw cap provided by Qiagen, when using blood, 2 ml 
tubes with cap when working with other material. 
 Load the sample tubes in the shaker and the rotor adaptors in the 
centrifuge making sure to match the numbers and according to 
loading chart (Figure 2A, available in the QIAcube accessory 
drawer or at www.qiagen.com/MyQIAcube).  Remember to use as 
many white rubbers in the specific slots to indicate the number and 
the position of the samples used (see Fig 2B). 
 Make sure the set of reagents are those needed for that specific 
protocol. Uncap the reagent bottles and place the caps in the 
Qiagen accessory drawer. Check that their amount as well as the 
amount of tips is enough for the run. 
 Prepare the Protease tube with the volume required for the number 
of samples used (check protocol sheet). Place the Protease tube in 
position A making sure the lid is placed in the slot (see Fig 2C).  
 
 
 
 
Loading chart 
 
 
 
 
 
 
 
B A 
C 
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Figure 2 
 
 
SWITCHING ON 
 Switch on the Qiacube at the power switch. Select the 
appropriate application from the main menu. Relevant protocol 
have to be uploaded to the machine before hand (see Installing 
New Protocols section) 
 Select the correct kit name by pressing up and down arrows. 
 To start a protocol run, press “Start” and follow the check steps. 
 Close the lid and press “Start” again. 
 The machine will perform a loading check. Do not leave until the 
protocol starts! 
 
SWITCHING OFF 
 If the run was successfully completed a message with “Run 
completed” will appear on the screen. In case some error has 
occurred, take note of the error number and contact Qiagen 
Technical service if necessary. 
 Take the adaptors out of the centrifuge and load them 
accordingly on the rotor adaptor rack. Take the spin column out 
of the tube, close the lid of the sample tube and discard of the 
rotor adapter and spin column in a biohazard bag. 
 Discard the used sample tubes and tips (placed in the front right 
drawer) in a biohazard bag. 
 Dispose of the biohazard bags in the yellow bins. 
 
 Re-Cap the reagent bottles and place the protease tube back in 
the fridge. 
 
MAINTENANCE: 
Cleaning reagents allowed: Mild detergents and 70% Ethanol 
 
Regular maintenance 
 Remove used disposable labware and unwanted samples or 
reagents from the worktable. 
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 Empty the waste drawer and if necessary clean the liner with 
a mild detergent (micosol) or 70% ethanol and then rinse 
with distilled water. 
 If necessary wipe the worktable surface with distilled water 
and then 70% ethanol. DO NOT USE 70% ETOH ON THE 
FRONT DOOR! 
 
Periodic maintenance 
 Refer to Qiacube user manual (Qiacube accessory drawer, 
www.qiagen.com/MyQIAcube, or User manual file cabinet) 
 
INSTALLING NEW PROTOCOLS 
 New protocols for the QIAcube can be downloaded at 
www.qiagen.com/MyQIAcube 
 To transfer new protocols to the QIAcube, first save them to 
the qiacube memory stick (kept in the QIAcube accessory 
drawer). Create a folder named “New_Protocols” on the 
memory stick. 
 Select the protocol to be downloaded and save it to the 
“New_Protocols” folder. 
 Connect the USB key to the QIAcube (USB port is on the 
front). 
 From the main menu, press “Tools”, “Data Exchange”, scroll 
up and down to find the desired protocol, and then press 
“Select”. Select “Protocols” and either “Load individually from 
USB” or “Load all from USB”.  
 
 
SERVICE ENGINEER: 
 Qiacube technical service 1800 555 049 
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7.13. Appendix 13: SNP Genotyping Protocol 
 
 
How KASP works  
  
KASP  
The purpose of this document is to provide an explanation of how KASPTM genotyping 
chemistry  
KASP overview  
Primer mix contains three assay-specific non-labelled oligos: two allele-specific forward primers and  
one common reverse primer. The allele-specific primers each harbour a unique tail sequence that  
corresponds with a universal FRET (fluorescence resonant energy transfer) cassette; one labelled 
with  
FAM™ dye and the other with HEX™ dye. The KASP Master mix contains the universal FRET  
cassettes, ROXTM passive reference dye, taq polymerase, free nucleotides and MgCl2 in an optimised  
buffer solution. During thermal cycling, the relevant allele-specific primer binds to the template 
and  
elongates, thus attaching the tail sequence to the newly synthesised strand. The complement of 
the  
allele-specific tail sequence is then generated during subsequent rounds of PCR, enabling the 
FRET  
cassette to bind to the DNA. The FRET cassette is no longer quenched and emits 
fluorescence.  
Bi-allelic discrimination is achieved through the competitive binding of the two allele-specific 
forward  
primers. If the genotype at a given SNP is homozygous, only one of the two possible 
fluorescent  
works and also to provide information on how data is collected and analysed in our service 
laboratory.  
     single nucleotide polymorphisms (SNPs) and insertions and deletions (Indels) at specific 
loci.  
a thermal cycling reaction is then performed, followed by an end-point fluorescent 
read. Bi-allelic  
with a unique tail sequence that corresponds with two universal FRET 
(fluorescence resonant energy  
discrimination is achieved through the competitive binding of two allele-specific forward primers, 
each  
KASPTM genotyping assays are based on competitive allele-specific PCR and enable bi-allelic scoring  
KASP genotyping assays are based on competitive allele-specific PCR and enable bi-allelic scoring 
of  
The assay-specific KASP Primer mix and the universal KASP master mix are added to DNA samples,  
transfer) cassettes; one labelled with FAM™ dye and the other with HEX™ dye.  
Detailed explanation of KASP genotyping chemistry  
The assay-specific KASP Primer mix and the universal KASP Master mix are added to DNA samples,  
of single nucleotide polymorphisms (SNPs) and insertions and deletions (Indels) at specific loci.  
a thermal cycling reaction is then performed, followed by an end-point fluorescent read. The KASP  
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signals will be detected. If the genotype is heterozygous, a mixed fluorescent signal will be 
detected.  
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7.14. Appendix 14:  Manuscript of the review paper published 
Weight Change, Genetics, and Anti-Epileptic Drugs 
Joseph Chukwu1,3, Norman Delanty2, 3, David Webb1, Gianpiero L. 
Cavalleri3*. 
1Department of Paediatric Neurology, Our Lady’s Hospital for Sick 
Children, Crumlin,  
2The Division of Neurology, Beaumont Hospital, Dublin, Ireland, 
3Molecular and Cellular Therapeutics, the Royal College of 
Surgeons in Ireland, Dublin, Ireland. 
* Author for Correspondence. gcavalleri@rcsi.ie 
Summary 
Weight gain caused by antiepileptic drugs (AEDs) constitutes a 
serious problem in the management of people with epilepsy.  AEDs 
associated with weight gain include sodium valproate, pregabalin, 
and vigabatrin.  Excessive weight gain can lead to non-compliance 
with treatment and to an exacerbation of obesity-related conditions. 
The mechanisms by which AEDs cause weight gain is not fully 
understood.   It is likely that weight change induced by some AEDs 
has a genetic underpinning, and recent developments in DNA 
sequencing technology should speed the understanding, prediction, 
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and thus prevention of serious weight change associated with 
AEDs. This review focuses on the biology of obesity in the context 
of AEDs. Future directions in the investigations of the mechanism 
of weight change associated with these drugs and the use of such 
knowledge in tailoring the treatment of specific patient groups are 
explored. 
The Biology of Weight 
Many biological factors have been implicated in the pathogenesis 
of obesity. An imbalance between energy intake and energy 
expenditure presents an over-simplistic view of the underlying 
mechanism of obesity. A complex interaction between 
environmental factors, central nervous system (CNS) 
neurotransmitters (e.g. serotonin, glutamate, GABA etc), 
neurotransmitter receptors, peripheral endocrine systems and 
some Circadian rhythms influence food energy intake and 
expenditure [1,2]. In the vast majority of cases, the role that an 
individual’s genetic makeup plays in the pathogenesis of this 
imbalance is polygenic. Food intake and thermogenesis are 
controlled by a complex interaction between the CNS and the 
peripheral nervous system (PNS). The peripheral and central 
control pathways of energy balance are linked at multiple points. 
The anabolic and catabolic neuropeptides are the two classes of 
neuropeptides involved in energy balance. 
The Genetics of Weight Regulation 
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Obesity is a multifactorial disorder with a significant genetic 
component. Indeed family and twin studies indicate that BMI has a 
heritability of between 0.7 - 0.8 [3,4]. Monogenic obesity is rare in 
humans but understanding the genes underlying these rare cases 
can provide a window on the biology of obesity more generally.  
Around 5% of early onset, severe obesity are explained by 
pathogenic mutations in the gene coding for the G-protein coupled 
melanocortin 4 receptor (MC4R) (Yeo et al., 1998[5]. The central 
melanocortin system regulates food intake, energy expenditure, 
body weight and glucose homeostasis through MC4Rs located in 
the hypothalamic and extra-hypothalamic nuclei [6]. Individuals 
carrying the MC4R mutations are typically of tall stature and 
experience severe early-onset obesity and hyper-insulinaemia 
[7,8]. Mutations in the MC4R gene are the most common cause of 
familial obesity.  A recent genome-wide association study (GWAS) 
study indicates that common variation across MC4R in the general 
population also contributes to BMI variations and to increased risk 
of sporadic obesity [9].  A much smaller number of familial obesity 
cases can be explained by mutations in the leptin and pro-
opiomelanocortin (POMC) genes. Mutations in both the leptin gene 
and its associated receptor can lead to severe, early-onset obesity 
with associated hyperphagia.  Leptin is a peptide hormone 
produced primarily in the white adipose tissue. It functions, through 
receptors on the hypothalamus, to inhibit appetite [10]. Mutations in 
POMC leads to obesity of later onset than those cases due to loss 
of MC4R signalling [11]. 
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Gene variants with minor allele frequency of < 5% have been 
mapped for many familial syndromes that have obesity as a central 
component of the clinical phenotype. Examples include Albright 
hereditary osteodystrophy (mutation in GNAS1), Bardet-Biedl 
syndrome (mutations in various BBS genes), Fragile X Syndrome 
(mutations in FMR1), lipodystrophy syndromes (mutations in 
LMNA), and Prader-Willi syndrome (deletions involving 15q11-q13). 
These variants are highly penetrant in patients and families with 
severe obesity as the predominant presenting feature and display 
classical Mendelian patterns of inheritance [11].    
 
Despite the above examples, the vast majority of the genetic 
influence on obesity is polygenic – a combination of genetic 
variation across a number of genes, each with individually small 
effect sizes. The development of GWAS has provided a framework 
for the study of the role of common genetic variation in obesity.  As 
of January 2013, over 13 GWAS studies have been published on 
weight-related phenotypes. The largest of these studies contained 
data on over 249,000 individuals, leading to the robust association 
of 32 loci with weight.  Loci including FTO, MC4R, ETV5 had 
previously been identified whilst others like GPRC5B, TNNI3K, 
PRKD1 were novel [12].  However, despite the size of the study, 
the 32 loci identified together only account for 1.45% of inter-
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individual variation in BMI, the largest locus-specific effect coming 
from FTO (0.34%).  In all, about 52 loci for obesity traits have now 
been discovered through GWAS.   These have only modest effect 
sizes with odd ratios (per allele) of between 1.2 and 1.5 [11].  
However, genes involved may provide insight to the biology of 
obesity. For example several are located in regions containing 
genes encoding for neuronal regulators of appetite, energy balance 
and neuroendocrine function [12]. 
 
Weight Change in Epilepsy 
Weight change of itself is not a central feature of epilepsy. 
However, particularly in refractory epilepsy, a sedentary life-style 
due to regular seizures increases the risk of obesity [13].  In 
addition, depression is common in people with epilepsy, which 
might contribute to the increased prevalence of obesity [14]. 
Exercise-induced seizures, AED side-effects and conflicting 
medical advice regarding the safety of exercise contribute to the 
problem. Very few studies have explored the issue of weight 
change in individuals with epilepsy.  In a Norwegian study the 
exercise pattern of patients with epilepsy closely matched those of 
age- and sex-matched individuals in the general population [15].  A 
survey of exercise patterns in 412 adults with epilepsy indicated 
that most undertook light exercise three or less times per week and 
that there was no difference in frequency and intensity between 
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those who reported that seizures were a barrier to exercise than 
those who did not [16].  The only study of epilepsy-related weight 
change in children and adolescents concluded that juveniles with 
epilepsy exercised less and were therefore more likely to be 
overweight than their siblings without epilepsy [17].  
 
Most of the weight changes in patients with epilepsy are related to 
treatment.  AEDs may be associated with weight gain, weight loss 
or they may be weight neutral (see Table 1). The principal AEDs 
associated with weight gain are sodium valproate, gabapentin, 
pregaballin, vigabatrin, and carbamazepine [18].  Those AEDs 
associated with weight loss are topiramate, zonisamide, and 
felbamate [19].  Unsurprisingly, AEDs associated with weight gain 
are of greatest concern for patients and their clinicians since weight 
gain not only affects body image and self-confidence but can also 
contribute to chronic illness related to obesity such as 
hypertension, type 2 diabetes mellitus, dyslipidaemia, and 
atherosclerosis [14,20-22].  These adverse effects may also affect 
seizure control as they could impair adherence to the treatment 
regimen.  Since AEDs are often taken for many years, physicians 
and their patients should be aware of the adverse metabolic effects 
of some AEDs [23].  The adverse health effects of weight gain can 
be exacerbated by the multiple medications taken by some 
individuals with epilepsy [21].  Best practice in epilepsy care 
indicates that in selecting AEDs, the patient’s profile should 
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carefully considered – this includes weight prior to the initiation of 
therapy and other medical or psychiatric morbidities [13].  Ideally an 
AED should be a weight neutral unless the patient’s profile dictates 
otherwise [22].  Regular weight checks after the initiation of 
treatment are important to monitor adverse reaction. 
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AED-associated Weight Change  
Sodium valproate (VPA): VPA, a broad-spectrum AED used in the 
treatment of both generalized and partial seizures has been 
reported to cause weight gain in up to 71% of exposed patients, 
although typically the rate is around 10% [22]. Weight gain usually 
occurs within the first 3 months and peaks at 6 months after 
initiation of therapy ([24]). The degree of weight gain is variable, 
with about 10% of the patients experiencing severe weight gain.  
Factors proposed to influence VPA-induced weight gain include 
body mass index pre-treatment ([25] [26-28]), gender [29], post-
pubertal status [30], age at which treatment was first initiated [31], 
neuro-cognitive status [32], and a diagnosis of primary generalized 
epilepsy[32]. It has also been reported that post-pubertal girls are 
more likely to gain weight than post-pubertal boys or prepubertal 
children of any gender [26,29,33-35] and that a longer duration of 
therapy correlates with weight gain [26,28,36]. Other studies have 
not reported predictors [37,38]. It should be noted that none of the 
proposed predictors listed above have been consistently replicated 
[25,29,32,39]. As a result, there are no accepted clinical predictors 
of VPA-induced weight gain. There have been no randomized 
control trials and some of the studies were underpowered to detect 
these predictors [22]. 
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The mechanisms underscoring VPA-associated weight gain are 
unclear.  VPA therapy is associated with hyperinsulinaemia [40,41], 
although the causal mechanism is poorly understood [42]. Insulin, a 
peptide hormone, plays a central role in energy metabolism in the 
well-fed state. Increased blood glucose in the well-fed state 
stimulates insulin secretion. Insulin then promotes glycogen 
storage in the liver and muscle and converts the excess glucose to 
fatty acids and triglycerides in the adipose tissue.  Interference with 
hepatic insulin metabolism leads to hyperinsulinaemia without 
concomitant increase in the C-peptide levels [43].  Interestingly, 
VPA inhibits GLUT-1 activity in normal astrocytes and fibroblasts 
resulting in reduced glucose transport [44]. 
VPA therapy is also associated with hyperleptinaemia and leptin 
resistance [42,45-48].  A high soluble leptin receptor/ leptin ratio 
has been observed in children with epilepsy [49].  Serum leptin 
levels strongly correlate with BMI in children on VPA therapy [50]. 
The relationship between increased leptin levels and increased BMI 
appears more marked in girls than in boys [46,51].  VPA therapy 
has also been associated with increased ghrelin levels at 6 months 
along with increased BMI in pre-pubertal children taking VPA 
compared to controls [52]. Ghrelin is a peptide hormone secreted 
by the stomach and proximal small intestine. It is the only hormone 
known to stimulate appetite and promote food intake, resulting in a 
positive energy balance and weight gain. 
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Indirect evidence from animal studies indicates that VPA therapy 
exerts a time- and dose- dependent inhibitory effect on adiponectin 
gene expression in mature mouse adipocytes [53]. The mechanism 
of this effect is probably through the inhibition of histone 
deacetylase activity.  Adiponectin is an adipokine produced by the 
adipose tissues and acts in the brain and peripheral organs to 
regulate glucose and in fatty acid metabolism [54]. Adiponectin 
decreases gluconeogenesis while increasing glucose uptake. It 
also promotes fat catabolism by promoting β-oxidation and 
clearance of triglycerides. Greco et al [55] noted that adiponectin 
levels were lower in obese epileptic patients when compared to 
those who did not gain weight [55].  Adiponectin deficiency can 
predispose to the metabolic syndrome [54]. 
Other studies have suggested a role for a variety of other 
neurohumoral factors in VPA-induced weight gain, such as 
glucagon-like peptide-1 [56], neuropeptide Y [45,48,57], galanin 
[48] GABA [58-60]). 
Pregabalin (PGB): In controlled trials of pregabalin (PGB), a 
weight gain of 7% or more was noted in about 8% of subjects 
treated with PGB, compared to 2% of those treated with placebo.  
A meta-analysis of pooled data from 106 studies involving 43,525 
patients treated with 150 - 600 mg of PGB indicates that the 
majority of patients maintained their weight within 7% of baseline 
weight while about 16% gained  >7% of baseline weight [2].  In 
contrast to VPA, dose [61] and duration of exposure are appear as 
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robust predictors of PGB-induced weight gain [62]. This ADR is not 
associated with baseline BMI, gender, or age [63].  Diabetic 
patients treated with PGB have been shown to gain an average of 
1.6 kg (range: -16 to 16 kg), compared to patients treated with 
placebo who gained an average of 0.3 kg (range: -10 to 9 kg) [63].  
The dose-dependent effect of PGB-induced weight gain has been 
demonstrated in a double blind placebo-controlled trial in epilepsy 
which showed a 12 to 14% weight gain for those patients treated 
with 600mg of PGB compared to 10% gain in those treated with 
150mg and 6% in the placebo group [13,64,65].  Although the exact 
mechanism of PGB-induced weight gain is unknown, enhancement 
of GABA transmission may play a role [64]. 
Topiramate (TPM): The reported incidence of weight loss in adults 
and children treated with TPM for 3 months to up to 1 year ranges 
from 16% up to 86% [66-70].  In a randomized double-blind trial of 
TPM in adults and children weight loss was noted in 6 - 15% of 
adults on 25 - 500mg/day, but not in any of the children on similar 
doses [67].  Most weight loss occurs within 3 – 5 months of 
exposure [66,70,71] and may be sustained for up to two years [72]. 
The degree of weight loss also varies widely and ranges between 
3.9% and 7.3% [66].  The degree of weight loss correlates with 
dose, pre-treatment weight, reduced caloric intake, higher baseline 
BMI and duration of treatment [66,70,71,73]   
The mechanism of weight loss is not understood [71,74]. TPM 
depresses appetite in children that lost weight while on the 
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medication [71,75].  Other mechanisms may include significant 
reduction in the serum galanin (a neuropeptide involved in the 
regulation of feeding behaviour ) levels [76], stimulation of 
lipoprotein lipase in brown fat [77,78] and [79] uncoupling of 
proteins 1 and 2 in mitochondria [80,81] increase in serum level of 
adiponectin.  
Interestingly, TPM therapy is associated with increased insulin 
sensitivity and has demonstrated efficacy in type-2 diabetes [82-
84].  Short term therapy with low dose TPM does not affect insulin 
sensitivity in obese non-diabetics [85].  TPM can preserve 
pancreatic β-cell activity in type-1 diabetics with epilepsy being 
treated with TPM [84]. In animal models with type 2 diabetes, TPM 
acts both as an insulin secretagogue and as an insulin sensitizer 
[86].  
Zonisamide (ZNS): Up to 35% of patients exposed to zonisamide 
(ZNS) experience some weight loss. The mean weight loss is 
usually around 3.7% +/- 9.1% [87]. ZNS used in the treatment of 
psychiatric conditions also results in weight loss [88].  There is 
inter-individual variability in the weight change ranging from -36% 
to +32% of pre-initiation weight [87]. In a randomised control trial in 
obese subjects treatment with 400mg of ZNS, a third of patients 
reported >10% weight loss [89]. BMI at initiation  of therapy 
appears to correlated with degree of weight loss although this 
observation requires replication [87]. 
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Inhibition of lipogenesis through its effect on the mitochondrial 
carbonic anhydrase isoforms CA VA and CA VB may be the main 
molecular mechanism for ZNS induced-weight loss. Weight loss in 
ZNS therapy is associated with low serum leptin levels in obese 
females [90].  Indeed, ZNS and TPM have been approved as anti-
obesity drugs in some regions [91,92]. 
Others: Additional AEDs including carbamazepine (CBZ) and 
gabapentin (GBP) have been reported to lead to weight gain. 
Whilst felbamate (FBM) has been associated with weight loss. 
However, the degree of weight change associated with these AEDs 
is less than for VPA, GBP, TMP and ZNS.  
 
CBZ is a sodium channel blocker and one of the most commonly 
prescribed AEDs. Weight gain has been reported in around 5% of 
individuals on CBZ treatment, an effect that appears idiosyncratic 
[93]. Work in murine and human cell lines has provided strong 
evidence that CBZ influences weight by targeting adipocytes to 
alter adipose tissue metabolism and differentiation [94]. 
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GBP is a gabba-aminobutyric acid (GABA) analogue that also acts 
on presynaptic calcium channels. Several observational studies 
have reported quantitative data on weight gain associated with 
GBP use. A study involving 610 epilepsy patients on GBP as an 
add-on therapy reported weight gain in 9% of patients, an effect 
that appeared dose dependent [95]. An earlier study in 44 epilepsy 
patients on high-dose GBP therapy reported weight gain in 23% of 
patients [96]. 
 FBM acts as a modulator of GABA receptors and blocker of NMDA 
receptors. The use of FBM is restricted to very severe forms of 
epilepsy such as Lennox-Gastaut syndrome, due to associated 
toxicity (which can lead to liver failure). A study of 65 children and 
adolescents on FBM therapy reported weight loss in 75% of 
patients, with the degree of weight loss correlating with age [97]. 
Significant weight loss (>5%) has been reported in long-term use of 
FBM in children [98].  
 Clinical summary: It is thus clear that a significant number of 
commonly used AEDs can impact on body weight in many 
individuals with epilepsy.  The mechanism of weight change 
effected by these AEDs is poorly understood, and may in large part 
have an underlying pharmacogenomic basis.  Weight loss and 
weight gain induced by AEDs may contribute to the important co-
morbidities of epilepsy, such as endocrine disturbance, risk and 
effects of seizure-related injuries, and lipid homeostasis.  The 
treating physician should consider the potential effects of AEDs on 
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weight when initiating treatment in an individual patient.  Thus, for 
example, valproate should generally be avoided when initiating 
therapy in someone with epilepsy and co-morbid obesity, whereas 
zonisamide would be best avoided in an individual with low body 
mass, or a history of anorexia.  Similarly, early consideration should 
be given to switching to an alternative therapy if a recently initiated 
AED appears to be negatively impacting weight and well-being in a 
patient with epilepsy.  Finally, predictive pharmacogenomic 
analysis would be an important advance in individualized 
pharmacotherapy in the epilepsies. 
Five-Year View 
Progress in genetic mapping has accelerated our understanding of 
genetics in the causation of human disease, response to treatment, 
drug resistance and adverse drug reactions [99,100].  In epilepsy 
there has been a significant increase in pharmacogenomic 
research over recent years [101,102].  GWAS and next-generation 
sequencing now allows a comprehensive screening of genetic 
variations across different patient populations. These techniques 
offer the potential not only to enhance the understanding of the 
molecular mechanisms underlying some epilepsy syndromes, but 
also to provide insight into the underlying mechanism of some 
previously unrecognised obesity syndromes. Improved knowledge 
of the molecular mechanism of epilepsy and obesity will not only 
enhance the understanding of the relationship between the two 
diseases but will also help in understanding the role of AEDs in 
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weight change. Well-powered GWAS- and next-generation 
sequencing-based mapping efforts have yet to be applied to 
weight-change related ADRs in epilepsy. Such an effort for AED-
associated weight change may further allow us to understand the 
complex biology of obesity.  Large consortia-based efforts including 
but not limited to EPIPGX and EPI4K provide a framework for 
discovery in this context [103,104]. 
 
  
Key Issues 
1. Obesity is a common public health problem with long-term 
medical and psychological implications 
2. Weight change is a common problem in patients with 
epilepsy, often due to treatment with AEDs such as sodium 
valproate. 
3. Anti-epileptics and anti-psychotic treatments contribute to the 
rising prevalence of obesity. While most of these drugs cause 
weight gain, others cause weight loss while others are weight 
neutral. 
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4. The biology of obesity is very complex and scientific 
knowledge in this area is rapidly evolving. 
5. Anti-epileptic and anti-psychotic medications interfere with the 
key biological mechanisms regulating energy balance. This might 
explain some of the weight-related adverse effects attributed to 
these medications. 
6. The development of gene sequencing technology has 
enhanced the understanding of the biology and genetics of 
obesity, and may also help us to understand AED-induced weight 
change. 
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Table 1:  A summary of epidemiological studies exploring AED-induced weight change.  
 
AED Dir. of 
effect 
% Patients 
showing effect 
Study design & ref Clinical predictor(s) Observed in adults 
&/or paed. 
subjects? 
VPA Gain 44% Retrospective [105]  Female gender Paediatric 
VPA Gain 11% Prospective [106]  Initial weight Z-score  
 Initial body mass index 
Paediatric 
VPA Gain 71% Retrospective [25])  No history of weight problems 
 BMI at initiation of therapy 
Adults 
VPA Gain 44% Retrospective [29]  None tested Paediatric 
 329 
 
AED Dir. of 
effect 
% Patients 
showing effect 
Study design & ref Clinical predictor(s) Observed in adults 
&/or paed. 
subjects? 
VPA Gain 27% in males 
56% in 
females 
 Prospective, observational [39]  Gender (female) 51 males; 55 
females 
VPA Gain 58%  Retrospective [32]  Weight at initiation 
 Neurocognitive status 
 Primary generalized epilepsy 
Paediatric 
PGB Gain 11% 
 
Randomised placebo-controlled 
trial [107] 
 None tested Adults 
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AED Dir. of 
effect 
% Patients 
showing effect 
Study design & ref Clinical predictor(s) Observed in adults 
&/or paed. 
subjects? 
PGB Gain  7%-
150mg/day 
14%-
600mg/day 
 Randomised double-blinded 
placebo-controlled trial [108] 
 
 Dose Adults 
PGB Gain 10% Prospective, observational [61]  Dose Adults 
PGB Gain 21%-600mg 
BID 
15%-600mg 
TID 
 
Randomised double-blinded 
placebo-controlled trial [65]) 
 None tested Adults 
 
TPM Loss 86% at 1 year Prospective observational [66]  Baseline BMI Adults 
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AED Dir. of 
effect 
% Patients 
showing effect 
Study design & ref Clinical predictor(s) Observed in adults 
&/or paed. 
subjects? 
TPM Loss 15%-200 or 
500mg/day 
 
 
Randomised double-blinded trial 
[67]  
 Dose Both 
TPM Loss 69%-
400mg/day 
Randomised double-blinded trial 
[68] 
 Dose Both 
TPM Loss 12%-
200mg/day 
Randomised double-blinded trial 
[69] 
 Dose (suggestive) Adults 
TPM Loss 13%-600-
1000mg/day 
Randomised double-blinded 
placebo-controlled trial [109] 
 Dose (suggestive) Adults 
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AED Dir. of 
effect 
% Patients 
showing effect 
Study design & ref Clinical predictor(s) Observed in adults 
&/or paed. 
subjects? 
TPM Loss 
 
13%600-
100mg/day 
Randomised double-blinded 
placebo-controlled trial [70] 
 Dose Adults 
ZNS Loss 35% Retrospective [87]  Weight pre-treatment Adults 
ZNS Loss 55%-
400mg/day 
Randomised double-blinded 
placebo-controlled trial [110]. 
 
Dose Adults 
 
 
   
 333 
 
Table 2: Reported possible molecular mechanisms of AED-induced weight change 
 
 
AED Molecular mechanism 
Sodium Valproate GABA stimulation of the hypothalamus: Increased 
[24,111,112]) 
Sodium Valproate Hyperinsulinism and insulin resistance [24,113-115];  
Sodium Valproate  Hyperleptinemia and leptin resistance [114,116-118]. 
Sodium Valproate Leptin, ghrelin and adiponectin [55,119,120] 
Sodium Valproate Increased serum level of GLP-1[121] 
Pregabalin Enhancement of GABA transmission [108] 
Topiramate Increased  expression of uncoupling proteins 1 & 
2[66,80,81,122-124] 
Topiramate Reduced serum galanin levels [74] 
Topiramate Inhibition of mitochondrial carbonic anhydrase 
isoforms VA and VB [125,126]; 
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Topiramate Stimulation of lipoprotein lipase in brown fat [77-79] 
Zonisamide Inhibition of mitochondrial carbonic anhydrase 
isoforms (VA and VB)[22,125-127] 
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